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1. Abstract 
 
 
Nuclear magnetic resonance spectroscopy represents an optimal tool in modern 
chemical and biochemical research; for this reason, numerous applications can be 
found in both biology, and biomedicine. Despite its lower sensitivity, nuclear magnetic 
resonance spectroscopy offers many unparalleled advantages over mass spectrometry 
in order to perform metabolomic analysis. Metabolomics is defined as the analysis of 
the complete ensemble of low molecular weight molecules, the metabolites, present in 
a biological specimen. It is an emerging technology that holds promise powerful 
insights into the mechanisms of human health and disease making personalized 
medicine even more personalized.  
In this methodological thesis, with the aim of demonstrating the potential of NMR-
based metabolomics in biomedical research different topics have been addressed and 
discussed: 1) the use of NMR-metabolomics to provide innovative means to predict 
response and recurrence of diseases; 2) the characterization of the metabolic signature 
of pathological states via NMR to uncover their underlying molecular mechanisms; 3) 
the application of NMR-base metabolomics in the framework of precision medicine by 
characterizing the human plasma metabolic phenotype and by monitoring the effect of 
drug treatments or life style interventions on the metabolome; 4) the investigation of 
potential applications of metabolomics in veterinary research. 
In conclusion, the results presented in this thesis, obtained by a combination of 
biochemistry, analytical chemistry, bioinformatics, and clinical data, showed that 
fingerprinting analysis by NMR has the potential not only to increase our knowledge 
on specific diseases, but also to be translated in clinical practice for diagnostic or 
prognostic purposes. 
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Chapter 1 
1. Introduction 
 
 
1.1 What is metabolomics? 
Biological systems are complex entities composed of dynamic and interrelated genetic, 
protein, metabolic and cellular components.  Environmental and many other external 
factors exert significant influence; therefore, comprehension of biological systems at a 
molecular level can be achieved more thoroughly only if they are considered and 
studied as a whole by combining biology, chemistry, mathematics, statistics, and 
bioinformatics. In this framework, systems biology aims at modelling complex 
biological interactions, by integrating data from interdisciplinary fields in a holistic 
fashion1.  
Omics sciences can be considered as the analytical basis of systems biology, since they 
enable the global characterization and quantification of many different biological 
molecules, such as genes, proteins and metabolites, which explain the complex 
structure, function and dynamics of cells, tissues or organisms2. Genomics, the first 
among all the omic sciences, is the systematic study of all nucleotide sequences, 
including structural genes, regulatory and non-coding sequences that are present in an 
organism’s genome. Transcriptomics studies the entire pool of mRNA in a cell or 
organism, which reflects the genes that are actively expressed at any given moment. 
Proteomics aims at characterizing the complete set of all expressed proteins in a cell, 
tissue or organism, determining their role in physiological and pathophysiological 
functions. Metabolomics is one of the latest omic technologies, broadly defined as the 
comprehensive measurement of the complete ensemble of metabolites present in a 
biological specimen, the so-called metabolome3. The metabolome can be described as 
a highly complex and finely organized biochemical network in which small molecules 
interact together, as well as with other biological macromolecules4. It is a dynamic and 
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evolving entity that can be regarded as the downstream end-product of the interaction 
of genetic expression, transcriptional changes, post-translational modifications of 
proteins, and various other external factors such as environment, diet, drug 
administration, diseases, life style and age5 (Figure 1). In contrast to genomics, which 
indicates what might happen, metabolomic profiling and phenotyping capture what is 
actually happening in the body6. For this reason, metabolites are considered the most 
proximal reporters of any disease status or phenotype, with potential for powerful 
insights into the mechanisms of human health and disease.  
 
 
Figure 1. Diagram illustrating omics sciences. The flow of information proceeds from genes to transcripts, 
to proteins and finally to metabolites, increasingly affected by external influences. This integrated scheme 
illustrates a temporal evolution from the genotype to the phenotype. 
 
Metabolomics is focused on the analysis of intermediates and end-products of 
metabolism, which comprise carbohydrates, fatty acids, amino acids, nucleotides, 
organic acids, vitamins, antioxidants, and many other classes of compounds. The total 
number of these metabolites is relatively small if compared with genes, transcripts or 
proteins; however, their levels are influenced by several internal stimuli and external 
perturbations. This makes metabolomics an extremely valuable tool enabling the 
identification of key players of diseases in the form of endogenous metabolites (gene-
derived metabolites) and exogenous metabolites (environmentally derived 
metabolites), which provides crucial information on the underlying causes of diseases 
at a molecular level7. 
 
1.2 Metabolomics: a technique, many approaches 
Dependent on the biological question at issue, metabolomic analysis can be addressed 
with two different methodological approaches: targeted and untargeted (Table 1). 
Targeted metabolomics approaches involve the monitoring of a panel of a priori 
selected metabolites on the basis of known metabolic pathways or pre-identified 
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biomarkers that are undoubtedly associated with the disease or condition of interest. 
Therefore, the analytical techniques used should provide selectivity and enough 
sensitivity to enable the unambiguous absolute quantification of the selected 
metabolite in the sample. 
Conversely, untargeted metabolomics provides a global view of a sample by analyzing 
all measurable analytes present. This purpose can be achieved via two approaches: 
metabolic fingerprinting or profiling. Metabolic fingerprinting is a global, rapid 
evaluation of all detectable metabolites in a biological sample, without identification of 
single metabolites. This approach is utilized to essentially provide sample classification 
and not for quantitative purposes. Usually, metabolic fingerprinting aims at 
discriminating between specimens with different biological statuses (e.g. presence or 
absence of disease, before or after treatment), in turn characterizing a specific health 
state with a unique metabolic pattern. Metabolic profiling, in contrast, concerns the 
quantification of all identified metabolites in a biological sample. This strategy enables 
the identification of metabolites and metabolic pathways associated with a specific 
physiological or pathological condition, providing new insights into pathophysiological 
molecular mechanism of diseases6. 
 
Table 1. Metabolomic glossary. 
Term Definition 
Metabolites 
Low molecular mass organic molecules (< 2000 g/mol) 
involved in metabolic processes as substrates or 
products with different biological functions (i.e. fuel, 
structure, signaling, catalytic and inhibitory effects on 
enzymes, defense). 
Metabolome 
The quantitative ensemble of all metabolites present 
within an organism, an organ, a biofluid, a tissue or a cell 
in a particular physiological or developmental state. 
Metabolomics 
The quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modifications. 
Targeted metabolomics 
The measurement of defined groups of biochemically 
and chemically characterized metabolites undoubtedly 
associated with a specific metabolic condition. 
Untargeted metabolomics 
The comprehensive analysis of all the measurable 
analytes in a sample, including chemical unknowns. 
Metabolic fingerprinting 
Global, high-throughput, rapid analysis of all 
metabolites presents in a biological sample to provide 
sample classification (even without metabolite 
identification). 
Metabolic profiling 
The identification and quantification of as many as 
possible metabolites present in a biospecimen. 
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1.3 Biological samples  
In principle, every biofluid, tissue or cell culture can be utilized for metabolomics 
analysis; however, urine and blood plasma or serum are by far the most commonly 
used. They contain hundreds to thousands of metabolites, and can be collected 
relatively non-invasively, ensuring easy and high-frequency sampling of large cohorts 
of samples. As systemic biofluids, they are always at dynamic equilibrium with the 
body; therefore, they rapidly reflect every evolving metabolic changes8. Blood is the 
primary carrier of dissolved gases, nutrients, hormones and body wastes (Table 2).  
 
Table 2. Chemical classes in the human blood metabolome, data retrieved from the literature9. 
Compound class Number Compound class Number 
Acyl glycines 10 Indoles and indole derivatives 12 
Acyl phosphates 10 Inorganic ions and gases 20 
Alcohol phosphates 2 Keto acids 8 
Alcohols and polyols 40 Ketones 6 
Aldehydes 3 Leukotrienes 8 
Alkanes and alkenes 10 Minerals and elements 40 
Amino acid phosphates 1 Miscellaneous 77 
Amino acids 114 Nucleosides 24 
Amino alcohols 14 Nucleotides 24 
Amino ketones 14 Peptides 21 
Aromatic acids 22 Phospholipids 2177 
Bile acids 19 Polyamines 11 
Biotin and derivatives 2 Polyphenols 22 
Carbohydrates 35 Porphyrins 6 
Carnitines 22 Prostanoids 23 
Catecholamines and derivatives 21 Pterins 14 
Cobalamin derivates 4 Purines and purine derivatives 11 
Coenzyme A derivatives 1 Pyridoxals and derivatives 7 
Cyclin amines 9 Pyrimidines and pyrimidine derivatives 2 
Dicarboxylic acids 17 Quinones and derivatives 3 
Fatty acids 65 Retinoids 11 
Glucoronides 8 Sphingolipids 3 
Glycerolipids 1070 Steroids and steroid derivatives 109 
Gluycolipids 15 Sugar phosphates 9 
Hydroxy acids 129 Tricarboxylic acids 2 
 
Blood plays a key role in the regulation of the pH and ion composition of interstitial 
fluids, in the defense against pathogens and in the stabilization of body temperature10.  
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Because of these complex and fundamental systemic roles, the concentrations of 
metabolites in blood are strongly controlled by feedback cycles, which regulate and 
maintain body homeostasis within strict parameters; therefore, they are not subjected 
to extreme daily variations. Since blood interacts essentially with every living cell in 
the human body, it offers a snapshot of the state of an organism and provides crucial 
information for detecting, monitoring and managing virtually all human diseases. 
Urine contains more than 2000 different metabolites at variable concentrations, the 
urine metabolome can be summarized in 24 superclasses (Table 3). Furthermore, fresh 
urines are characterized by the presence of many cellular and non-cellular 
components10. As urine essentially contains metabolic wastes, urine samples are 
significantly affected by diet, environment, lifestyle, drug administration and bacterial 
by-products. Within the same individual, the urinary metabolic profile presents high 
rates of circadian and day-to-day variability, and therefore, in contrast to blood, urine 
provides a time-averaged representation of the physiological state. For all the 
abovementioned reasons, repeated sampling at different times for the same individual 
(20 samples per subject11) represents the best approach for urine studies. 
 
Table 3. Chemical superclasses in the human urine metabolome, data retrieved from the literature12. 
Compound Superclass Number Compound Superclass Number 
Aliphatic Acyclic Compounds 93 Homogenous Metal Compounds 45 
Aliphatic Heteromonocyclic 
Compounds 
43 
Homogenous Non-Metal 
Compounds 
15 
Aliphatic Heteropolycyclic Compounds 40 Lignans and Norlignans 12 
Aliphatic Homomonocyclic Compounds 18 Lipids 866 
Aliphatic Homopolycyclic Compounds 5 
Mixed Metal/Non-metal 
Compounds 
7 
Alkaloids and Derivatives 45 Nucleic Acids and Analogues 49 
Amino Acids, Peptides, and Analogues 286 Organic Acids and Derivatives 108 
Aromatic Heteromonocyclic 
Compounds 
67 Organic Halides 3 
Aromatic Heteropolycyclic Compounds 728 Organometallic Compounds 1 
Aromatic Homomonocyclic 
Compounds 
432 Organophosphorus Compounds 17 
Aromatic Homopolycyclic Compounds 6 Polyketides 74 
Carbohydrates and Carbohydrate 
Conjugates 
116 Tannins 2 
 
 
Beyond blood and urine, cerebrospinal fluid (CSF) is widely used to study neurological 
diseases, although its sampling is much more invasive. Cerebrospinal fluid is both 
produced and resorbed within the central nervous system (CNS). Filling the ventricles 
and the subarachnoid space of the brain and spinal column, CSF protects the brain from 
physical shock, it circulates nutrients and chemicals filtered from the blood, and  
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transports waste products into the venous blood stream13. Since CSF composition is 
directly related to brain metabolic activity, it can be considered by far the ideal 
specimen for the study of central nervous system (CNS) disorders such as Alzheimer’s 
disease, Parkinson's disease, and multiple sclerosis. The CSF metabolome has been 
characterized as shown in Table 4. 
 
Table 4. Chemical classes in the human CSF metabolome, data retrieved from the literature13. 
Compound class Number Compound class Number 
Amino acids 56 Carnitines 5 
Minerals and elements 27 Prostanoids 5 
Fatty acids 18 Aromatic acids 4 
Steroids and steroid derivatives 18 Pyrimidines and their derivatives 4 
Hydroxy acids 16 Amino ketones 4 
Alcohols and polyols 16 Aldehydes 4 
Dicarboxylic acids 13 Leukotrienes 2 
Peptides 12 Tricarboxylic acids 2 
Carbohydrates 11 Ketones 2 
Nucleosides 10 Biotin and derivatives 1 
Inorganic ions and gases 10 Porphyrins 1 
Cyclic amines 10 Glycolipids 1 
Catecholamines and derivatives 9 Amino acids phosphates 1 
Pterins 9 Cobalamin derivatives 1 
Nucleotides 9 Quinolines 1 
Keto-acids 7 Acyl phosphates 1 
Indoles and indole derivatives 6 Amino alcohols 1 
Purines and purine derivatives 5 Lipids 1 
 
For the sake of completeness, it is important to mention that also saliva proved to be a 
valuable and very easy accessible biospecimen to monitor overall health status14, and 
that the analysis of faecal extracts provides an innovative and non-invasive way to 
study gut microbiota and to diagnose intestinal diseases or alterations15. 
 
1.4 Analytical techniques used in metabolomics 
The two leading analytical techniques used to perform metabolomic analyses are mass 
spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. Both 
techniques yield information about many different molecules in a single measurement, 
and   can   be   used   to   determine  structures   and   concentrations   of   metabolites16.  
Nevertheless, each of technique has its own strengths and limitations (Table 5).  
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MS determines the molecular composition of biological samples base on the mass-to-
charge ratio (m/z) of ionized metabolites. This method often requires the separation 
of metabolites from the biofluid matrix. As such, MS is coupled with liquid 
chromatography (LC), gas chromatography (GC), or capillary electrophoresis (CE). 
Specifically, appropriate phases or columns allow LC-MS to analyze numerous 
metabolites with molecular characteristics ranging from hydrophilic to hydrophobic, 
and the use of ultra-high performance liquid chromatography (UHPLC) has lowered 
the detection limit from the usual nanomolar scale down to femtomolar.  
Despite these recent improvements, reproducibility still remains the biggest limitation 
of MS; for this reason, although overshadowed by MS in terms of sensitivity, NMR 
spectroscopy offers crucial advantages. NMR data are highly reproducible17 and 
intrinsically quantitative over a wide dynamic range; NMR is non-destructive, and 
enables the analysis of intact tissues. Moreover, it is more suitable for untargeted 
metabolomics with the aim of characterizing metabolic phenotype of diseases. It is 
important also to mention that standards of each metabolite to be analyzed at known 
concentration need to be used for MS experiments to generate calibration curves for 
absolute quantification; conversely no-standards are needed for NMR, making the 
analysis straightforward and possibly high throughput. 
 
Table 5. Advantages and limitations of NMR spectroscopy and MS spectrometry as 
metabolomic analytical platforms.  
Mass Spectrometry (MS) 
Nuclear Magnetic Resonance 
spectroscopy (NMR) 
Advantages 
Sensitivity (1 nM) Reproducibility 
Low sample volumes Non-destructive 
Robust Robust 
Selectivity Minimal sample preparation 
Quantitative High throughput sample analysis 
Low-medium costs Quantitative 
 Analysis of intact tissues 
 Not affected by matrix components 
Limitations 
Destructive Low sensitivity (1-10 μM) 
Complex sample preparations High sample volumes (100-700 μL) 
No high throughput analysis Expensive instrumentations 
No analysis of intact tissues  
Affected by matrix components  
 
In the NMR spectra, the integrals of each peak relate directly to the number of nuclei 
(with nonzero spin) giving rise to the peak, and hence to the relative concentrations of 
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the molecules in the sample, making NMR an intrinsically quantitative technique. The 
most important nuclei in biomolecular NMR studies are 1H (proton), 13C, 15N, and 31P. 
One-dimensional (1D) 1H NMR is the most widely used NMR approach in 
metabolomics, since the proton is the most sensitive and abundant nucleus; however, 
multidimensional NMR experiments offer further possibilities that can be sometimes 
exploited for unambiguous identification of metabolites in complex mixtures like 
biofluids or tissues.  
In conclusion, MS and NMR are two complementary techniques with comparative 
strengths and weaknesses. NMR represents the first choice to perform untargeted 
metabolomics with the aim of generating new scientific hypotheses. Conversely, MS is 
the best technology to confirm or validate a preexisting hypothesis with a targeted 
approach, since its high sensitivity enables the detection of all metabolites present in a 
specific metabolic cycle, particularly the ones below the NMR detection limit.  
In view of the fact that during my PhD I have been involved in hypothesis-generating 
studies, the untargeted approach obviously was the one to be chosen, and NMR was the 
analytical platform utilized for all the analyses. 
 
1.5 NMR-based metabolomic workflow 
A workflow scheme of a typical untargeted NMR-based metabolomic study is 
presented in Figure 2.  
 
 
Figure 2. A typical untargeted NMR metabolomic experimental pipeline. 
 
Sample collection, handling, storage and preparation constitute the first step of a 
metabolomic analysis, and the adoption of standard operating procedures is essential 
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to best maintain sample stability and obtain reproducible results. Thus, specimens that 
are not collected, stored or processed uniformly can be corrupted and the data 
obtained from analyses of these samples can be invalid or erroneous.  
Sample preparation can vary widely, depend on the chosen analytical technique, and 
processes such as extraction or buffering could be necessary. The second step involves 
analysis of the samples by NMR spectroscopy with appropriate pulse sequences. 
Before statistical analysis, the analytical data obtained are subjected to pre-processing 
(alignment, phasing, baseline correction, bucketing) and pre-treatment procedures 
(normalization, centering, scaling) to make metabolomic features more comparable18. 
Since metabolomics generates large amount of data, multivariate statistical analyses 
are always performed alongside with the common univariate analyses (i.e. student’s t 
test, analysis of variance, Kruskal–Wallis test, Wilcoxon signed-rank test). Generally, 
the initial experimental hypothesis guides the selection of the appropriate statistical 
algorithm. Many pattern recognition methods can be applied to assess how the spectra 
of biological samples, belonging to the groups of interest, cluster. Principal component 
analysis (PCA), cluster analysis and correlation analysis are most used methods for 
unsupervised analyses, together with partial least squares discriminant analysis (PLS-
DA), orthogonal projection to latent structure discriminant analysis (OPLS-DA), 
canonical analysis (CA) and support vector machines (SVMs) for supervised 
discriminations6. The robustness of the calculated models needs also to be checked to 
avoid overfitting of the data using internal cross-validation procedures, permutation 
tests or receiver operating characteristic (ROC) curve estimation, or using an external 
independent validation set when available.  
Finally, the statistically significant metabolites among the groups of interest can be 
placed in metabolic networks, by using on line tools like MetaboAnalyst19, to enable 
biological understanding of occurring phenomena and to provide new insights into 
fundamental mechanisms of diseases. 
 
1.6 State-of-the-art of metabolomics and biomedicine 
In the past decades, biomedical research has been led by the fundamental assumption 
that many chronic or serious pathologies should have genetic origins; therefore, huge 
efforts aimed at characterizing the whole human genome, transcript profiles and single 
nucleotide polymorphisms (SNPs) have been made. The Human Genome Project 
indeed revolutionized biomedical research and provided fundamental insights into 
biology, but the expected “genetic revolution” has yielded far fewer results than 
originally expected for diagnosis, prevention and treatment of human diseases20,21. 
This phenomenon could be explained by considering more-recent epidemiological 
surveys, which have revealed the crucial role of environment on disease development 
and risk of death, underlying the importance of the epigenome and the 
microbiome7,22,23. Metabolomics, which monitors the global outcome of all influencing 
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factors (exogenous and endogenous) without making assumptions about the effect of 
any single contribution to that outcome, overcomes any differences and as such could 
be a perfect tool to investigate and understand the molecular mechanisms of human 
health and disease16. Unlike genes and proteins, metabolites are easier to correlate 
with phenotype and serve as direct signatures of biochemical activity, since they play 
a central role in disease development, cellular signaling and physiological control. For 
these reasons, many biomedical fields, summarized in three broad areas in Figure 3, 
could benefit from metabolomic studies.  
 
 
Figure 3. Applications of metabolomics in biomedical research. Adapted from Nicholson et al.16. 
 
Classically, metabolomics is applied to characterize disease metabolic profiles with the 
intent of discovering new biomarkers and identifying biochemical pathways involved 
in disease pathogenesis. Metabolomics has already increased our understanding of 
comprehensive cellular and physiological metabolism helping to identify many 
unexpected chemical causes for several important chronic and complex diseases, such 
as cancer4,24,25, cardiovascular diseases2,26, and diabetes27,28. Furthermore, the 
metabolomic approach can also offer a cost-effective and productive route to uncover 
new targets for drug discovery. Actually, not only most prominent diseases such as 
cardiovascular diseases, hypertension, obesity, or diabetes have undeniable metabolic 
basis, but also many other chronic and serious illnesses have been found to have 
unexpected or underappreciated metabolic causes29–34. 
For all the abovementioned research potentials, metabolomics represents a powerful 
tool in biomedicine with the most ambitious objective of detection of early metabolic 
perturbations even before the manifestation of disease symptoms, providing new 
promise for early diagnosis, preventing therapies and precision medicine approaches. 
The goal of precision medicine is indeed to customize subjects’ therapeutical 
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treatments according to their specific omic-profiles (individual profiling). In current 
clinical practice, small numbers of molecules have been used to diagnose complex 
metabolic diseases (e.g. blood glucose for diabetes, blood phenylalanine for 
phenylketonuria); conversely, current metabolomic technologies go well beyond the 
scope of standard clinical chemistry techniques and achieve detection of dozens to 
hundreds of metabolites. Metabolomics enables patient diagnosis and prognosis, 
prediction of individual response to drug treatment (pharmacometabolomics) and 
monitoring of therapies and lifestyles interventions; therefore there can be little doubt 
that metabolomics can play a crucial role into informing the practice of precision 
medicine7. 
Finally, metabolic profiling of populations could enable the development of the so 
called 'molecular epidemiology', defined as the ability to assess the susceptibilities of 
specific groups of individuals to disease16. This might allow the development of novel 
risk tests for screening and prevention, with future implications for health screening 
programs.  
For the sake of completeness, it is important to underline that the use of the 
metabolomic approach is not confined to human medicine. Several potential 
applications in the veterinary industry are possible, in particular in the framework of: 
disease diagnosis and investigation, optimization of health and production, drug 
discovery and animal welfare35. 
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Chapter 2 
2. Aims of the thesis 
 
 
Metabolomics is an emerging technology that holds promise of powerful insights into 
the mechanisms of health and disease. In this methodological thesis, different topics 
will be addressed and discussed with the aim of demonstrating the potential of NMR-
based metabolomics in biomedicine, with particular attention paid to:  
1) provide a means to predict response and recurrence of diseases. Specifically, 
robust statistical models were built with the aim of developing novel risk tests for 
screening and prevention using data from large multicenter studies, regarding 
breast cancer risk of recurrence in early stage patients, and patient risk of death 
within 2-years after acute coronary syndrome;  
2) provide predictive, prognostic, and diagnostic markers/fingerprints of distinct 
pathological states, such as primary biliary cirrhosis, Alzheimer’s disease, and 
chronic inflammatory rheumatic diseases, to uncover the underlying molecular 
mechanisms of diseases, and to enable stratification of patients based on metabolic 
pathways impacted by the diseases;  
3) prove the usefulness of metabolomics in the framework of precision medicine by 
a) unraveling biomarkers/fingerprints for drug response phenotypes, providing 
an effective means to predict variation in individual response to treatment 
(pharmacometabolomics). In particular, the effects of steroid treatment and 
withdrawal in patients with chronic obstructive pulmonary disease has been 
assessed; b) describing the molecular individual response to life style 
interventions, such as the effects of a healthy life style in women at increased risk 
to develop breast cancer, or to stressful situations, like a 6-months spaceflight; and 
c) characterizing the human metabolic phenotype, in particular age and sex effects 
on plasma metabolic phenotype and on metabolite association networks in healthy 
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subjects. The investigation of how common variables influence the expression of 
the metabolic phenotype is actually a critical component for development of 
metabolomics as a population screening and precision medicine platform. 
4) Furthermore, the potential applications of metabolomics in veterinary research 
has been investigated by characterizing the blood metabolic profiles of calves with 
acute bronchopneumonia and monitoring the effects of boron supplementation on 
peripartum dairy cows’ health as a treatment to prevent the negative energy 
balance (NEB) at the onset of lactation via blood metabolomic analysis. 
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Chapter 3 
3. Methodological aspects 
 
 
3.1 NMR metabolomic analysis 
NMR spectroscopy exploits the behavior of molecules when placed in a magnetic field 
and irradiated with specific radiofrequency waves, to identify different nuclei (with 
nonzero spin) based on their resonance frequency. One-dimensional (1D) 1H NMR 
spectroscopy is the most widely used approach in metabolomics; therefore, compared 
to other applications of NMR, the pulse sequences employed in metabolomics require 
a lower level of sophistication and relatively more rapid acquisition times.  
The main problem that must be addressed in any NMR sequence used for metabolomic 
scopes is the detection of hydrogen nuclei (protons) of biological molecules in  aqueous 
samples at μM or lower concentrations against a background concentration of 110 M 
water protons36. Thus, suppression of the water signal is definitely required. The most 
widespread solvent suppression method used is the so-called presaturation: the water 
resonance is selectively saturated by frequency irradiation with a long (typically 2 s), 
low power RF pulse before the acquisition phase, thus leading to a suppression of its 
signal. The big advantage of this technique is the high chemical shift selectivity; 
conversely, the main disadvantage comes from the long duration of the pulse applied 
that induced also the saturation of hydrogen atoms in chemical exchange with water 
(e.g. urea protons) and protons having signals under the water line36. 
According to the properties of the biospecimen under study, different NMR sequences 
can be used to collect metabolomic data. The most widespread pulse sequence used is 
1D 1H-Nuclear Overhauser Effect SpectroscopY (NOESY); NOESY spectra present 
signals from both low- and relatively high-molecular weight metabolites, providing a 
highly reproducible, robust and high-quality method to obtain the complete overview 
of the sample metabolome. As an example, a typical 1H NMR spectrum of urine contains 
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thousands of sharp lines mainly from low molecular weight metabolites (Figure 4), 
while blood plasma or serum contain both low and high molecular weight components 
(Figure 5A): broad signals from macromolecules (e.g. proteins, lipids and lipoproteins) 
contribute strongly to the NMR profile, with sharp signals from small molecules 
superimposed on them. The reference compound usually used in aqueous samples is 
the sodium salt of 3-trimethylsilylpropionic acid (TMSP) with the methylene groups 
deuterated. 
 
 
 
Figure 4. 600 MHz 1H NOESY NMR spectrum of a urine sample. The spectrum is calibrated at the 
trimethylsilyl-[2,2,3,3-2H4]propionate (TMSP) signal (0.0 ppm). Residual water signal (*) after 
presaturation is also reported. Only sharp signals due to the presence of low molecular weight metabolites 
are present. 
 
Standard NMR pulse sequences can be used, in biofluids like blood plasma, serum and 
CSF, to selectively highlight the signals from low-molecular weight metabolites or to 
enhance only the contributions from macromolecules. The 1H Carr–Purcell–Meiboom–
Gill (CPMG) spin-echo sequence37 exploits the different NMR transverse relaxation 
times of low and high molecular weight molecules to remove signals of 
macromolecules  through T2-spectral editing (Figure 5B). Conversely, the 1H diffusion-
edited pulse sequence is routinely used to effectively suppress small molecule 
resonances on the basis of molecular diffusion coefficients, making it possible to 
selectively study macromolecule profiles (Figure 5C)36. 
In order to obtain high quality and robust NMR data, exchange data among 
laboratories, create NMR databases of small biological molecules, and enable the wide 
diffusion of metabolomics applications, best practices and standard NMR sequences 
need to be adopted. Therefore, for samples that contain just low molecular weight 
metabolites, like urine, 1D 1H NOESY spectra are the standard spectra acquired to 
accomplish a metabolomic analysis; instead, for samples like blood serum or plasma 
1D 1H NOESY, 1H CPMG, and 1H diffusion-edited spectra are standardly acquired 
providing a complete analysis of both low and high molecular weight molecules. 
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Figure 5. 600 MHz 1H NMR spectra of a serum sample: A) NOESY presat spectrum; B) Diffusion-edited 
spectrum; C) CPMG spectrum. The spectra are calibrated at the anomeric glucose signal (5.24 ppm). 
Residual water signal (*) after presaturation is also reported. 
 
As abovementioned, the use of 2D NMR spectroscopy in metabolomics is limited; 
usually, only small sample arrays are analyzed with these kinds of approaches with the 
aim at increasing signal dispersions to simplify the spectra, thereby making spectrum 
assignment easier. These spectroscopic methods include 2D J-resolved experiments38 
(Figure 6), which provide information on the multiplicity and coupling patterns of 
resonances, but also correlation spectroscopy (COSY) and total correlation 
spectroscopy (TOCSY) experiments, which provide spin–spin coupling connectivity, 
giving information on which protons of a molecule are close in terms of chemical 
bond36. 
 
 
 
Figure 6. 600 MHz 2D 1H-1H J-resolved NMR spectrum of blood serum. 
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Other types of nuclei with spin I = ½, such as naturally abundant 13C, 15N or 31P, can be 
used to perform heteronuclear experiments, such as the 1H-13C HSQC experiment. 
These 2D experiments require much longer acquisition times than the standard 1D 
pulse sequences, and therefore are used only to help identify and assign metabolites in 
the NMR spectra39,40.  
Furthermore, 31P NMR can be used to study cellular energy states also in vivo, and 13C 
detection enables the study of metabolic reaction rates (fluxes) to elucidate the 
dynamics and mechanisms of metabolite transformations and regulations 
(fluxomics)41. 
For the sake of completeness, it is important to mention that NMR metabolomic 
analysis can be extended also to intact tissues via High Resolution Magic Angle 
Spinning (HR-MAS) NMR spectroscopy. Indeed, using this technology the effects of 
line-broadening mechanisms seen in conventional NMR spectra of non-solution state 
samples are attenuated by the rapid rotation of the sample around an axis that is 
inclined at an angle of 54.7356° (magic angle) with respect to the external main 
magnetic field, yielding well-resolved NMR spectra42. 
 
3.2 Spectral pre-processing and pre-treatment 
NMR data pre-processing and pre-treatment can be considered as an intermediate step 
between recording of raw spectra and performing statistical analysis. These 
procedures make metabolomic features more comparable, ensuring thus more robust 
and accurate analyses and modelling. 
For NMR data, raw free induction decay (FID) phasing, baseline correction and 
referencing to an internal standard (usually TMSP at 0.0 ppm or, if there are proteins 
like albumin in blood that bind TMSP, the anomeric glucose peak at 5.24 ppm) are 
considered pre-processing procedures. 
Binning is the widespread pre-treatment procedure applied to NMR processed data, it 
is a way to reduce the number of total variables, to cope with subtle chemical shift 
variability, and to filter noise from the data. NMR spectra are simply subdivided into 
bins and each bin is integrated to obtain a matrix of variables. 
There are many methods for pre-treatment of data matrices of the sort produced by 
NMR metabolomic spectra; the three most applied ones are centering, normalization 
and scaling.  
Centering is an operation performed across the samples to convert all the 
concentrations to fluctuations around zero instead of around the mean of the 
metabolite concentrations by subtracting from each bin the mean of that chemical shift 
bins (column mean). Therefore, it adjusts for differences in the offset between 
metabolites present in high and low concentrations. 
Metabolite concentrations in biofluids can vary on a large dynamic range and,  as in 
urine, may be subject to significant dilution variations, thus leading to considerable 
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heterogeneity in the data43. Normalization is an operation performed across samples 
to reduce between-sample variation. The most popular normalization technique is 
total integral normalization, where each bin of a spectrum is divided by the total 
spectral intensity of that sample; however, more sophisticated method can be also 
applied. In particular, Probabilistic Quotient Normalization (PQN)44 is a more accurate 
and more robust alternative to the total integral normalization when large variations 
of dilution occur (e.g. in urine samples). PQN assumes that biologically interesting 
concentration changes influence only few parts of the NMR spectrum, while dilution 
effects will affect all signals. PQN involves an integral normalization of each spectrum 
and the calculation of a reference spectrum, such as a median spectrum. Then, for each 
bin of each spectrum, the quotient with respect to the reference spectrum is calculated 
and the median of all quotients is estimated. Finally, all bins of each spectrum are 
divided by the median quotient43. 
Scaling methods are data pretreatment approaches that divide each variable (bin or 
metabolite) by a factor, the scaling factor, which is different for each variable. The aim 
is to adjust for the fold differences between the different metabolites, making profiles 
more comparable. These methods are often used when, within the same dataset, data 
from different sources (i.e. metabolomic and clinical data) need to be analyzed. 
 
3.3 Statistical analysis 
Since NMR metabolomic analysis generates large amount of complex data, in order to 
obtain accurate and comprehensive results, statistical matters must constitute a crucial 
part of a metabolomic study. Multivariate statistical approaches are routinely used to 
visualize biological data, to identify possible clusters among the conditions of interest, 
and to build predictive models; conversely, univariate statistical methods are used to 
identify metabolites and thus metabolic pathways altered in response to physiological 
or pathophysiological specific conditions. 
Multivariate statistical approaches can be divided in two main classes: unsupervised 
and supervised methods. Unsupervised learning methods are utilized to summarize, 
explore, and discover clusters or trends in the data unlabeled with any class 
membership; therefore, no prior assumptions or knowledge of the data are needed45. 
Unsupervised methods represent usually the first step in data analysis, helping to 
visualize data and to discover possible outliers.  
Among the different unsupervised machine learning methods, principal component 
analysis (PCA)46 and cluster analysis are the most popular methods. PCA is a dimension 
reduction technique, which enables to express the variance within a dataset in a new 
reduced matrix of variables, the principal components (PCs), each of them orthogonal 
and independent from all the others. Each PC is a linear combination of the original 
variables (bins), so each successive PC shows the maximum percentage of possible 
variance, not represented in the previous PCs. As a consequence, while the first 
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principal components contain the largest percentage of variance and thus the greatest 
content of meaningful information, the last ones are far less important and express 
mostly noise.  
Geometrically PCA can be viewed as a rotation of the reference system to maximize the 
data structure and minimize noise: the original data matrix (X) can be described 
through two new matrices, the score matrix T and the loading matrix P (Equation 1). 
 
T  X	P                                                                      (1) 
 
The score matrix T encloses the coordinates of the original data in the new principal 
component space, each column represents the coordinates of all the samples along a 
particular PC. The score matrix T represents a simplified description of the original 
observations in the new lower dimensional space while maintaining all the 
relationships present among the original data.  The first columns of the matrix T 
(usually the first two or three), that contain the largest amount of variance, can be 
plotted together in the so-called score plot (Figure 7A); in this plot each sample is 
represented by a dot and based on the distances among the dots data distributions, 
clusters or outliers can be visualized. Similarly, the coefficients of the linear 
combinations that describe the main components in terms of the experimental 
variables are arranged in the loading matrix P, these coordinates describe the 
coefficients responsible for the separation among the groups of interest (Figure 7B). 
 
 
 
Figure 7. Example of PCA analysis. A) Score Plot: PC1 vs PC2, each dot in the plot represents a different 
sample; black dots: group 1; white dots: group 2; gray dots: group 3. B) Loadings Plot of PC1. Most 
significant metabolites in the score plot showed the highest loadings in the PC1. 
 
Cluster analysis aims at clustering experimental units into classes according to 
similarity criteria; classes are built by maximizing homogeneity within each class and 
inhomogeneity among the different classes. K-means and Hierarchical Cluster Analysis 
are the main used approaches. 
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In contrast to the unsupervised methods just described, supervised approaches use a 
priori knowledge to generate models that are tightly focused on the effects of interest. 
These approaches can be divided in two main classes: projection based methods and 
machine learning methods. Among the former, Projections to Latent Structures by 
Partial Least Squares (PLS)47 is the most widely used method; its robustness in the 
presence of highly correlated variables and its ability to provide highly predictive 
models using a small number of latent variables makes it useful to address the study of 
a large number of systems48. PLS can be thought as the supervised extension of PCA, it 
addresses the data reduction problem in a regression-based framework: instead of 
describing the maximum variation in the measured data (X), which is the case for PCA, 
PLS aims at deriving latent variables, analogous to PCs, which maximize the co-
variation between the measured data (X) and the response variable (Y) regressed 
against49. This algorithm can be used for classification purposes as PLS discriminant 
analysis (PLS-DA), using a ‘dummy’ Y matrix that comprises an orthogonal unit vector 
for each class. Orthogonal signal correction partial least squares discriminant analysis 
(O-PLS-DA) is an extension of PLS which uses orthogonal signal correction to maximize 
the explained covariance between X and Y on the first latent variables (n-1 variables, 
with n the number of groups of interest), and all the orthogonal (or unrelated) variance 
in the other following latent variables. 
A more sophisticated version of the PLS is the multilevel PLS50 which enables the 
analysis of within-subject variability without being confounded with the other 
variation sources (e.g. matched samples of the same subject at two time-points, or two 
repeated measurements on the same sample). In a multilevel PLS between-subject 
variation is separated from the within-subject variation by subtracting the individual 
specific average, and only the within-subject variation is analyzed. 
Reduction techniques like PCA and PLS can be used in combination with Canonical 
Analysis (CA) to enhance group discriminations. CA finds discriminant projection by 
maximizing between-class distance and minimizing within-class distance (e.g. 
maximize the ratio between the two values). 
Machine learning supervised methods are widely used for classification and prediction 
purposes, they enable the resolution of the problem of identifying to which set of 
groups a new observation belongs (e.g. healthy or diseased), on the basis of an existing 
training dataset containing observations whose group memberships is known. k-
Nearest Neighbours (k-NN)51, Support Vector Machines (SVMs)52 and Random Forest 
(RF)53 can be considered the most widespread algorithms.  
k-NN is probably the simplest non-parametric method to classify a new object into one 
of k classes. This method works in a local neighborhood around of the considered test 
object to be classified. The neighborhood is usually determined by the Euclidean 
distance, and the closest k objects of the training set are used for estimation of the 
group membership of the new object54. As a consequence, k is the fundamental 
parameter to be set: small k values can lead to the construction of a model subject to 
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significant statistical fluctuations, while large k values can reduce statistical errors but 
flatten many details of the distribution (Figure 8A). 
SVMs are statistical techniques that enable sample classification based on the 
boundaries between classes comprising the whole data set. SVMs identifies a line, a 
plane, or, for more than three dimensions, a hyper-plane that maximizes the separation 
between the two classes (Figure 8B), creating thus a classifier. The hyper-plane found 
by the SVMs in the feature space corresponds to a non-linear decision boundary in the 
input space. 
 
  
Figure 8: Classification of an unknown object (white triangle) among two groups (grey dots and black 
squares) with different methods: A) k-NN classification; B) SVM. 
 
Random forests is a relatively new and powerful approach for data exploration and 
predictive modelling. The classification is derived from a randomly grown ensemble 
(forest) of decision trees based on the following steps: 1) the original data are 
randomly divided using bootstrapping into a training and test set; 2) an ensemble of 
decision trees is grown using the training set, where each of the trees is built on 
randomly selected variables (bins) at each decision node; 3) as soon as all the trees are 
built an unbiased assessment of the classification error using the out-of-bag samples is 
performed, enabling the estimation of the model performances55. Furthermore, for 
each sample, the percentage of trees in the forest that assign one sample to a specific 
class can be inferred as a probability of class belonging, making this approach very 
useful for predictive modelling purposes. 
Modeling results need to be validated by simply using an independent validation set 
(when available) or with more sophisticated approaches like cross-validation schemes. 
Cross-validation (CV) techniques create a random internal validation set by removing 
one (Leave-One-Out, LOO) or many (Leave-Many-Out, LMO) samples from the training 
set. The model is built on the training set and the removed samples are used to assess 
the model performances generating a confusion matrix that express sensitivity, 
specificity, and accuracy. Sensitivity is defined as the ratio between true positives (TP) 
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and all positives (P), while specificity is the ratio between true negative (TN) and all 
negatives (N). Accuracy is defined as the ratio between the sum of TP and TN, and the 
total population analyzed (P+N). Furthermore, permutation tests can be used to 
calculate the statistical significance of a model. 
In order to find a metabolite or panels of metabolites that can be considered possible 
new biomarkers of a specific pathology or condition under investigation, each 
metabolite needs to be analyzed independently from all the other without considering 
any possible interactions. Univariate statistical analysis is the key to achieve this goal: 
statistical tests, correlation analysis and Receiver Operating Characteristic (ROC) 
curves are the most used approaches. 
On the biological asymptotic assumption that metabolite concentrations are not 
normally distributed, non-parametric tests must be utilized. Wilcoxon Rank Sum test56 
is the non-parametric analogue of the t-test to compare two groups. The null 
hypothesis (H0) claims that two randomly selected samples from two populations 
actually belong to the same population, and as a consequence, their medians are equal; 
the alternative hypothesis (Ha) states that H0 is false and the two population are 
distinct, and therefore, their medians are different. It is worth mentioning that this test 
is nearly as efficient as the t-test on normal distributions, and a variant of this test, the 
Wilcoxon signed-rank test57, also exists that is suited when comparing two related 
samples, matched samples, or repeated measurements on the same sample to assess 
whether their population median ranks differ. Kruskal-Wallis test58 (analogue of the 
parametric analysis of variance) is the extension of the Wilcoxon Rank-Sum test for 
comparison of three or more groups. 
The output of all these tests is a P-value: it expresses the probability of obtaining the 
same as, or of greater magnitude value than, the actual observed results, when the null 
hypothesis is true. Conventionally, when the P-value is less than the significance level 
of 0.05 or 0.01 the null hypothesis is rejected. However, since P-values are strongly 
dependent on the total number of analyzed samples, usually a huge number in 
metabolomics, multiple testing corrections need to be adopted: Bonferroni59 and 
Benjamini-Hochberg60 are the most widespread methods.  
Furthermore, effect size analysis which is independent of the population size can be 
also performed. Effect size is a quantitative measure of the strength of a phenomenon 
and it expresses how different sample means are. For non-parametric data, like 
metabolite concentrations, Cliff’s delta (d) is the utilized test61, and it measures how 
often one value in one distribution is higher than the values in the second distribution. 
Cliff’s delta ranges between +1 when all values of one distribution are higher than the 
ones of the other distribution, and -1 when reverse is true. Two overlapping 
distributions would have d of 0. According to the usual convention, an absolute value 
of d (|d|) lower than 0.147 means a negligible effect, |d| lower that 0.33 but larger than 
0.147 means a small effect, |d| lower that 0.474 but larger than 0.33 means a medium 
effect, and |d| higher than 0.474 represents large effects. 
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ROC curves are graphical representations that illustrate the diagnostic ability of a 
binary classifier system as its discrimination threshold is varied (Figure 9A). These 
plots show false positives (1-specificity) on the horizontal axis, and the true positives 
on the vertical axis (sensitivity). Accuracy is measured by the area under the ROC curve 
(AUC). An area of 1 represents a perfect test; an area of 0.5 represents a worthless test. 
Pearson correlations can be calculated to test whether there is an association, 
understood as linear dependence, between metabolites and clinical data or biological 
features (Figure 9B). Correlations are expressed by a coefficient (R) which ranges 
between +1 (totally correlated), 0 (no correlation) and -1 (totally anticorrelated). 
 
 
Figure 9. Univariate statistical analyses: A) ROC curve; B) Pearson correlation of two variables. 
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Chapter 4 
4. Results 
 
 
4.1 Metabolomics in molecular epidemiology 
The usefulness of metabolomics for molecular epidemiology to build novel risk tests 
for screening and prevention is probably the most innovative topic explored in this 
work of thesis. Our studies demonstrated that the NMR-based metabolomic approach 
can be successfully applied to build statistical models able to predict the prognosis of 
early-stage breast cancer (eBC) and acute coronary syndrome (ACS) patients 
independently from traditional established clinicopathological risk factors. 
In the precision medicine era, development of tailored oncological treatment for BC is 
lagging; moreover, clinical studies have clearly demonstrated that, although adjuvant 
chemotherapy improves disease free survival, many patients remain disease free after 
surgery alone62. The ability to discern between patients with eBC at high risk of disease 
recurrence, and those who need to be cured by locoregional therapy alone would 
represent an invaluable tool for clinicians, offering more aggressive adjuvant therapies 
to the former group and preventing the latter one from treatments whose benefit-risk 
ratio is poor. Metabolomics provides the analysis of subjects and their biological 
idiosyncrasies within the dynamic context of a disease process, considering both the 
effects that a cancer exerts upon an individual, and the individual upon the cancer, and 
therefore represents a valuable tool to stratify eBC patients.  
We analyzed via NMR serum samples collected in the framework of two phase III breast 
cancer clinical trials run by the International Breast Cancer Research Foundation in 
South Asia and Africa for a total of eleven different hospitals involved; for this reason, 
as far, this study represents the broadest multicenter metabolomic breast cancer study 
published. The cohort of 699 breast cancer patients enrolled was divided according to 
the cancer stage in metastatic (109) and early (590) patients, among which 127 
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developed recurrence in the 6-years after surgery and tamoxifen treatment, and their 
serum samples were analyzed with the aim of predicting the real risk of disease 
relapse. 
Our results (see paragraph 4.1.1) show not only that the serum metabolomic patterns 
can discriminate between early and advanced breast cancer patients (90% 
discrimination accuracy), but also that the score built using our model is prognostic for 
disease recurrence in a validation set (prediction accuracy 71%, AUC 0.747), 
independent of traditional risk factors (e.g. hormone receptor status, HER2 status, 
nodal status, tumor size). All these data confirmed the results published previously by 
our group in a smaller single center study63. Moreover, survival analysis of the early 
group (see paragraph 4.1.2), subdivided according to primary tumor size (T) and nodal 
status (N), particularly emphasized the performance of the metabolomic prediction 
within the T>1N0 group (hazard ratio [HR] 3.5, 95% CI 1.7-7.3; P=0.0012), probably 
the most complex for the decision of recommending - or not - adjuvant therapy.  
In the same application field, we investigated the metabolomic fingerprint of acute 
coronary syndromes (ACS), the most common cause of emergency hospital admission 
also associated with the highest mortality and morbidity, by analyzing patient serum 
samples with the aim of evaluating the possible role of NMR metabolomics in the 
prognosis stratification. For this purpose, 978 serum samples of post ACS patients 
(samples were collected in the 24-48 h after the cardiovascular event) were analyzed 
according to their 2-year outcomes: 832 survivors and 146 deaths. We found that the 
metabolic fingerprint is able to discriminate patients who died within two years after 
the ACS event from long survivors (see paragraph 4.1.3) with a high accuracy (78.2% 
discrimination accuracy, 0.859 AUC) and this result was duplicate in a validation set 
(72.64% predictive accuracy, 0.801 AUC). To the best of our knowledge, this is the first 
study which assessed the capability of metabolomics to predict mortality in the setting 
of acute coronary syndromes. Furthermore, the score built using our model showed to 
be independent from the classical clinical parameters and the widely used GRACE 
(Global Registry of Acute Coronary Events) score, and to achieve better results in 
predicting all-cause death within two years from ACS considering both logistic 
regression and ROC analysis. Using a metabolomic profiling approach, we also found 
that short survivors are characterized by significantly higher levels of 3-
hydroxybutyrate, proline, creatinine, acetate, acetone, formate and mannose, and 
significantly lower levels of valine and histidine.  
Our data support the usefulness of the metabolomic approach to identify a more 
precise risk profile in ACS patients by identifying a metabolic fingerprint associated 
with a poor prognosis, and therefore, by recognizing those patients who need to 
undergo a very early and aggressive treatment. 
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4.1.1 Serum metabolomic profiles identify ER-positive early breast cancer 
patients at increased risk of disease recurrence in a multicentre population 
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Supplementary materials: 
Supplementary figure S1 - Receiver operator characteristic (ROC) analysis of the RF risk score 
as a predictor of relapse in the initial cohort, for CPMG spectra: A) training set; B) validation 
set. 
 
 
 
 
Supplementary figure S2 - Spectral clustering by treatment centre, demonstrated by score plots 
of the first three components of unsupervised PCA using (A) the entire dataset, and (B) the 
reduced data-matrix (bins related to lactate removed). In these plots each dot represents a 1H 
NMR CPMG patient spectrum. The colors represent the sample provenance: red, Vietnam, 
Hanoi - Hospital K; orange, Philippines, Manila - PGH; yellow, Vietnam, Danang - Danang 
General; green, Philippines, Cebu - Vicente Sotto Hospital; cyan, Philippines, Manila - Santo 
Tomaso Hospital; turquoise, Philippines, Manila - Rizal; sky blue, Philippines, Manila - East 
Avenue; blue, Nigeria, Ibadan - University College Hospital; purple, Bangladesh, Dhaka - Dhaka 
Medical College; magenta, Bangladesh, Khulna - Khulna Medical College; pink, Bangladesh, 
Dhara - BSMMU. 
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Supplementary figure S3 - Clustering of serum metabolomic profiles using Random Forest 
classification to discriminate EBC patients according to different clinicopathological 
parameters. This illustrates the degree to which each parameter influences the spectra. A) Age 
of patients, divided into two groups using the median age as threshold (red dots - age < 43 
years; blue dots - age {greater than or equal to} 43 years); B) HER2 positivity (red dots - HER2 
positive; blue dots - HER2 negative); C) Size of the tumor (red dots - size {less than or equal to} 
5 cm; blue dots - size > 5 cm); D) Nodal status (red dots - node negative; blue dots - node 
positive); E) Grade of the tumor (red dots - grade 1; blue dots - grade 2; green dots - grade 3). 
For each analysis the confusion matrix is also reported. 
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Supplementary figure S4 - Illustration of the significant differences in metabolomic spectra 
between serum samples from current study and those from the MSKCC cohort used in a 
previous study. Differences due to location far overwhelm differences between EBC and MBC 
spectra, and preclude the RF risk score from predicting relapse. A. Clustering of CPMG spectra 
using first two components of supervised PCA-CA. Each dot represents an EBC patient and each 
triangle a MBC patients. In red are reported the samples collected for this study and in green 
the MSKCC samples. The confusion matrix and the accuracy of the discrimination between the 
samples of the two studies are also reported. B. Predictive ability of the RF risk score developed 
on the MSKCC data set in the current cohort, using ROC analysis. AUC and the confusion matrix 
are presented for the CPMG RF scores, calculated using the model built on the MSKCC samples, 
in the test set. 
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Supplemental Table S1 - Comparison of individual metabolite concentrations in arbitrary units 
in the serum NMR spectra of EBC and MBC patients, for a single centre (Philippines General 
Hospital - PGH). Adjusted P-values are for the significance of any difference between EBC and 
MBC. MAD = median absolute deviation. 
 
  PGH 
      EBC    MBC    
  Median MAD Median MAD P-value   
Choline 
Higher levels 
in MBC 
373.02 530.59 611.49 612.46 > 0.05   
Methionine 112.32 25.28 144.36 25.44 2.23E-02   
Formate 12.85 3.38 16.18 5.36 4.76E-02   
Citrate 104 18.05 129.18 27.65 2.23E-02   
Phenylalanine 313.47 78.57 379.41 57.07 2.23E-02   
Lactate 1524.8 277.18 1774.02 435.75 > 0.05   
Acetate 432.07 160.24 499.07 127.67 > 0.05   
Glutamate 383.41 95.27 435.07 135.42 > 0.05   
Glycine 965.14 276.75 1094.29 193.79 > 0.05   
Leucine 719.97 210.22 811.03 199.2 > 0.05   
Alanine 2151.05 368.72 2367.21 449.61 > 0.05   
Mannose 67.74 13.79 73.23 17.16 > 0.05   
Proline 96.51 25.34 103.75 33.78 > 0.05   
Creatinine 189.83 34.73 200.97 62.74 > 0.05   
Tyrosine 195.01 45.46 204.89 42.98 > 0.05   
Isoleucine 194.88 41.6 198.94 41.48 > 0.05   
Valine 1250.74 219.42 1274.87 282.54 > 0.05   
Creatine 159 55.47 160.32 31.91 > 0.05   
Glucose 
Lower levels 
in MBC 
3275.59 395.92 3209.56 433.32 > 0.05   
Histidine 193.82 43.51 188.92 43.72 > 0.05   
3-hydroxybutyrate 63.66 36.63 61.81 29.25 > 0.05   
Glutamine 77.19 36.52 59.7 50.14 > 0.05   
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Supplementary Table S2 - Comparison of individual metabolite concentrations in 
arbitrary units in the serum NMR spectra of relapsing and non-relapsing EBC patients. 
Adjusted P-values for the comparison of relapsing and non-relapsing EBC Adjusted P-
values are for the significance of any difference between EBC and MBC. MAD = median 
absolute deviation. 
 
 
 EBC with recurrence EBC without recurrence Adjusted P-value 
  Median MAD Median MAD  
Phenylalanine 
Higher levels in 
EBC with 
recurrence 
265.537 74.807 191.621 43.661 5.66E-08 
Leucine 637.139 192.335 460.075 94.221 1.09E-04 
Histidine 173.526 46.016 136.511 23.005 1.09E-04 
Glutamate 304.663 112.451 253.009 120.452 4.12E-02 
Glycine 818.751 216.682 726.373 169.731 4.12E-02 
Tyrosine 166.198 42.299 148.327 25.349 4.36E-03 
Acetate 338.31 171.11 305.928 208.532 > 0.05 
Formate 11.579 3.381 10.574 3.3 > 0.05 
Lactate 1319.428 274.716 1209.747 319.439 4.83E-02 
Valine 1176.013 205.037 1091.636 142.323 4.43E-02 
Proline 93.228 26.273 86.778 22.181 > 0.05 
Isoleucine 172.142 39.988 162.562 29.006 6.76E-03 
Alanine 1946.47 399.423 1902.673 343.637 > 0.05 
Choline 298.2 459.43 148.25 253.23 4.83E-02 
Glucose 
Lower levels in EBC 
with recurrence 
3291.47 348.202 3297.304 262.102 > 0.05 
Citrate 110.867 22.105 112.61 20.218 > 0.05 
Methionine 114.868 25.027 117.193 26.012 > 0.05 
Creatine 141.096 43.452 147.571 39.941 > 0.05 
Mannose 67.697 13.56 71.275 13.901 > 0.05 
Creatinine 185.727 36.025 196.867 35.02 > 0.05 
3-Hydroxybutyrate 79.355 51.141 86.638 48.975 > 0.05 
Glutamine 93.457 41.566 113.765 52.878 > 0.05 
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4.1.2 De-escalating and escalating treatment beyond endocrine therapy in 
patients with luminal breast cancer 
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4.1.3 NMR-based Metabolomics identifies high risk of death patients within two 
years after acute coronary syndrome. Metabolomics in the AMI-Florence II 
study 
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NMR-based Metabolomics identifies high risk of death patients within two years 
after acute coronary syndrome 
 
Metabolomics in the AMI-Florence II study 
 
 
  
Abstract 
Background. Risk stratification and management of patients continue to be 
challenging despite considerable efforts made in the last decades by many clinicians 
and researchers.  
 
Objectives. The aim of this study was to investigate the metabolomic fingerprint of 
acute coronary syndromes using nuclear magnetic resonance spectroscopy of patient 
serum samples and to evaluate the possible role of metabolomics in the prognostic 
stratification of ACS patients. 
 
Methods. 978 ACS patients were enrolled for the study, among these 146 patients died, 
whereas 832 survived within 2 years from the ACS. Serum samples were analyzed via 
high resolution 1H-NMR and the spectra were used to characterized the metabolic 
fingerprint of patients. Multivariate statistics were used to create a prognostic model 
for the prediction of death within 2 years from the cardiovascular event. 
 
Results. In the training set, metabolomics showed significant differential clustering of 
the two outcomes cohorts. A prognostic risk model predicted death with 76.9% 
sensitivity, 79.5% specificity, and 78.2% predictive accuracy, and an area under the 
ROC curve of 0.859. These results were reproduced in a validation set, obtaining 72.6% 
sensitivity, 72.64% specificity and 72.64% predictive accuracy. The known prognostic 
factors (i.e. GRACE score, age, sex, Killip class, etc.) were compared by regression 
analyses with the metabolomic RF risk score, calculated on the validation set. In the 
univariate analysis, many prognostic factors were statistically associated with the 
outcomes, but the RF score shows the P-value by far more significant (P=2.65e-12). 
Moreover, in the multivariate regression only age, Killip class and RF score still remain 
statistically significant, demonstrating their independence from the other variables. 
 
Conclusions. Discrimination between patients with different outcomes after an ACS is 
demonstrated for the first time using metabolic profiling technologies, which seem to 
be more accurate than the standard stratification based on clinical and biohumoral 
parameters. 
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Condensed Abstract  
Risk stratification and management of patients continue to be challenging despite 
considerable efforts made in the last decades. In 978 ACS patients from AMI Florence 
II Study, the metabolic fingerprint was evaluated by high resolution 1H-Nuclear 
Magnetic Resonance. The multivariable prognostic risk model, which included 
metabolic fingerprint and clinical variables, predicted death with higher accuracy than 
the model including only clinical variables.  
Discrimination between patients with different outcomes after an ACS is demonstrated 
for the first time using metabolic profiling technologies, which seem to be more 
accurate than the standard stratification based on clinical and biohumoral parameters.  
 
 
Keywords 
Acute coronary syndrome, nuclear magnetic resonance, serum, metabolomics, 
biomarker, prognosis 
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CVDs = cardiovascular diseases 
ACS = acute coronary syndrome 
NMR = nuclear magnetic resonance 
MI = myocardial infarction 
RF = random forest 
ROC = receiver operating characteristics  
AUC = area under the curve 
PCI = percutaneous coronary intervention 
NOESY = nuclear Overhauser effect spectroscopy pulse sequence 
CPMG = Carr-Purcell-Meiboom-Gill pulse sequence 
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Introduction 
Among Cardiovascular diseases (CVDs), acute coronary syndrome (ACS) represents 
the most common cause of emergency hospital admission and it is associated with the 
highest mortality and morbidity (1, 2). The prognosis is directly associated with timely 
initiation of revascularization, and misdiagnosis or late diagnosis may have 
unfavorable clinical implications. Established risk stratification tools such as the Global 
Registry of Acute Coronary Events (GRACE) and the Thrombolysis In Myocardial 
Infarction (TIMI) risk scores are derived from demographic, clinical, laboratory, and 
electrocardiogram (ECG)-related variables (3, 4). These do not incorporate the use of 
newer biomarkers, which could represent different pathophysiologic processes and 
provide complementary prognostic information, thereby improving risk stratification 
beyond traditionally used variables. 
In the last years, several studies evaluated the potential clinical usefulness of new 
biomarkers able to identify patients who underwent a poor outcome. In particular, high 
levels of inflammatory markers such as C-Reactive Protein (CRP) and Interleukin-8 (IL-
8) had long-term prognostic utility in patients with acute coronary syndrome that 
undergone coronary revascularization (5, 6). 
However, no conclusive and consistent data about the prognostic utility of measuring 
the inflammatory markers in the early phase of the acute coronary syndrome are 
available in literature.  
A number of studies have evidenced that a global approach such as genomics, 
proteomics and metabolomics may represent a valid strategy for improving the 
knowledge of pathophysiological mechanism and for identifying ACS patients at high 
risk.  
Metabolomics analysis by nuclear magnetic resonance (NMR) is a high-throughput and 
high-reproducible analysis, as demonstrated by numerous ring trials performed over 
the years by many different NMR laboratories (7, 8), which gives qualitative and 
quantitative information on the hundreds of different small molecules present in a 
biological sample (9), and may provide a global picture  of a wide range of metabolic 
processes  underlying complex and multifactorial diseases such as acute coronary 
syndromes. During the last years the metabolomic approach was applied to identify a 
risk profile in heart failure patients (10, 11), atrial fibrillation patients (12)  and 
diabetic patients (13).  In the setting of ACS, few case-control studies characterized the 
metabolic biosignature of Myocardial Ischemia (14, 15), identified altered signatures 
in lipid metabolism in patients with angina or MI with respect to control subjects (16) 
or microbial metabolites in urine associated with coronary heart disease (17). 
Risk stratification should identify individuals at high risk requiring more intensive 
therapy or conversely, patients with a favorable prognosis could avoid drug overuse 
and associated side effects. In this framework, the aim of the present study is to 
evaluate the impact of metabolomics profile on the occurrence of cardiovascular death 
in ACS patients after percutaneous coronary intervention. 
 
56| 
Methods 
This study was part of a collaborative project between the Department of Medical and 
Surgical Critical Care of the University of Florence and the University of Florence 
Magnetic Resonance Centre (CERM).  
 
Study population 
The study population comprised a group of 978 out of 1496 patients admitted to the 
Coronary Unit of the Careggi University Hospital, Florence, Italy from April 2008 to 
April 2009 enrolled on the frame of the Florence Acute Myocardial Infarction-2 (AMI-
Florence 2) registry (18). In the present study, we evaluated 978 patients (345 females 
and 633 males, median age 74), among them 146 patients died within two years from 
the ACS event (dead patients) and 832 patients survived for at least two years (survivor 
patients), the two-year vital status was assessed by consulting the registry office of the 
city of residence. Thirty-five percent of the AMI-Florence 2 population was excluded 
from this study for the lack of good quality blood sample (never thawed before) for the 
metabolomic analyses; however, according to a standard power analysis (19) using a 
t-test as the test statistics, and fixing an alpha level of 0.05 for a significant comparison, 
146 dead and 832 survivors demonstrated to be enough to detect small-medium effects 
(Cohen’s d~0.25) with a statistical power of 80%. Blood samples were collected in the 
24-48 h after PCI and overnight fasting. All information about inclusion criteria and 
treatments of the patients are detailed in depth in the Supplementary Materials. 
All subjects gave informed consent; the study protocol complies with the Declaration 
of Helsinki, and received the approval by the local ethics committee. 
 
NMR analyses 
Samples were prepared following the standard protocols detailed by Bernini et al. (20). 
According to standard practice (21, 22), all spectra were acquired at 310 K using a 
Bruker 600 MHz spectrometer (Bruker BioSpin), and for each serum sample three 
monodimensional 1H NMR spectra, namely NOESY, CPMG and Diffusion-edited 
spectra, were acquired allowing the selective detection of different molecular weight 
metabolites. A detailed description about sample preparation and experiments is 
presented in the Supplementary Materials. 
Each 1D spectrum in the range 0.2-10.00 ppm was segmented into 0.02 ppm chemical 
shift bins and the corresponding spectral areas were integrated using AMIX software 
(version 3.8.4, Bruker BioSpin). Binning is a mean to reduce the number of total 
variables, to compensate for subtle signal shifts, and filter noise in the spectra, making 
the analysis more robust and reproducible (23, 24). The region between 4.5 and 5.0 
ppm containing the residual water signal was removed and the dimension of the 
system was reduced to 466 bins. The total spectral area was calculated on the 
remaining bins and total area normalization was carried out on the data prior to 
pattern recognition.  
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Statistical analysis 
Data analyses were performed using the open source software R. For the demographic 
and baseline characteristics, the t-test was used for comparison between groups and 
the chi-square test for comparison between categorical variables. 
For the multivariate data analyses of the NMR data the group of 978 patients was 
randomly split into two independent cohorts: a training set constituted by 80 survivors 
and 40 dead patients (25), and a validation set constituted by all the remaining patients 
(106 dead patients and 752 survivor patients).  
The initial analysis was restricted to the training set and the first step was to establish 
if serum metabolomic profiles could distinguish between dead and survivor patients 
within two years from the cardiovascular event, for this purpose, a Random Forest (RF) 
classifier (26) was built (considering for each sample all spectrum, thus, no choice of 
particular metabolite has been performed). The percentage of trees in the forest that 
assign one sample to a specific class can be inferred as a probability of class belonging, 
and it gives an unbiased assessment of the classification error using the out-of-bag 
samples (27). 
The RF classifier uses data from the training set to build an ensemble of decision trees. 
Each tree is used to predict whether a sample is associated with death or survival. For 
each patient, a score was created that expresses the extent to which the serum 
metabolomic profile appears to be similar to the one of patients with a negative 
outcome, designated as the ‘RF risk score’. This score is based on the percentage of 
trees in the ensemble that misclassify the sample as belonging to the cohort of dead 
patients. For each patient, three RF scores were derived using the three types of spectra 
acquired. For all calculations, the R package ‘Random Forest’ (26) was used to grow a 
forest of 2000 trees, using the default settings.  
The next step was to test the hypothesis that a metabolomic signature similar to the 
one of dead patients would be really predictive of death within two years from the CV 
event. Using receiver operating characteristics (ROC) analysis (“colAUC” function of the 
R package “caTools”) and Harrell's c index (“cindex” function on the R package 
“dynpred”), the performance of the RF risk scores were compared with the actual 
outcome. To delineate high risk of death, a cut-off for the RF risk score was calculated 
in the training set that optimized accuracy, sensitivity and specificity, and the 
performance of the model was subsequently tested in the validation set.  
The independent prognostic capacity of the RF risk score model was evaluated in 
comparison with standard prognostic features in a multivariate logistic regression, 
using the standard R function “glm”. 
The spectral regions related to the metabolites were assigned in the CPMG NMR 
spectra by using matching routines of AMIX 3.8.4 (Bruker BioSpin) in combination with 
the BBIOREFCODE (Bruker BioSpin), and freely available dataset i.e. Human 
Metabolome DataBase (HMDB) (28). The metabolites quantification was determined 
by an in-house developed software in MATLAB programming suite (version R2014b).  
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Our algorithm is based upon the unconstrained non-linear minimization (fitting) of the 
metabolite NMR signals, employing a combination of lorentzian-gaussian functions.  By 
this approach, each NMR region of interest is decomposed and deconvoluted into its 
component parts, and then integrated to obtain the metabolite concentrations in 
arbitrary units (Supplementary Figure 1). Wilcoxon signed-rank test (29) was chosen 
to infer differences between the metabolites concentrations of the outcomes groups on 
the biological  assumption that metabolite concentrations are not normally distributed, 
and false discovery rate correction was applied using the Benjamini-Hochberg method 
(30). An adjusted p-value < 0.05 was deemed significant. Effect size using Cliff’s delta 
(31) was calculated by means of the R package “effsize”. 
The statistical approach described above was also used to build gender-specific 
statistical models based on NOESY spectra. 
NMR and clinical data will freely available in the Open-Access Database Repository 
MetaboLights from October 2017 with the accession number MTBLS395 
(http://www.ebi.ac.uk/metabolights). 
 
Results 
Demographic and clinical characteristics of the enrolled patients are shown in Table 1. 
In Supplementary Table 1 the characteristics of patients according to gender are also 
reported.  
 
NMR spectra 
For each sample three NMR metabolomic profiles were obtained using NOESY, CPMG, 
and Diffusion-edited sequences (Supplementary Figure 2). According to the peculiar 
characteristics of each NMR experiment high and low molecular weight metabolites 
can be detected. An exploratory Principal Component Analysis of the dataset is 
reported in Supplementary Figure 3. 
 
Discrimination of the outcomes and the RF scores in the training set 
Using the Random Forest classifier, the metabolomic profiles of 80 survivors and 40 
dead patients (training set) were classified, and showed significant differential 
clustering, with a good separation of the two groups using each type of NMR spectra 
NOESY (Figure 1A), CPMG (Supplementary Figure 4A), and Diffusion (Supplementary 
Figure 4B).  
Using ROC analyses, the areas under the curve (AUC) obtained were 0.859 for NOESY 
spectra (Figure 1B), 0.857 and 0.775 for CPMG and Diffusion editing spectra, 
respectively (Supplementary Figure 4 C-D). NOESY and CPMG models showed 
approximately the same performances, and the discrimination between the two 
outcome groups can be ascribed to both low (mostly) and high molecular weight 
metabolites. Thus, it was decided to use the NOESY spectra in the further analyses 
because they contain both high and low molecular weight metabolite information.  
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The NOESY RF risk score was thus optimized in the training set choosing the best 
threshold for the maximization of sensitivity and specificity in the outcome 
discrimination. A threshold of ≥ 0.454 was set optimizing accuracy, sensitivity and 
specificity; this optimized threshold yielded 76.9% (95% CI 76.5-77.3%) sensitivity, 
79.5% (95% CI 78.4-80.6%) specificity, and 78.2% (95% CI 77.6-78.7%).  
Moreover, the NOESY RF model demonstrated to be robust with respect to different 
strategies of model-validation, indeed, with a 100 cycles of classical Monte Carlo cross-
validation scheme with 80-20 % splitting of the data (training set, validation set) a 
mean AUC of 0.805 (95% CI, 0.795-0.814) was obtained. Furthermore, the model was 
robust with respect to the origin of samples: using samples coming from the Careggi 
University Hospital as training set and the other samples as validation set (and vice-
versa) affected only slightly the AUC obtained (Supplementary Figure 5). 
 
Outcome prediction by NOESY RF score in a validation set of patients 
The validation set (106 dead patients and 752 survivor patients) was evaluated using 
an unsupervised analysis. Spectra of the validation samples were classified as either 
‘dead’ or ‘survivor’ using the optimized NOESY RF risk score model derived from the 
training set. Comparison between metabolomic classification and actual outcome 
demonstrated high correlation with AUC of 0.801 (Figure 1C). Using the threshold 
maximized in the training set we obtained 72.60% sensitivity, 72.64% specificity and 
72.64% overall predicting accuracy.  
The AUC score calculated on the Random Forest score was assessed for significance 
against the null hypothesis of no prediction accuracy in the data, by means of 10,000 
randomized class-permutation test: the estimate AUC score obtained after 
randomization is 0.570 (95% CI 0.569-0.571), demonstrating the significance of our 
result (AUC 0.801, p-value of 2.21·10-06). 
For the sake of completeness, comparison between actual outcome and the 
metabolomic classification with CPMG and Diffusion editing models were also 
performed, results are reported in Supplementary Figure 4 E-F. 
 
Comparison of the NOESY RF score with known prognostic factors and the GRACE score 
The known prognostic factors age, sex, previous CABG, previous PCI, heart failure, 
atrial fibrillation, cerebrovascular disease, diabetes, creatinine concentration, killip 
class, and acute coronary syndrome classification were compared with the NOESY RF 
risk score, calculated on the validation set, in univariate and multivariate regression 
analyses, and the results are displayed in Table 2. A similar analysis using age as a 
continuous variable has been performed, details are reported in the Supplementary 
Materials. 
In the univariate analysis, many prognostic factors were statistically associated with 
the outcomes, but the NOESY RF score shows the P-value by far more significant (p = 
2.00·10-16). Moreover, in the multivariate regression only the age, the killip class and 
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the RF score remain statistically significant, demonstrating their independence with 
respect to the other variables. Interestingly, also in this cohort the smoker's paradox, 
already described by other several studies (32), has been observed. 
Moreover, using the ROC analysis, the NOESY RF score performance was tested against 
some well-known parameters that are commonly measured in the clinical practice 
(training and validation set were considered together and in these analyses were 
included only patients from whom all the clinical parameters were available). As 
displayed in Figure 2, our score showed the best AUC 0.767, and only age showed a 
comparable result (AUC 0.738) in predicting death within 2 years from the CV event. 
Furthermore, the performance of our approach was also tested in two distinct sub-
groups of patients, divided according to the ACS severity (STEMI and NSTEMI). The 
results, reported in the Supplementary Materials (Supplementary Figure 6), 
demonstrated that our approach is marginally affected by these two subcategories. 
The performances of the NOESY RF score in predicting two-year outcomes were also 
compared with the ones of the Global Registry of Acute Coronary Events (GRACE) 
hospital discharge risk score (33) for those patients for which all clinical parameters, 
needed to calculate the GRACE score, were available (84.5% of patients). Results 
(Harrell's c index and AUC), displayed in Supplementary Table 2, demonstrated that 
the NOESY RF score played slightly better both in the training and in the validation sets, 
confirming undoubtedly how the metabolomic approach here described could be 
useful for risk stratification in the setting of post ACS patients. Moreover, calculations 
to create a combined score (GRACE + NOESY RF scores) were performed 
(Supplementary Figure 7): the combined model, obtained via a linear combination, 
showed improved results with respect to the two separated ones in both training and 
validation sets.  
 
Metabolites analysis 
An analysis of the NMR spectra was conducted to identify which metabolites are 
statistically different between dead and survivor patients. All patients (training and 
validation sets) were included in the analysis. We observed that patients with worst 
prognosis are characterized by significantly (adjusted p-value < 0.05) higher levels of 
3-hydroxybutyrate, proline, creatinine, acetate, acetone, formate and mannose, and 
significantly lower levels of valine and histidine (Table 2).  
Metabolite analysis replicated in training and validation sets separately are provided 
in the Supplementary Materials (Supplementary Figure 8). 
 
Gender-specific RF models 
The presence of gender-specific differences in human metabolism is well-known and  
the nuclear magnetic resonance metabolomics is sensitive to these differences (34). 
Therefore, we decided to build two different RF models for females and males to obtain 
an outcome clusterization and prediction unbiased by gender.  
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For each gender-specific group using the Random Forest classifier, the metabolomic 
NOESY1D profiles of 60 survivors and 30 dead patients were classified. Both gender 
models showed significant differential clustering, with a good separation of the two 
outcomes groups (Figure 3 A, D).  
Using the NOESY NMR spectra of the female and male cohorts separately, the Random 
Forest classifier discriminated dead from survivor patients in the training set with area 
under the curve (AUC) of 0.786 and 0.834, respectively (Figure 3 B, E). Thresholds of ≥ 
0.46 for the female cohort and ≥ 0.476 for the male cohort were set in the training set 
by optimizing accuracy, sensitivity, and specificity and the results for both cohorts are 
shown in Supplementary Table 3.  
Applying these models to the validation set of female and male cohorts we attained an 
AUC of 0.782 and 0.821 respectively (Figure 3 C, F) and using the threshold maximized 
in the training set we obtained 74.7% and 73.4% overall accuracy for predicting the 
likelihood of outcome of in female and male cohorts respectively (details in 
Supplementary Table 3).  
By analyzing the spectra of the female and the male cohorts, we observed that female 
dead patients were characterized by higher levels of creatinine, whereas male dead 
patients were characterized by higher levels of 3-hydroxybutyrate, proline, creatinine 
and formate, and significantly lower levels of histidine and valine. 
 
Discussion 
In ACS patients enrolled in the AMI Florence 2 Study we found a metabolic fingerprint 
which is able to discriminate patients who died within two years after the CV event 
from survivors with a high accuracy (0.859 AUC) and this result was duplicate in a 
validation set (0.801 AUC). Moreover, gender-specific Random Forest models were 
built: for males, the ability of predicting the outcomes showed better results (77.2% 
accuracy for male and 74.5% accuracy for female), and this evidence is confirmed also 
in the validation set. To the best of our knowledge, this is the first study which assessed 
the capability of metabolomic assay to predict mortality in the setting of acute coronary 
syndromes.  
The metabolic fingerprint can be deemed as a holistic super-biomarker with a 
discriminative and predictive power undoubtedly higher than the simple sum of the 
few quantified metabolites (35). ACS, as the majority of human diseases, has a 
multifactorial aetiology and a complex physiopathology that alter concurrently several 
metabolic pathways (36); therefore, the metabolic fingerprint, composed by the 
superimposition of all the visible signals of the low and high molecular weight 
endogenous metabolites, represents an optimal level at which to analyze pathological 
changes in biological systems (37), indeed it takes into account all metabolite 
variations even the slightly ones. 
The NOESY RF score, based on the metabolic fingerprint here presented, showed to be 
independent from the classical clinical parameters and the widely used GRACE score, 
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and to achieve better results in predicting all-cause death within two years from ACS 
considering both logistic regression and ROC analysis. 
In this substantial cohort of ACS patients of the AMI Florence 2 Registry we found that 
dead patients are characterized by significantly higher levels of 3-hydroxybutyrate, 
proline, creatinine, acetate, acetone, formate and mannose, and significantly lower 
levels of valine and histidine.  
It has been demonstrated that the lifestyle and medication administered to a patient 
influence the molecular signatures in plasma/serum samples, and the relative 
metabolite concentrations reflect tissue lesions and organ dysfunctions. In this 
framework, previous studies have underlined the usefulness of metabolomics of 
serum/plasma in determining   the individual’s disease risk, prognosis, and therapeutic 
options  in different clinical settings (27, 38–40). For instance, sera of heart failure 
patients possess a strong signature of the disease, estimation of the HF-related 
metabolic disturbance and a better prognostic value than conventional biomarkers 
(11, 39).  
In a prospective study of three population-based cohorts from Finland, and free of CVD 
at baseline (41) the metabolomic analysis had evidenced that circulating 
phenylalanine, monounsaturated and polyunsaturated fatty acids were strongly 
predictive of cardiovascular risk as the conventional lipid risk factors, and were 
markers of CVD onset during a long-term follow-up (more than a decade).  
In our study, we do not find any role for these metabolites in predicting mortality. 
However, the different study populations (CVD free vs ACS patients) with different 
lifestyle and dietary habits, may explain the different molecular signature. 
The usefulness of the metabolomic approach was also demonstrated in a general 
cohort of patients at risk for cardiovascular events undergoing cardiac catheterization 
(42), as baseline plasma metabolomic profiles independently predicted cardiovascular 
death after adjustment for multiple clinical covariates. In this study, a significant 
predictive role for 5 metabolomic factors, including the branched-chain amino acids 
and related catabolites, was demonstrated. Consistently, in the present study we found 
that higher levels of valine are protective factors in ACS patients.  At variance with our 
study, increased concentrations of branched-chain amino acids levels in coronary 
artery patients compared with control subjects were shown (43) and high levels of 
these essential aminoacids (AA) significantly correlated with the severity of CAD (44). 
However, these studies were case-control studies and did not evaluate CAD patients in 
the acute phase of the disease. The pathways of the branched-aminoacids in humans 
are very complex and it is likely that in ACS patients an altered metabolic pathway of 
these aminoacids may represent a prognostic risk factor. 
Our study, performed in a large sample population of ACS patients, followed for 2 years, 
provided new data about the role of high 3-hydroxybutyrate circulating levels on post-
ACS mortality. A previous paper, which evaluated the ketone bodies in the urine of 5 
ACS patients demonstrated that ketone bodies and particularly 3-hydroxybutyrate 
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were altered during the acute event (45). Furthermore, it has been demonstrated that 
high levels of 3-hydroxybutyrate are associated with high prevalence of heart failure 
and diabetes (46). In insulin deficiency, when the release of free fatty acids from 
adipose tissues exceeds the capacity of the tissues to metabolize them, severe and 
potentially fatal diabetic ketoacidosis can occur where blood 3-hydroxybutyrate levels 
can reach up to 25 mM (47). However, it remains unclear whether the elevation of 
ketone bodies represents an adaptive mechanism required to maintain cell metabolism 
or if it actually contributes to the disease progression.  
As expected, patients with worst prognosis showed higher level of serum creatinine, a 
well-known marker of renal insufficiency. Indeed, it has already been demonstrated 
that the elevated admission serum creatinine levels are associated with impaired 
myocardial flow and poor prognosis on one-year mortality (48, 49). 
Previous studies evidenced an interaction between gender and adverse cardiovascular 
events in CAD patients (50–52) as MI morbidity and mortality resulted to be higher in 
women than in men. Consistently, our results demonstrated a higher prevalence of 
cardiovascular mortality in women than in men (19.4% vs 12.5%).  The excess risk of 
mortality in women could be ascribed to the differences in cardiovascular risk factor 
i.e. age, hypertension, diabetes and co-morbidities prevalence. Accordingly, in our 
study, females show higher median age and higher prevalence of hypertension, atrial 
fibrillation and heart failure with respect to males. 
Building gender-specific models has enabled to obtain an improvement of the outcome 
prediction in the male cohort, but not in the female one. Thus, male metabolic 
fingerprint seems to show a higher association with cardiovascular mortality with 
respect the female one. However, it needs to be consider that the female cohort is less 
numerous than the male cohort and this may affect the predictive capability of the 
model; therefore, to build robust gender-specific models wider cohorts of patients are 
needed. 
 
Conclusions 
In conclusion, our data support the usefulness of the metabolomic approach to identify 
a more precise risk profile in ACS patients. The metabolomic analysis by NMR enables 
fast, approachable and reproducible characterization of the ACS metabolic fingerprint 
associated with a poor prognosis improving the cardiovascular risk assessment, 
beyond that achieved by established risk factors, and most likely identify those patients 
who need to undergo a very early and aggressive treatment. 
Although our study has several strengths, including the number of patients studied, the 
two-year follow-up, and the analysis replication in a validation set, some limitations 
should also be considered: NMR is less sensitive than mass spectrometry (even if it is 
more suitable for metabolic fingerprinting), sample collections were done only in the 
acute phase of the disease, and lack a further validation set obtained from an 
independent population. Moreover, the biggest obstacle to the translation of 
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metabolomics in clinical practice is the acquisition of standard operating procedures 
for sample collection and storage, only in this possible future scenario this approach 
could be successfully translated in very large multicenter studies. 
 
Perspectives 
Competency in medical knowledge: 
NMR metabolomics has the potential to identify patients with high risk of death within 
two years from ACS, and thus to improve prognostic risk stratification and 
management of ACS patients. 
 
Translational outlook: 
Additional clinical studies on multicenter cohorts are still needed to fully translate the 
present results into a standard clinical tool and to build a comprehensive 
clinical/metabolomic integrated model that will predict outcomes in ACS patients with 
higher accuracy. 
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List of Figures and Tables 
 
CENTRAL ILLUSTRATION   
Title: Metabolomics as tool to improve the risk of death stratification in ACS patients 
Legend: ACS is a generic term that encompasses the different clinical manifestations of 
ischemic heart disease. Although current patient management procedures have 
resulted in a reduction of hospital mortality for the acute phase, the first-year mortality 
is still increasing. Therefore, new methods of risk assessment and stratification are 
required. Applying NMR-based metabolomic approach is possible to identify ACS 
patients with an adverse prognosis within the first two years after the cardiovascular 
event with 78% accuracy. The results are also reproduced in an independent test set 
obtaining an AUC of 0.801, and 72.64% accuracy. 
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FIGURE 1   
Title: Clusterization of serum metabolomic profiles and comparisons between 
metabolomic classification and outcomes in the training set and the validation set. 
Legend: A) Discrimination between survivor (blue dots, n = 80) and dead (red dots, n 
= 40) patients using the Random Forest classifier on NOESY spectra in the training set. 
The ROC curves and the AUC scores are presented for B) Training set; C) Validation 
test. 
 
 
 
 
FIGURE 2   
Title: NOESY RF score and clinical parameters ROC curves. 
Legend: The ROC curves and the AUC scores are presented for NOESY RF score, age, 
heart frequency, diastolic pressure, systolic pressure, glycemia, creatinine, platelets, 
troponine max and creatine kinase-MB max. 
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FIGURE 3   
Title: Gender-specific models and predictions using NOESY1D spectra 
Legend: Clusterization of serum metabolomic profiles discriminating between survivor 
(blue dots) and dead (red dots) patients using the Random Forest classifier for A) male; 
D) female. Comparison between metabolomic classification and outcomes in the 
training set:  the ROC curves and the AUC scores are presented for B) male; E) female. 
Prediction of outcomes in the validation set: the ROC and the AUC scores are presented 
for C) male; F) female. 
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TABLE 1  Demographic and Clinical Characteristics 
 
Survivor patients (832) Dead patients (146) P-value 
Demographic characteristics,    
Age (years), median (IQR) 72 (62-80) 82 (78-83) < 2.20E-16 
Gender, females, n (%) 278 (33.4) 67 (45.9) 4.86E-03 
Cardiovascular risk factors, n (%) 
  
 
Hypertension 537 (64.5) 104 (71.2) 1.21E-01 
Dyslipidemia 294 (35.3) 32 (21.9) 3.55E-03 
Current smokers 226 (27.2) 20 (13.7) 1.45E-04 
Ex-smokers 21 (2.5) 8 (5.5) 4.01E-01 
CAD 220 (26.4) 17 (11.6) 5.03E-04 
Diabetes 197 (23.7) 61 (41.8) 6.32E-06 
Medical history, n (%) 
  
 
Myocardial infarction 164 (19.7) 48 (32.9) 5.23E-04 
Angina, onset > 1 month 119 (14.3) 24 (16.4) 8.96E-01 
Angina, onset ≤ 1 month 149 (17.9) 15 (10.3) 3.78E-02 
CABG 41 (4.9) 10 (6.8) 4.39E-01 
PCI 136 (16.3) 32 (21.9) 1.20E-01 
Chronic heart failure 33 (4.0) 26 (17.8) 2.62E-10 
Atrial fibrillation 42 (5.0) 21 (14.4) 4.60E-05 
Cerebrovascular disease 50 (6.0) 28 (19.2) 1.28E-07 
Presentation features 
  
 
ACS classification, STEMI, n (%) 343 (41.2) 35 (24.0) 1.15E-04 
Killip II-IV, n (%) 114 (13.7) 61 (41.8) 6.33E-16 
Creatinine > 1.2 mg/dL, n (%) 129 (15.5) 54 (37.0) 4.08E-09 
Heart rate (bpm), median (IQR) 80 (67-91) 90 (80-105) 3.66E-06 
Positive peak troponine max, n (%) 804 (96.6) 143 (97.9) 6.98E-01 
Positive peak CK-MB max, n (%) 422 (50.7) 50 (32.2) 1.88E-03 
 
CAD = coronary artery diseases; CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; ACS = acute coronary syndrome; 
STEMI = ST-segment elevation myocardial infarction; CK-MB = creatine kinase-MB 
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TABLE 2  Association with the Outcome: unadjusted and adjusted Odds Ratios 
 
Odds ratio 
(univariate) 
P-value 
Odds ratio 
(multivariate) 
P-value 
Age 
  
  
68 -79 4.1579 9.09e-04 1.7916 3.15e-01 
> 79 14.112 8.01e-11 4.7021 7.96e-03 
Male sex 0.5644 6.30e-03 0.6785 2.74e-01 
Hypertension 1.2710 2.86e-01 0.3745 1.04e-02 
Dyslipidemia 0.5380 1.26e-02 0.3412 1.62e-02 
Smoking habits 
  
  
Yes 0.3028 2.56e-04 0.7043 4.42e-01 
Ex-smokers 0.9612 9.44e-01 6.78e-08 9.83e-01 
CAD 0.4101 4.22e-03 1.2303 6.33e-01 
Previous CABG 1.4639 3.43e-01 1.9080 3.87e-01 
Previous PCI 1.2995 3.20e-01 1.5356 4.14e-01 
Heart failure 4.9639 2.65e-07 2.0267 1.57e-01 
Atrial fibrillation 2.5118 6.43e-03 1.0956 8.60e-01 
Cerebrovascular disease 3.9224 2.15e-06 1.8436 1.90e-01 
Diabetes 2.4871 2.17e-05 1.8466 8.09e-02 
Creatinine (>1.2 mg/dL) 2.9582 1.73e-06 1.3379 4.43e-01 
Killip class 
  
  
II 3.7494 6.58e-07 1.2553 6.09e-01 
III 5.8838 9.66e-08 5.6398 3.74e-04 
IV 10.383 9.95e-02 19.4783 5.70e-02 
ACS classification 
  
  
STEMI 0.5379 7.66e-03 0.7458 4.28e-01 
Random Forest Risk Score 
  
  
≥ 0.454 7.0378 2.00e-16 3.3625 1.26e-03 
Correlation with the outcome for prognostic features and RF risk score in the validation set, using univariate and multivariate analysis. Age 
split into tertiles. Abbreviations as in Table 1. In the multivariate odd ratios all the variable were included together in the analysis. 
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Supplementary materials 
 
Supplementary methods 
Study population 
The study population comprised a group of 978 out of 1496 patients admitted to the Coronary 
Unit of the Careggi University Hospital, Florence, Italy from April 2008 to April 2009 enrolled 
on the frame of the Florence Acute Myocardial Infarction-2 (AMI-Florence 2) registry. 
The AMI-Florence Registry prospectively included all patients who arrived alive to the 
emergency departments of one of the six participating hospitals in the Florence health district 
with a suspected STEMI between March 2000 and February 2001. All patients fulfilling the 
diagnostic criteria for acute or sub-acute (symptom onset ≤ 24 or > 24 hours, respectively) 
STEMI were screened for enrolment in the registry, without any exclusion criteria. The AMI-
Florence 2 registry is a second-wave survey of the AMI-Florence registry, and was extended to 
include all cases of suspected ACS arriving alive to any of the six hospitals, with no exclusion 
criteria (AMI-Florence 2 included both STEMI and NSTEMI cases).  
ACS was diagnosed according to criteria established by the European Society of Cardiology (1). 
Briefly, AMI was defined as typical rise and gradual fall of troponin, or more rapid rise and fall 
of CK-MB, defined as > 99% of normal levels (troponin T >0.05 ng/mL; CK-MB >10 ng/mL), 
with at least one of the following: acute onset of typical ischaemic chest pain; some Q waves in 
V1-V3 , 30 ms Q waves  1 mm in two contiguous leads; ST- segment elevation or depression in  
2 leads, 0.2 mV in V1-V3, >0.1 mV in other leads. Unstable angina was defined as a history of 
new-onset, more frequent, more persistent or rest episode of chest pain, without typical 
changes of myocardial enzymes and with ECG evidence of myocardial ischaemia (transient ST 
segment displacement >0.1 mV during chest pain). All patients underwent coronary 
angiography performed by the Judkins’ technique and PCI. Before PCI, all patients received a 
loading dose of 500 mg of acetylsalicylic acid (ASA) and 300 mg of clopidogrel, followed by 100 
(15.9%) or 325 mg (84.1%) of ASA daily and 75 mg of clopidogrel daily. The use of glycoprotein 
(GP)IIb/IIIa inhibitors was at discretion of the operator and was carried out in 48.5% of 
patients. Unfractioned heparin 70IU/kg was used in all patients during PCI as anticoagulant. 
Clinical follow-up information was obtained by contacting all the patients at 24 months, and 
source documents of potential events were recorded. 
Current smoking status was determined at the time of blood collection. The subjects were 
classified as having hypertension according to the guidelines of European Society of 
Hypertension/ European Society of Cardiology (2) or if they reported taking antihypertensive 
medications, as verified by the physician. Diabetic subjects were defined in agreement with the 
American Diabetes Association (3) or on the basis of self-report data (if confirmed by 
medication or chart review). Dyslipidemia was defined according to the Third report of the 
National Cholesterol Education Program (NCEP-III) (4) or if they reported taking 
antidyslipidaemic drugs, as verified by the physician. A positive family history was defined as 
the presence of at least one first-degree relative who had developed CAD before the age of 55 
years for men and 65 years for women. 
 
In-hospital data collection 
A web-based form was used to collect information on demographics, medical history, clinical 
and ECG characteristics, treatment and outcomes during hospitalization, and prescriptions at 
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discharge. Time intervals from onset of symptoms to hospital admission and revascularization 
were recorded. The Coordinating Centre periodically reviewed data for inconsistencies, and, 
when necessary, queries were sent to local investigators for further checks before data 
processing. Completeness of enrolment was periodically checked by comparing hospital 
discharge data for Acute Coronary Syndromes ICD9-CM codes (primary diagnosis: 410.*, 411.* 
and 413.*, or 427.5 associated with 410.*, 411.*, 413.* as secondary diagnosis; asterisks 
indicates only three ICD 9 digits, irrespective of the other digits (fourth and fifth)) from 
hospitals in the area with data of patients actually entered. When a discharge record could not 
be tracked in the study database, the original clinical record was checked, and, if enrolment 
criteria were met, the case was eventually included. Therefore, the series enrolled is 
population-based and fully representative of incident AMI cases in the area over the study 
period. 
 
Follow-up data collection 
Two-year vital status was assessed by consulting the registry office of the city of residence. 
 
Serum sample collection and storage 
Blood withdrawals were obtained drew by trained medical personnel and, serum samples 
were obtained by centrifuging blood sample at 2,000 g for 10 min a 4°C and then stored in 
aliquots at -80°C until analysis. 
 
NMR sample preparation 
Frozen serum samples were thawed at room temperature and shaken before use. The NMR 
samples were prepared according to the standard operating procedures (5). A total of 300 µL 
of a sodium phosphate buffer (10.05 g Na2HPO4·7H2O; 0.2 g NaN3; 0.4 g sodium trimethylsilyl 
[2,2,3,3-2H4]propionate (TMSP) in 500 mL of H2O with 20% (v/v) 2H2O;  pH 7.4) was added 
to 300 µL of each serum sample, and the mixture was homogenized by vortexing for 30 s. A 
total of 450 µL of this mixture was transferred into a 4.25 mm NMR tube (Bruker BioSpin srl) 
for the analysis. 
 
NMR spectra acquisition and processing 
Monodimensional 1H NMR spectra for all samples were acquired using a Bruker 600 MHz 
spectrometer (Bruker BioSpin) operating at 600.13 MHz proton Larmor frequency, and 
equipped with a 5 mm CPTCI 1H-13C-31P and 2H-decoupling cryoprobe including a z axis 
gradient coil, an automatic tuning-matching (ATM) and an automatic sample changer. A BTO 
2000 thermocouple served for temperature stabilization at the level of approximately 0.1 K at 
the sample. Before measurement, samples were kept for at least 3 minutes inside the NMR 
probehead, for temperature equilibration at 310 K.  
According to standard practice, for each serum samples three monodimensional 1H NMR 
spectra with different pulse sequences were acquired: 
(i)   a standard nuclear Overhauser effect spectroscopy pulse sequence NOESY 1Dpresat 
(noesygppr1d.comp; Bruker BioSpin), using 64 scans, 98304 data points, a spectral 
width of 18028 Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s and a mixing time 
of 0.1 s, was applied to obtain a spectrum in which both signals of low molecular weight 
metabolites and high molecular weight aggregates (lipids and lipoproteins) are visible. 
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(ii) a standard spin echo Carr-Purcell-Meiboom-Gill (CPMG) (6) (cpmgpr1d.comp; Bruker 
BioSpin) pulse sequence, with 64 scans, 73728 data points, a spectral width of 12019 Hz 
and a relaxation delay of 4 s, was used for the selective observation of low molecular 
weight metabolites, suppressing signals arising from high molecular weight aggregates.  
(iii) a standard diffusion-edited (7) (ledbgppr2s1d.comp; Bruker BioSpin) pulse sequence, 
using 64 scans, 98304 data points, a spectral width of 18028 Hz and a relaxation delay 
of 4 s, was applied to suppress the signals of low molecular weight metabolites. 
Free induction decays were multiplied by an exponential function equivalent to a 1.0 Hz line-
broadening factor before applying Fourier transformation. Transformed spectra were 
automatically corrected for phase and baseline distortions and calibrated (anomeric glucose 
doublet at 5.24 ppm) using TopSpin 3.2 (Bruker Biospin srl). 
Each 1D spectrum in the range 0.2-10.00 ppm was segmented into 0.02 ppm chemical shift 
bins and the corresponding spectral areas were integrated using AMIX software (version 3.8.4, 
Bruker BioSpin). Binning is a mean to reduce the number of total variables, to compensate for 
subtle signal shifts, and filter noise in the spectra, making the analysis more robust and 
reproducible (8, 9). The region between 4.5 and 5.0 ppm containing the residual water signal 
was removed and the dimension of the system was reduced to 466 bins. The total spectral area 
was calculated on the remaining bins and total area normalization was carried out on the data 
prior to pattern recognition. 
 
Statistical analysis 
Data analyses were performed using the open source software R. For the demographic and 
baseline characteristics, the t-test was used for comparison between groups and the chi-square 
test for comparison between categorical variables. 
For the multivariate data analyses of the NMR data the group of 978 patients was randomly 
split into two independent cohorts: a training set constituted by 80 survivors and 40 dead 
patients (10), and a validation set constituted by all the remaining patients (106 dead patients 
and 752 survivor patients). 
The initial analysis was restricted to the training set and the first step was to establish if serum 
metabolomic profiles could distinguish between dead and survivor patients within two years 
from the cardiovascular event, for this purpose, a Random Forest (RF) classifier (11) was built. 
The percentage of trees in the forest that assign one sample to a specific class can be inferred 
as a probability of class belonging, and it gives an unbiased assessment of the classification 
error using the out-of-bag samples (12). 
The RF classifier uses data from the training set to build an ensemble of decision trees. Each 
tree is used to predict whether a sample is associated with positive or negative outcome. For 
each patient, a score was created that expresses the extent to which the serum metabolomic 
profile appears to be similar to the one of patients with a negative outcome, designated as the 
‘RF risk score’. This score is based on the percentage of trees in the ensemble that misclassify 
the sample as belonging to the cohort of patients with a negative outcome. For each patient, 
three RF scores were derived using the three types of spectra acquired. For all calculations, the 
R package ‘Random Forest’ (11) was used to grow a forest of 2000 trees, using the default 
settings.  
The next step was to test the hypothesis that a metabolomic signature similar to the one of 
patients with a negative outcome would be really predictive of death within two years from 
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the CV event. Using receiver operating characteristics (ROC) analysis (“colAUC” function of the 
R package “caTools”) and Harrell's c index (“cindex” function on the R package “dynpred”), the 
performance of the RF risk scores were compared with the actual outcome. To delineate high 
risk of death, a cut-off for the RF risk score was calculated in the training set that optimized 
accuracy, sensitivity and specificity, and the performance of the model was subsequently tested 
in the validation set. Sensitivity, specificity, and accuracy were calculated according to the 
standard definition of, respectively: proportion of death patients that are correctly identified 
as such with respect to the total death patients; proportion of alive patients that are correctly 
identified as such with respect to the total alive patients; proportion of correctly classified 
individuals (both death and alive) that are correctly identified with respect to the total cohort. 
 
 
Supplementary Results 
Exploratory unsupervised analysis of the dataset  
Principal Component Analysis (PCA) was performed as first exploratory analysis. It is apparent 
that no unsupervised discrimination between the main hospital (Careggi University Hospital) 
and the other centers is present. The score plot of the first two principal components is 
provided (Supplementary Figure 3). 
 
Distinct metabolomic models calculated according to ACS severity  
Patients enrolled in this study were 378 STEMI and 600 NSTEMI. Using a Random Forest 
classifier, it is possible to discriminate between these two subgroups with 66.5% accuracy 
(Supplementary Figure 6), indicating that the serum metabolic fingerprint is weakly affected 
by the ACS severity. The possible implications of these differences due to sub-phenotypes of 
STEMI and NSTEMI has been further investigated by building two distinct models for the 
outcome prediction: 100 cycles of classical Monte Carlo cross-validation scheme with 80-20 % 
splitting of the data (training set, validation set) have been performed for each sub-group, and 
a mean AUC of 0.829 (95% CI, 0.812-0.846) and of 0.784 (95% CI, 0.774-0.794) were obtained 
for STEMI and NSTEMI, respectively. Comparing these results with the mean cross-validated 
AUC obtained using all the dataset together (AUC 0.805), we can conclude that the division of 
patients according to severity contributes only marginally to the metabolomic fingerprint 
associated with the outcome,  and, as a consequence, that the prognostic value of the metabolic 
fingerprint reported here is not just a proxy of the clinical status, but a real instrument able to 
improve the risk stratification in the framework of post ACS patients. 
 
Comparison of the NOESY RF score with age as a continuous variable 
Logistic analysis was performed also using age as a continuous variable. In this case, an odd 
ratio of 1.11 and a P-value of 1.12e-14 in the univariate analysis (multivariate results: odd ratio 
1.07 and P-value 4.07e-05) was obtained. The effect of using age as a continuous variable on 
the odd ratios and P-values of the other significant variables is only marginal (NOESY RF score 
odd ratio 3.21 and P-value 2E-03; Killip class III odd ratio 5.02 and P-value 9e-04). 
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SUPPLEMENTARY TABLE 2  Comparison between NOESY RF and GRACE scores. 
 NOESY RF score GRACE score 
Training set,    
AUC 0.843 0.815 
Harrell's c index 0.806 0.776 
Test set,   
AUC 0.801 0.750 
Harrell's c index 0.789 0.740 
 
AUC: area under the ROC curve 
 
 
SUPPLEMENTARY TABLE 3  Results for the gender-specific models 
 Male cohort Female cohort 
Training set, % (95% CI)   
Sensitivity 83.3% (95% CI 82.6-83.6%) 84.6% (95% CI 84.2-84.9%) 
Specificity 74.2% (95% CI 73.2-75.2%) 70.0% (95% CI 68.7-71.3%) 
Accuracy 77.2% (95% CI 76.5-77.9%) 74.9% (95% CI 74.0-75.7%) 
Test set, %   
Sensitivity 73.1% 68.8% 
Specificity 73.5% 75.7% 
Accuracy 73.4% 74.7% 
 
CI = confidence interval 
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SUPPLEMENTARY FIGURE 1. Upper: The NMR spectrum region with the above study metabolite 
annotated.  Below:  Our algorithm metabolites NMR signals deconvolution.  Firstly, all NMR 
peaks in the above study NMR spectral region are fitted and the fitting procedure residuals are 
identified.  Finally, the metabolite’s NMR peaks (or part of them) of our interest are extracted 
and integrated, resulting to the metabolite’s quantification with high level of accuracy. The 
figures are reported for A) acetone; B) phenylalanine. 
 
A) 
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B) 
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SUPPLEMENTARY FIGURE 2.  Metabolomic profiles for one randomly selected patient from 
each group of outcomes. For each patients NOESY, CPMG, and Diffusion spectra are displayed. 
 
 
 
 
 
SUPPLEMENTARY FIGURE 3.  Discrimination between Careggi University Hospital (blue dots, n 
= 579) and other centers (orange dots, n = 399) using Principal Component Analysis. 
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SUPPLEMENTARY FIGURE 4.  Discrimination between survivor (blue dots, n = 80) and dead 
(red dots, n = 40) patients using the Random Forest classifier in the training set. A) CPMG; B) 
Diffusion. The ROC curves and the AUC scores in the training set are presented for C) CPMG; D) 
Diffusion. The ROC curves and the AUC scores in the validation set are presented for E) CPMG; 
F) Diffusion. 
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SUPPLEMENTARY FIGURE 5.  Receiver Operating Characteristic Curves and the corresponding 
Area are reported for two models: Model 1, A) Training set: Careggi University Hospital; B) 
Validation set: Other Hospitals. Model 2, C) Training set: Other Hospitals; B) Validation set: 
Careggi University Hospital. 
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SUPPLEMENTARY FIGURE 6.  Discrimination between NSTEMI (blue dots, n = 600) and STEMI 
(red dots, n = 378) patients using the Random Forest. Discrimination accuracy is 66.5%. 
 
 
 
SUPPLEMENTARY FIGURE 7.  Linear combined model (NOESY RF + GRACE score). ROC curve 
and AUC are reported for: A) training set; B) validation set. 
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SUPPLEMENTARY FIGURE 8.  Metabolite concentrations in: A) All dataset; B) Training set; C) 
Validation set. Metabolites are reported as log2 of the Fold Change, and positive values mean 
higher concentrations in dead patients. Green bars represent statistically significant P-values 
(P<0.05 after correction), conversely red bars mean not significant P-values. 
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4.2 Characterizing the metabolic signature of diseases 
In the last years, metabolomics has already proved to be useful in the characterization 
of several important chronic and complex diseases by analyzing samples from human 
origins. Exploring pathologies through this holistic approach can shed new light on 
their mechanisms and their impact on humans, discovering new possible biomarkers 
and identifying biochemical pathways involved in disease pathogenesis. In this thesis, 
NMR-based metabolomics has been used to characterize disease signatures using 
biological samples. Three different studies are presented in this section. 
Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder that slowly 
destroys memory, thinking skills, and eventually the ability to accomplish even the 
simplest daily tasks. It is the most common neurodegenerative disease, affecting about 
5% to 7% of the population over 60 years of age64. The need to identify novel molecular 
targets for AD to use in early diagnosis, prognosis, prediction of the disease evolution, 
and therapeutics is crucial65; therefore, to effectively address all these challenges 
detailed information about the underlying molecular biochemistry of AD are required.  
In our study (see paragraph 4.2.1), for the first time to the best of our knowledge, we 
performed a comparative analysis of the CSF metabolome with an untargeted NMR-
based approach in a cohort of patients showing a typical protein CSF AD profile (altered 
CSF levels of Aβ42, total tau and phosphorylated tau proteins), both at pre-dementia 
(MCI-AD, 19 patients) and dementia (AD, 41 patients) stages, and of patients with MCI 
not due to AD (MCI with normal CSF profile, MCI-MCI, 21 patients), with the aim of 
identifying the metabolomic pattern correlating with the CSF AD biomarker profile.  
Our results confirm the usefulness of CSF metabolomics to discriminate AD from MCI-
MCI patients (sensitivity 76%, specificity 81%, accuracy 78%), and introduce also the 
evaluation of MCI-AD patients, as metabolically intermediate. A panel of seven 
metabolites (creatine, acetoacetate, 3-methyl-2-oxovalerate, 3-hydroxybutyrate, 
pyruvate, valine, and glycine) has been found lower in MCI-MCI with respect to AD 
patients. These data allowed us to confirm in AD the shift of the brain metabolism from 
glucose to ketone bodies, probably the first evidence of AD that precedes the onset of 
any functional impairment or neurological damage, and also to identify alterations in 
the metabolism of creatine and 3-methyl-2-oxovalerate. Interestingly, MCI-AD patients 
showed intermediate trends, indicating that the progression from MCI-MCI to AD is a 
sort of continuum metabolic spectrum. These data are particularly interesting if 
compared with the CSF core biomarker concentrations: using the available biomarkers 
the MCI-AD group can be considered identical to overt AD though they are still in a pre-
dementia stage, while this is not true from the point of view of CSF metabolome. 
In the second study presented in this section, we adopt an untargeted metabolomic 
approach to investigate the influence of chronic inflammatory rheumatic diseases 
(CIRDs) on the urine metabolome by the comparison with healthy controls and another 
immuno-mediated disorder, the multiple sclerosis (MSC) (see paragraph 4.2.2). The 
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pathological mechanisms of rheumatic diseases are complex involving both genetic 
and environmental factors; furthermore, their underlying mechanisms remain still 
poorly understood. Urines collected from 39 CIRDs patients, 25 healthy subjects and 
26 MSC patients were analyzed using 1H NMR spectroscopy, and the NMR spectra were 
examined using PLS-DA. Clear discriminations between CIRDs patients and healthy 
controls (average diagnostic accuracy 83.5%±1.9%), as well as between CIRDs patients 
and MSC patients (diagnostic accuracy 81.1%±1.9%), were obtained; conversely, no 
statistically significant discrimination between CIRDs and MSC patients has been 
found. Furthermore, we have also identified several metabolites down-regulated in the 
urine of CIRDs patients: significantly lower urinary levels (p < 0.05) of leucine, valine, 
alanine, 3-hydroxyisobutyric acid, 3-hydroxyisovaleric acid, glycine, citric acid, 
creatinine, hippuric acid and methylnicotinamide relative to controls were observed. 
Some of these metabolites (leucine, alanine, 3-hydroxyisobutyric acid, citric acid, 3-
hydroxyisovaleric acid and creatinine) were also significantly lower in CIRDs urines 
comparing to the MSC ones. These data can provide new insights to better clarify the 
pathophysiological mechanisms underlying these disorders, identifying anomalous 
metabolic traits like alterations in the protein metabolism and muscle turnover, and 
the presence of other connected pathologies. 
Finally, the last study here presented (see paragraph 4.2.3) concerned the 
characterization of the metabolic signature of primary biliary cirrhosis (PBC), a chronic 
autoimmune liver disease characterized by ongoing inflammatory destruction of the 
interlobular bile ducts, eventually leading to chronic cholestasis and biliary cirrhosis, 
by comparing PBC patients and healthy controls (HC). Secondly, this study aims at 
evaluating the possible association between the metabolomic profile of PBC and celiac 
disease (CD) patients. Serum and urine samples of 23 PBC patients, 21 CD patients and 
19 sex-matched healthy controls (HC) were analyzed for our purposes. PBC can be 
discriminated with respect to HC with 76.9-83.1% accuracies using serum and 78.1% 
accuracy using urine; moreover, PBC patient sera were characterized by altered levels 
(P-value <0.05) of citrate, lactate, lysine, phenylananine, proline, pyruvate, serine and 
tyrosine, and PBC urines showed lower levels of hippuric acid, p-cresolsulfate, 
pyruvate and trigonelline with respect to HC. Several hypotheses can be made to 
explain these results: since the liver plays a central role in the aromatic amino-acid 
catabolism, the hepatic function impairment probably caused the alterations of the 
aromatic amino acid levels; moreover, the evidence of an impaired energy metabolism 
in PBC can be probably associated with altered gut microbiota. 
PBC can be also discriminated with respect to CD with 78.2-88.3% accuracy for serum 
and 78.1% accuracy for urine, indicating thus two distinct metabolic signatures for 
these associated pathologies. In particular, PBC patients feature higher levels of 
cholesterol and high-density lipoprotein-cholesterol (HDL-C) with respect to CD 
patients. These differences are a clear result of a marked and opposite alterations in 
the lipid metabolism in these two disorders. 
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4.2.1 Cerebrospinal fluid metabolic profile correlates with Alzheimer’s core 
biomarkers 
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Cerebrospinal fluid metabolic profile correlates with Alzheimer’s core 
biomarkers 
 
 
Abstract 
Background: Metabolomics can identify different biochemical alterations in 
Alzheimer disease (AD). Metabolomic studies on AD patients using Nuclear Magnetic 
Resonance (NMR) spectroscopy are lacking. We sought for CSF metabolomic profile in 
AD patients characterized according to CSF AD biomarkers (Aβ42, p-tau, and t-tau), 
both at pre-dementia (mild cognitive impairment due to AD, MCI-AD) and dementia 
stage (ADdem), and in patients with MCI not due to AD (non-pathological CSF 
biomarker profile, MCI-MCI) using an untargeted NMR-based approach. 
 
Methods: 1H NMR analysis was performed on CSF samples collected from 41 AD-dem 
patients, 19 MCI-AD and 21 MCI -MCI.  
 
Results: In all NMR-spectra, 27 metabolites were identified. Metabolomic profiles well 
discriminated ADdem from MCI-MCI (Sens 76%, Spec 81%, Acc 78%). ADdem patients 
showed significantly higher levels of creatine, 3-methyl-2-oxovalerate, 3-
hydroxybutyrate, pyruvate, acetoacetate, valine and glycine as compared to MCI-MCI, 
while in MCI-AD the concentrations showed intermediate values. The combination of 
pyruvate, creatine and 3-methyl-2-oxovalerate gave the best discrimination between 
ADdem and MCI-MCI (81%, Spec 75%, AUC=0.87). This metabolite-based model 
classified as ADdem 10 out of 13 MCI-AD who developed dementia during the follow-
up (median 2 years follow up), while 3 out of 4 MCI-AD who did not convert to 
dementia were classified as MCI-MCI. 
 
Conclusions: The CSF metabolomic profile is different in ADdem patients as compared 
to patients with non-pathological CSF AD biomarker profile and it is significantly 
associated with the dementia stage. Our data also suggest the possible role of the 
metabolomic profile as prognostic factor of conversion to dementia in MCI-AD patients. 
This issue deserves further investigation. 
 
 
Keywords: Alzheimer’s disease, Metabolomics, Nuclear Magnetic Resonance, 
Cerebrospinal fluid, Aβ, total tau and phosphorylated tau. 
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Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, representing 
the commonest cause of dementia in older people (1). The pathophysiological changes 
that lead to cognitive decline, functional and behavioral impairment in AD patients, 
take place several years before the clinical symptoms appear (2). Variations in the 
levels of CSF core AD biomarkers total tau (t-tau), phosphorylated tau (p-tau) and 
amyloid beta 1-42 peptide (Aβ42) reflect the key aspects of disease pathogenesis (i.e. 
neuronal degeneration, tangles formation and aggregation and deposition of amyloid 
plaques) (3). AD patients typically show low concentrations of CSF Aβ42 and high 
concentrations of t-tau and p-tau already during the preclinical asymptomatic phase of 
AD (4–6). In clinical practice, abnormal CSF core AD biomarkers levels allow to identify 
patients affected by AD even in the prodromal phase (7). 
Very little is known about the molecular pathways involved in the onset and 
progression of AD. In this framework, metabolomics may provide an interesting 
approach to identify alterations in multiple biochemical networks over the course of 
AD. Metabolomics enables the identification, quantification and characterization of the 
complete ensemble of metabolites present in a biological specimen. Nuclear Magnetic 
Resonance spectroscopy (NMR) is one of the main analytical techniques for 
metabolomics. NMR metabolomics approach has proved to be useful as diagnostic (8–
11), prognostic (12, 13) and theragnostic (14) tool in different pathological conditions. 
Previous studies, performed both in animal models (15–18) and in human-derived 
samples like plasma, saliva, CSF and brain (19–25), have shown that metabolomics can 
provide powerful insights into the biochemical mechanisms of the AD clinical 
spectrum. So far, the available metabolomic studies on CSF have been performed by 
means of mass spectrometry (19, 26, 27), while no data have been reported for NMR 
in AD. 
Differently to a classical analytical approach focused on target diagnostic parameters, 
NMR metabolomics is an untargeted method, which provides a comprehensive picture 
of the most abundant metabolites in the metabolome of a sample (concentrations > 1 
μM). 
Since the complex metabolic changes associated with AD progression, namely calcium 
dysregulation, mitochondrial dysfunction, oxidative stress, inflammation, altered cell 
signaling and lipid homeostasis (28–31), may occur prior to the development of clinical 
symptoms, metabolomics in conjunction with the available biomarkers for AD 
diagnosis could give a richer information on the pathophysiological processes taking 
place during disease development. Encouraging data have been provided by 
investigations carried out in AD patients: CSF AD biomarkers have been found to be 
related to several metabolic derangements both in pre-dementia (mild cognitive 
impairment, MCI) and in dementia phases (32).  
To the best of our knowledge, this is the first study in which the CSF metabolome 
assessed by means of an untargeted NMR-based approach is evaluated in a cohort of 
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patients with a typical protein biomarker CSF AD profile based Aβ42, p-tau, and t-tau 
levels, both at pre-dementia (MCI-AD) and dementia (ADdem) stage, and patients with 
MCI not due to AD (MCI with normal CSF profile, MCI-MCI). The aim is to find out if a 
specific metabolomic pattern is associated with the CSF AD biomarker profile. 
 
Methods and Materials 
Patient cohort  
The patients included in this study were consecutively enrolled at the Center of 
Memory Disturbances of the University of Perugia. According to NIA-AA criteria (33, 
34), the cohort was composed of 41 patients affected by dementia diagnosed as high 
likelihood of AD pathophysiology (ADdem) (34), 19 MCI patients with CSF AD-like 
profile (MCI due to AD, MCI-AD)(33), and 21 MCI patients with normal CSF profile 
(MCI-MCI). Patients underwent clinical and neuropsychological assessments once a 
year (follow-up ranging from 1 to 4 years, median: 2 years). 
At baseline, clinical examination, extensive neuropsychological testing including Mini-
Mental State Examination (MMSE), blood chemistry and brain MRI scan (for excluding 
other causes of cognitive deficits) were carried out in all subjects included in the study. 
During the follow up, 13 out of 19 MCI-AD patients progressed to dementia according 
to the clinical and neuropsychological evaluation. 
All the procedures were performed following the Helsinki Declaration and in 
agreement with the local Ethics Committee policy. All patients and/or their legal 
representatives gave informed written consent for the lumbar puncture. 
 
CSF sampling 
CSF collection was performed according to previously published procedures (35) and 
following international guidelines (36, 37). Briefly 12mL of CSF were collected via 
lumbar puncture in sterile polypropylene tubes (Sarstedt), centrifuged at room 
temperature for 10min (2000× g), and divided into 0.5mL aliquots. Tubes were frozen 
at –80° C pending analysis. 
CSF Aβ42, t-tau and p-tau were measured with ELISA assays (Innotest β Amyloid 1–42, 
hTAU-Ag, p-TAU 181 Ag; Fujirebio, Gent, Belgium) (38). 
 
NMR sample preparation 
No standard operating procedures (SOPs) are available for CSF NMR sample 
preparation; since in CSF both high and low molecular weight metabolites are present, 
samples were prepared according to blood serum/plasma SOPs (39). Frozen CSF 
samples were thawed at room temperature and thoroughly mixed before use. A total 
of 350 µL of a sodium phosphate buffer (10.05 g Na2HPO4·7H2O; 0.2 g NaN3; 0.4 g 
sodium trimethylsilyl-[2,2,3,3-2H4]-propionate (TMSP) in 500 mL of H2O with 20% 
(v/v) 2H2O; pH 7.4) was added to 350 µL of each sample, and the mixture was vortexed 
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for 30 s. A total of 600 µL of each mixture was transferred into a 5 mm NMR tube 
(BrukerBioSpinsrl) for the analysis. 
 
NMR analysis 
Monodimensional 1H NMR spectra for all samples were acquired using a Bruker 600 
MHz spectrometer (BrukerBioSpin) operating at 600.13 MHz proton Larmor 
frequency and equipped with a 5mm PATXI 1H-13C-15N and 2H-decoupling probe 
including a z axis gradient coil, an automatic tuning-matching (ATM) and an automatic 
and refrigerated (6°C) sample changer (SampleJet). A BTO 2000 thermocouple served 
for temperature stabilization at the level of approximately 0.1 K at the sample. Before 
measurement, samples were kept for at least 5 min inside the NMR probehead, for 
temperature equilibration at 310 K.  
Water suppressed Carr–Purcell–Meiboom–Gill (CPMG) (40) spin echo pulse sequence 
(RD-90°-(τ-180°-τ)n-acq) with a total spin echo (2nτ) of 80 ms was used in order to 
obtain monodimensional 1H-NMR spectra in which broad signals from high molecular 
weight metabolites are attenuated (Supplementary Figure 1). 256 FIDs were collected 
into 73728 data points over a spectral width of 12019 Hz, with a relaxation delay (RD) 
of 4 s and acquisition time (acq) of 3.1 s. 
 
Spectral Processing 
Free induction decays were multiplied by an exponential function equivalent to a 0.3 
Hz line-broadening factor before applying Fourier transform. Transformed spectra 
were automatically corrected for phase and baseline distortions and calibrated (TMSP 
signal 0.0 ppm) using TopSpin 3.2 (BrukerBiospin).  
Each 1D CSF spectrum in the range between 0.5 and 10.00 ppm was segmented into 
0.02 ppm chemical shift bins and the corresponding spectral areas were integrated 
using AMIX software (version 3.8.4, BrukerBioSpin). Binning is a mean to reduce the 
number of total variables, to compensate for subtle signal shifts, and filter noise in the 
spectra, making the analysis more robust and reproducible (41, 42).  Regions between 
4.2 and 5.5 ppm containing residual water signal were removed and the dimension of 
the system was reduced to 411 bins. The total spectral area was calculated on the 
remaining bins and total area normalization was carried out on the data prior to 
pattern recognition. 
 
Statistical analysis 
All data analyses were performed using R, an open source software for the statistical 
analysis of data (43, 44). Multivariate analysis was conducted on processed data; 
instead, univariate analysis was performed on the whole spectra. 
Data reduction was carried out by means of projection into a Partial Least Square (PLS) 
subspace, only the first 30 components were retained in the model and the canonical 
analysis (CA) was applied to obtain the supervised separation of the analyzed groups. 
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For the purpose of classification, we used the K-nearest neighbors (k-NN) method 
(k=5) applied on the PLS-CA scores (8). Accuracy, sensitivity and specificity for the 
different classifications were assessed by means of a Monte Carlo cross-validation 
scheme (R script in-house developed). Briefly, 90% of the data were randomly chosen 
at each iteration as a training set to build the model. Then the remaining 10% was 
tested, and sensitivity, specificity and accuracy for the classification were assessed. The 
procedure was repeated 100 times to derive the average discrimination accuracy for 
each group of subjects. 
The spectral regions related to the metabolites were assigned in the NMR profiles by 
using matching routines of AMIX 3.8.4 (BrukerBioSpin) in combination with the 
BBIOREFCODE (BrukerBioSpin), a freely available dataset i.e. Human 
MetabolomeDataBase (HMDB) (45), and published literature when available. The 
metabolites quantification was determined by an in-house developed software (Takis 
et al. in preparation) in MATLAB programming suite (Mathworks, MATLAB version 
R2014b).  Our algorithm is based upon the unconstrained non-linear minimization of 
the metabolites NMR signals, employing a combination of lorentzian-gaussian 
functions By this approach, each NMR complex region (i.e. overlapping signals 
including macromolecules broad 1H NMR peaks, baseline distortions) of our interest 
is decomposed into its component parts, where the metabolites NMR peaks are 
deconvoluted and integrated, resulting into the accurate metabolite’s concentration 
determination. These concentrations were analyzed to determine the discriminating 
metabolites between the groups of patients. Wilcoxon–Mann–Whitney test (46)  was 
chosen to infer differences between the groups on the biological  assumption that 
metabolite concentrations are not normally distributed, and false discovery rate 
correction was applied using the Benjamini-Hochberg method (47). An adjusted P-
value < 0.05 was deemed significant. 
The prognostic role of biomarkers was tested with logistic regression; the results were 
evaluated with receiver operating characteristics (ROC) analysis. 
Moreover, the Pearson correlations among the clinical variables and CSF metabolites 
were calculated using the function “corr.test” implemented in the R-library “psych”. 
The levelplot of the correlation matrix was built using the R-function “levelplot”, 
implemented in the “lattice” package. 
 
Results 
Cohort characteristics 
Demographic data, MMSE score and CSF protein biomarkers levels of the cohort are 
reported in Table 1. As the classification criterion of the patients was based on the CSF 
profile, as expected, CSF biomarkers were substantially similar in MCI-AD and ADdem 
and significantly different from MCI-MCI. Likewise, the lowest MMSE scores were 
observed in the ADdem group. 
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NMR analysis 
1H NMR CSF metabolomic profiles were obtained for all patients included in the study 
using the CPMG sequence (Supplementary Figure 1) in order to suppress broad 
resonances originating from large macromolecules. This procedure improves the 
baseline by avoiding the use of filtration or extraction methods, thus facilitating the 
quantification process. In all NMR spectra 27 metabolites, representing ~80% of all 
quantifiable peaks present in each CSF spectrum, were unambiguously identified 
(Supplementary Figure 2) and quantitated in arbitrary units.  
Correlations between clinical data and metabolite concentrations were calculated 
(Figure 1, Supplementary Table 1). Among all metabolites, creatinine showed the 
highest correlations with t-tau and p-tau, and 3-methyl-2-oxovalerate presented the 
highest anticorrelations with Aβ42/p-tau and Aβ42/t-tau ratios. 
 
Comparative metabolomic analysis  
Using a PLS-CA-kNN model, the CSF metabolomic profiles of ADdem and MCI-MCI 
patients were classified, and showed significant differential clustering (Figure 2), with 
a remarkable separation of the two groups yielding 76% sensitivity (95% CI 73-79%), 
81% specificity (95% CI 79-83%), and 78% accuracy (95% CI 75-80%). The 
discrimination accuracy obtained with the PLS-CA model was validated in a 
permutation test obtaining a P-value of 0.01. 
An analysis of the concentrations of the metabolites assigned in the NMR spectra was 
conducted to identify which metabolites are statistically different between the two 
groups of patients: ADdem patients were characterized by significantly (adjusted P-
value< 0.05) higher levels of seven metabolites: creatine, 3-methyl-2-oxovalerate, 3-
hydroxybutyrate, pyruvate, acetoacetate, valine, and glycine; moreover, the 
pyruvate/lactate ratio was significantly more elevated in ADdem patients (Table 2). 
Pairwise discrimination, using the PLS-CA model, of MCI-MCI vs. MCI-AD, and ADdem 
vs. MCI-AD did not reach statistical significance (respectively, 51% and 43% 
discrimination accuracy). Interestingly, however, the metabolites showing higher 
levels in ADdem with respect to MCI-MCI exhibit intermediate levels in the MCI-AD 
group (Figure 3, Supplementary Table 2). 
 
Using the most significant metabolites to discriminate AD from MCI-MCI 
A classification model able to discriminate ADdem from MCI-MCI was built using a 
logistic regression based on creatine, pyruvate, and 3-methyl-2-oxovalerate 
concentrations. These metabolites were chosen on the basis of the P-values being the 
three most statistically significant metabolites (adjusted P-value <0.05) in the MCI-MCI 
vs. ADdem comparison. 
The area under the ROC curve (AUC) for each metabolite separately was found to be 
0.83 for creatine, 0.77 for pyruvate, and 0.79 for 3-methyl-2-oxovalerate; interestingly, 
the combined model reached an AUC of 0.87 (Figure 3). Using this combination of 
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metabolites, 81% sensitivity, 75% specificity, and 79% accuracy were obtained setting 
a threshold of 0.64 on the fitted values obtained by logistic regression, thus maximizing 
both sensitivity and specificity. 
This metabolite-based model was used to analyze the MCI-AD group (considering only 
the 17 patients for whom follow up information was available): 65% of the patients 
were classified as ADdem and 35% as MCI-MCI. These results are particularly 
interesting if the follow up information is considered: indeed, 10 out of 13 patients 
classified as ADdem by the model had developed ADdem at follow up, and 3 out of 4 
patients classified as MCI-MCI did not show an evolution of the disease at follow up, 
despite the positivity of CSF biomarkers. These data suggest that the metabolomic 
profile, obtained through this metabolite-based model, could predict whether a patient 
classified as MCI-AD could progress to dementia or not. 
 
Discussion 
CSF AD biomarkers (i.e. Aβ1-42, t-tau, p-tau) have been defined as “the CSF AD 
signature” (48), since they are found altered independently of the stage of the disease, 
including preclinical and prodromal phases. Their robustness justifies their use for 
diagnostic purposes in routine clinical work, where it is mandatory to formulate an 
early and accurate AD diagnosis, in view of forthcoming disease-modifying drugs. The 
untargeted metabolomic approach represents an important source for anchoring the 
CSF AD signature to a restricted panel of metabolites characterizing AD also in its 
prodromal phase. 
By using NMR, we investigated the CSF metabolomic pattern in a cohort of patients 
characterized according to CSF AD biomarkers and clinical follow-up.  
The CSF metabolomic profile well discriminated ADdem from MCI-MCI, albeit, as 
expected, with lower accuracy than AD core biomarkers. Conversely, CSF metabolomic 
profile poorly discriminated MCI-AD patients from MCI-MCI, indicating a largely 
overlapping metabolomic picture in these two conditions. Twenty-seven metabolites 
were clearly identified and quantified in each analyzed CSF sample, and the univariate 
analysis of their concentrations enables the identification of those significantly 
different in ADdem as compared to MCI-MCI patients. ADdem patients showed higher 
levels of creatine, 3-methyl-2-oxovalerate, 3-hydroxybutyrate, pyruvate, 
pyruvate/lactate ratio, acetoacetate, valine, and glycine (Table 2). Interestingly, MCI-
AD patients showed intermediate values of metabolite concentrations (Supplementary 
Table 2). 
Based on CSF Aβ42, t-tau and p-tau profile (representing the pathophysiological 
fingerprint of Alzheimer’s pathology), the MCI-AD group is similar to ADdem, while CSF 
metabolomic pattern shows a sort of dynamic pattern from MCI-AD to ADdem. Of 
interest, the combination of pyruvate, creatine and 3-methyl-2-oxovalerate classified 
the MCI-AD patients in agreement with the clinical follow-up. These data allowed us to 
hypothesize that the metabolomic profile may reflect the risk of progression to 
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dementia in prodromal AD, thus assuming the role of prognostic marker of conversion 
from MCI-AD status to AD dementia. Further investigations are needed to confirm this 
hypothesis. 
The concomitant increase of pyruvate, pyruvate/lactate ratio and ketone bodies (i.e. 3-
hydroxybutyrate and acetoacetate) found in the ADdem group might be explained 
considering the reduction of the cerebral oxidative metabolism, a largely documented 
event already present in the early stage of disease (49–53). The decline in glucose 
metabolism in specific brain regions is associated with decreased expression of 
glycolytic enzymes and reduced activity of the pyruvate dehydrogenase complex (54, 
55), which is responsible for the conversion of pyruvate in Acetyl-CoA (51). The 
alteration of cerebral metabolism is also accompanied by the activation of alternative 
compensatory metabolic pathways utilizing less usual substrates such as ketone 
bodies (56), thus explaining the increase of 3-hydroxybutyrate and acetoacetate 
concentrations found in CSF of ADdem group. 
Creatine levels were also significantly higher in ADdem patients vs. MCI-MCI. The 
presence of creatine deposits has been observed in brain of transgenic AD mice and in 
post-mortem brain of AD patients (57, 58). Although the mechanism that causes 
creatine deposits is still unknown, it has been hypothesized that it might be the 
consequence of an altered creatine kinase (CK) activity (58). CK is a key enzyme in the 
brain energetic metabolism, and observations of aberrant CK activity in brain of AD 
patients have been previously reported (59, 60), thus suggesting a direct link between 
perturbed energy state, creatine metabolism and Alzheimer’s pathology. 
Of interest, from our data creatine appears as an unsuspected progression marker of 
Alzheimer’s disease: creatine itself well discriminated ADdem vs MCI-MCI, and the 
three metabolite-based model showed high efficiency in predicting MCI-AD 
progression to dementia. 
Glycine and valine also showed increased values in ADdem with respect to MCI-MCI 
and MCI-AD patients. Alterations of amino acids levels in AD patients have already been 
reported (27, 61–63). Conversely, no available data can help in interpreting the higher 
levels of 3-methyl-2-oxovalerate we found in ADdem group, where its concentration 
was significantly associated with Aβ42/t-tau and Aβ42/p-tau ratios. 
Limitations of our study are the small sample size of the subjects studied, and the lack 
of a validation set by an independent population. However, the accurate clinical and 
biochemical characterization of the patients included and the availability of follow up 
information, partly counteract the abovementioned limitations. 
In conclusion, the data obtained from this NMR-based investigation assessing the CSF 
metabolome in patients classified according to their CSF AD profile, show a panel of 
seven metabolites significantly increased in Alzheimer’s dementia patients with 
respect to non- Alzheimer’s patients. Furthermore, the use of a three-metabolite model 
(creatine, pyruvate, 3-methyl-2-oxovalerate) may predict dementia progression (or 
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may support the prediction of dementia progression) in MCI-AD subjects, who show 
an intermediate metabolomic profile. 
  
References 
1. Alzheimer’s Association (2016): 2016 Alzheimer’s disease facts and figures. 
Alzheimers Dement J Alzheimers Assoc. 12: 459–509. 
2. Morris JC, Price JL (2001): Pathologic correlates of nondemented aging, mild 
cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci MN. 17: 
101–118. 
3. Blennow K, Hampel H, Weiner M, Zetterberg H (2010): Cerebrospinal fluid and 
plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 6: 131–144. 
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. 
(2009): CSF biomarkers and incipient Alzheimer disease in patients with mild 
cognitive impairment. JAMA J Am Med Assoc. 302: 385–393. 
5. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et 
al. (2009): Cerebrospinal fluid biomarker signature in Alzheimer’s disease 
neuroimaging initiative subjects. Ann Neurol. 65: 403–413. 
6. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y, et al. (2009): 
Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology 
in patients with subjective cognitive impairment or mild cognitive impairment in 
the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8: 619–627. 
7. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. (2014): 
Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. 
Lancet Neurol. 13: 614–629. 
8. Calabrò A, Antonio, Gralka E, Luchinat C, Saccenti E, Tenori L (2014): A 
Metabolomic Perspective on Coeliac Disease. Autoimmune Dis. 2014: e756138. 
9. Tenori L, Hu X, Pantaleo P, Alterini B, Castelli G, Olivotto I, et al. (2013): 
Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance 
spectroscopy analysis. Int J Cardiol. 168: e113-115. 
10. Clish CB (2015): Metabolomics: an emerging but powerful tool for precision 
medicine. Cold Spring Harb Mol Case Stud. 1. doi: 10.1101/mcs.a000588. 
11. Johnson CH, Ivanisevic J, Siuzdak G (2016): Metabolomics: beyond biomarkers and 
towards mechanisms. Nat Rev Mol Cell Biol. 17: 451–459. 
12. Hart CD, Vignoli A, Tenori L, Uy GL, Van To T, Adebamowo C, et al. (2017): Serum 
Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at 
Increased Risk of Disease Recurrence in a Multicenter Population. Clin Cancer Res 
Off J Am Assoc Cancer Res. 23: 1422–1431. 
13. Tenori L, Giusti B, Vignoli A, Gori AM, Luchinat C, Grifoni E, et al. (2017): 
Metabolomics by Nuclear Magnetic Resonance identifies patients with high risk of 
death within two years after a cardiovascular event: The case of the amiflorence II 
study. Nutr Metab Cardiovasc Dis. 27: e39–e40. 
 
RESULTS | 101 
14. Wishart DS (2016): Emerging applications of metabolomics in drug discovery and 
precision medicine. Nat Rev Drug Discov. 15: 473–484. 
15. Dedeoglu A, Choi J-K, Cormier K, Kowall NW, Jenkins BG (2004): Magnetic 
resonance spectroscopic analysis of Alzheimer’s disease mouse brain that express 
mutant human APP shows altered neurochemical profile. Brain Res. 1012: 60–65. 
16. Marjanska M, Curran GL, Wengenack TM, Henry P-G, Bliss RL, Poduslo JF, et al. 
(2005): Monitoring disease progression in transgenic mouse models of 
Alzheimer’s disease with proton magnetic resonance spectroscopy. Proc Natl Acad 
Sci U S A. 102: 11906–11910. 
17. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, Randle S, et al. (2010): A 
metabolomic study of the CRND8 transgenic mouse model of Alzheimer’s disease. 
Neurochem Int. 56: 937–947. 
18. Trushina E, Nemutlu E, Zhang S, Christensen T, Camp J, Mesa J, et al. (2012): Defects 
in mitochondrial dynamics and metabolomic signatures of evolving energetic 
stress in mouse models of familial Alzheimer’s disease. PloS One. 7: e32737. 
19. Trushina E, Dutta T, Persson X-MT, Mielke MM, Petersen RC (2013): Identification 
of altered metabolic pathways in plasma and CSF in mild cognitive impairment and 
Alzheimer’s disease using metabolomics. PloS One. 8: e63644. 
20. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y (2012): Identification of 
a new plasma biomarker of Alzheimer’s disease using metabolomics technology. J 
Lipid Res. 53: 567–576. 
21. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C (2009): A 
proposed metabolic strategy for monitoring disease progression in Alzheimer’s 
disease. Electrophoresis. 30: 1235–1239. 
22. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, et al. (2011): 
Metabolomics in early Alzheimer’s disease: identification of altered plasma 
sphingolipidome using shotgun lipidomics. PloS One. 6: e21643. 
23. Sato Y, Nakamura T, Aoshima K, Oda Y (2010): Quantitative and wide-ranging 
profiling of phospholipids in human plasma by two-dimensional liquid 
chromatography/mass spectrometry. Anal Chem. 82: 9858–9864. 
24. Paglia G, Stocchero M, Cacciatore S, Lai S, Angel P, Alam MT, et al. (2016): Unbiased 
Metabolomic Investigation of Alzheimer’s Disease Brain Points to Dysregulation of 
Mitochondrial Aspartate Metabolism. J Proteome Res. 15: 608–618. 
25. Trushina E, Mielke MM (2014): Recent advances in the application of 
metabolomics to Alzheimer’s Disease. Biochim Biophys Acta. 1842: 1232–1239. 
26. Czech C, Berndt P, Busch K, Schmitz O, Wiemer J, Most V, et al. (2012): Metabolite 
Profiling of Alzheimer’s Disease Cerebrospinal Fluid. PLOS ONE. 7: e31501. 
27. Ibáñez C, Simó C, Martín-Álvarez PJ, Kivipelto M, Winblad B, Cedazo-Mínguez A, 
Cifuentes A (2012): Toward a predictive model of Alzheimer’s disease progression 
using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem. 84: 
8532–8540. 
 
102| 
28. Supnet C, Bezprozvanny I (2010): Neuronal calcium signaling, mitochondrial 
dysfunction and Alzheimer’s disease. J Alzheimers Dis JAD. 20: S487–S498. 
29. Di Paolo G, Kim T-W (2011): Linking Lipids to Alzheimer’s Disease: Cholesterol and 
Beyond. Nat Rev Neurosci. 12: 284–296. 
30. Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S (2017): Role of inflammatory 
molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci. 376: 
242–254. 
31. Magi S, Castaldo P, Macrì ML, Maiolino M, Matteucci A, Bastioli G, et al. (2016): 
Intracellular Calcium Dysregulation: Implications for Alzheimer’s Disease. BioMed 
Res Int. 2016: 6701324. 
32. Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, et al. 
(2013): Alterations in metabolic pathways and networks in Alzheimer’s disease. 
Transl Psychiatry. 3: e244. 
33. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. (2011): 
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: 
recommendations from the National Institute on Aging-Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 
J Alzheimers Assoc. 7: 270–279. 
34. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. 
(2011): The diagnosis of dementia due to Alzheimer’s disease: recommendations 
from the National Institute on Aging-Alzheimer’s Association workgroups on 
diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers 
Assoc. 7: 263–269. 
35. Chiasserini D, Biscetti L, Farotti L, Eusebi P, Salvadori N, Lisetti V, et al. (2016): 
Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease 
Detection in Clinical Routine. J Alzheimers Dis JAD. 54: 55–67. 
36. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. 
(2009): A consensus protocol for the standardization of cerebrospinal fluid 
collection and biobanking. Neurology. 73: 1914–1922. 
37. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, 
et al. (2012): Recommendations to standardize preanalytical confounding factors 
in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. 
Biomark Med. 6: 419–430. 
38. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, et al. 
(2012): Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as 
predictors of dementia in a cohort of patients with mild cognitive impairment. J 
Alzheimers Dis JAD. 29: 229–238. 
39. Bernini P, Bertini I, Luchinat C, Nincheri P, Staderini S, Turano P (2011): Standard 
operating procedures for pre-analytical handling of blood and urine for 
metabolomic studies and biobanks. J Biomol NMR. 49: 231–243. 
 
RESULTS | 103 
40. Meiboom S, Gill D (1958): Modified Spin-Echo Method for Measuring Nuclear 
Relaxation Times. Rev Sci Instrum. 29: 688–691. 
41. Spraul M, Neidig P, Klauck U, Kessler P, Holmes E, Nicholson JK, et al. (1994): 
Automatic reduction of NMR spectroscopic data for statistical and pattern 
recognition classification of samples. J Pharm Biomed Anal. 12: 1215–1225. 
42. Holmes E, Foxall PJ, Nicholson JK, Neild GH, Brown SM, Beddell CR, et al. (1994): 
Automatic data reduction and pattern recognition methods for analysis of 1H 
nuclear magnetic resonance spectra of human urine from normal and pathological 
states. Anal Biochem. 220: 284–296. 
43. Ihaka R, Gentleman R (1996): R: A Language for Data Analysis and Graphics. J 
Comput Stat Graph. 5: 299–314. 
44. R Core Team (2014): R: A language and environment for statistical computing. . 
Retrieved from http://www.R-project.org/. 
45. Wishart DS, Lewis MJ, Morrissey JA, Flegel MD, Jeroncic K, Xiong Y, et al. (2008): 
The human cerebrospinal fluid metabolome. J Chromatogr B. 871: 164–173. 
46. Mann HB, Whitney DR (1947): On a test of whether one of two random variables 
is stochastically larger than the other. Ann Math Stat. 18: 50–60. 
47. Benjamini Y, Hochberg Y (1995): Controlling the False Discovery Rate: A Practical 
and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 57: 289–
300. 
48. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015): Clinical 
utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s 
disease. Alzheimers Dement J Alzheimers Assoc. 11: 58–69. 
49. Schubert D (2005): Glucose metabolism and Alzheimer’s disease. Ageing Res Rev, 
Stress, Neuropeptides and Age-Related Diseases. 4: 240–257. 
50. Blass JP (2000): The mitochondrial spiral. An adequate cause of dementia in the 
Alzheimer’s syndrome. Ann N Y Acad Sci. 924: 170–183. 
51. Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RD (2011): Shift in Brain 
Metabolism in Late Onset Alzheimer’s Disease: Implications for Biomarkers and 
Therapeutic Interventions. Mol Aspects Med. 32: 247–257. 
52. Mosconi L, Pupi A, De Leon MJ (2008): Brain glucose hypometabolism and 
oxidative stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci. 1147: 180–
195. 
53. Parnetti L, Gaiti A, Polidori MC, Brunetti M, Palumbo B, Chionne F, et al. (1995): 
Increased cerebrospinal fluid pyruvate levels in Alzheimer’s disease. Neurosci Lett. 
199: 231–233. 
54. Imahori K (2010): The biochemical study on the etiology of Alzheimer’s disease. 
Proc Jpn Acad Ser B Phys Biol Sci. 86: 54–61. 
55. Sorbi S, Bird ED, Blass JP (1983): Decreased pyruvate dehydrogenase complex 
activity in Huntington and Alzheimer brain. Ann Neurol. 13: 72–78. 
 
104| 
56. Henderson ST (2008): Ketone bodies as a therapeutic for Alzheimer’s disease. 
Neurother J Am Soc Exp Neurother. 5: 470–480. 
57. Gallant M, Rak M, Szeghalmi A, Del Bigio MR, Westaway D, Yang J, et al. (2006): 
Focally elevated creatine detected in amyloid precursor protein (APP) transgenic 
mice and Alzheimer disease brain tissue. J Biol Chem. 281: 5–8. 
58. Bürklen TS, Schlattner U, Homayouni R, Gough K, Rak M, Szeghalmi A, Wallimann 
T (2006): The Creatine Kinase/Creatine Connection to Alzheimer’s Disease: CK 
Inactivation, APP-CK Complexes, and Focal Creatine Deposits. J Biomed Biotechnol. 
2006. doi: 10.1155/JBB/2006/35936. 
59. Burbaeva GS, Aksenova MV, Makarenko IG (1992): Decreased Level of Creatine 
Kinase BB in the Frontal Cortex of Alzheimer Patients. Dement Geriatr Cogn Disord. 
3: 91–94. 
60. Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR (1994): 
Alterations of cerebral metabolism in probable Alzheimer’s disease: a preliminary 
study. Neurobiol Aging. 15: 117–132. 
61. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG (2007): Free amino acid 
and dipeptide changes in the body fluids from Alzheimer’s disease subjects. Amino 
Acids. 32: 213–224. 
62. Jiménez-Jiménez FJ, Molina JA, Gómez P, Vargas C, de Bustos F, Benito-León J, et al. 
(1998): Neurotransmitter amino acids in cerebrospinal fluid of patients with 
Alzheimer’s disease. J Neural Transm Vienna Austria 1996. 105: 269–277. 
63. Enche Ady CNA, Lim SM, Teh LK, Salleh MZ, Chin A-V, Tan MP, et al. (2017): 
Metabolomic-guided discovery of Alzheimer’s disease biomarkers from body fluid. 
J Neurosci Res. n/a-n/a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
RESULTS | 105 
List of Figures and Tables 
 
Figure 1. Correlations among clinical data (Aβ42 peptide, protein t-tau and p-tau, mini-
mental state examination score, age, Aβ42/p-tau and Aβ42/t-tau ratios) and 
metabolite concentrations reported as level plot.  
 
 
 
 
Figure 2. Clustering in the first two components of the PLS-CA model on NMR CSF 
profiles of ADdem patients (41 red dots) and MCI-MCI patients (21 green dots). 
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Figure 3. Box plot showing levels of representative metabolites in ADdem (red), MCI-
AD (cyan), and MCI-MCI patients (green). 
 
 
 
 
Figure 4. The Receiver Operating Characteristic (ROC) curve of the creatine-pyruvate-
3-methyl-2-oxovalerate model. The area under the ROC curve (AUC) is also reported. 
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Table 1. Clinical, demographic and biomarker feature of the patients  
MCI-MCI MCI-AD ADdem 
No (M/F) 21 (15/6) 19 (9/10) 41 (16/25) 
MMSE 26.3 ± 2.2 24.1 ± 2. 6 16.6 ± 4.0 
Aβ42 (pg/mL) 1010 ± 392 407 ± 92 478 ± 150 
t-Tau (pg/mL) 288 ± 125 680 ± 271 782 ± 361 
p-Tau (pg/mL) 51 ± 16 108 ± 54 108 ± 57 
mean ± SD 
 
 
Table 2. Comparison of CSF metabolite concentrations in ADdem and MCI-MCI 
patients (Wilcoxon test) 
 
 
ADdem 
(median ± MAD) 
MCI-MCI 
(median ± MAD) 
P-value 
Adjusted 
P-value 
Effect size 
(Cliff's Δ) 
Creatine 990 ± 116 828 ± 71 P< 0.0001 0.0002 0.6632 
3-methyl-2-oxovalerate 98 ± 21 51 ± 45 0.0002 0.0036 0.5563 
Pyruvate/lactate 0.3 ± 0.1 0.07 ± 0.06 0.0014 0.0109 0.489 
Pyruvate 1204 ± 428 243 ± 205 0.0015 0.0109 0.4866 
3-hydroxybutyrate 127 ± 27 82 ± 16 0.0043 0.022 0.4402 
Acetoacetate 130 ± 37 101 ± 22 0.0045 0.022 0.4379 
Valine 285 ± 53 235 ± 56 0.0058 0.0241 0.4262 
Glycine 470 ± 79 383 ± 44 0.0067 0.0243 0.4193 
Acetate 846 ± 462 1706 ± 812 0.0172 0.0553 -0.3705 
Citrate 2588 ± 373 2322 ± 369 0.0269 0.073 0.3449 
Leucine 475 ± 88 427 ± 71 0.0302 0.073 0.338 
Mannose 281 ± 53 233 ± 39 0.0302 0.073 0.338 
Alanine 342 ± 75 307 ± 48 0.0741 0.1389 0.2799 
Ethanol 32 ± 15 64 ± 52 0.0693 0.1389 -0.2846 
Glucose 9117 ± 811 8829 ± 558 0.0766 0.1389 0.2776 
Lactate 3862 ± 370 3569 ± 373 0.0626 0.1389 0.2915 
Acetone 347 ± 72 294 ± 53 0.1339 0.2103 0.2358 
Glutamine 1248 ± 94 1179 ± 53 0.1378 0.2103 0.2334 
Isoleucine 89 ± 22 76 ± 22 0.146 0.2116 0.2288 
2-hydroxybutyrate 193 ± 40 162 ± 36 0.1726 0.2383 0.2149 
Isobutyrate 182 ± 20 171 ± 18 0.2362 0.3114 0.187 
Creatinine 1258 ± 133 1196 ± 118 0.2607 0.315 0.1777 
Formate 151 ± 25 139 ± 13 0.2544 0.315 0.18 
Phenylalanine 202 ± 25 189 ± 33 0.2735 0.3173 0.1731 
Myo-inositol 731 ± 137 764 ± 126 0.4692 0.5234 -0.115 
3-hydroxyisovalerate 213 ± 40 213 ± 47 0.6473 0.6473 0.0732 
Choline 240 ± 71 251 ± 75 0.6263 0.6473 0.0778 
Tyrosine 138 ± 34 129 ± 30 0.6473 0.6473 0.0732 
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Supplementary materials 
 
Supplementary Figure 1. CPMG spin-echo pulse sequence (cpmgpr1d.comp; Bruker BioSpin) 
used for CSF sample acquisitions. 
  
 
Supplementary Figure 2. A CPMG spectrum of CSF sample with the metabolites assigned and 
quantified for all samples. A) Aliphatic region of the spectrum; B) Aromatic region of the 
spectrum, the area in the box is magnified for clarity. 
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Supplementary Table 1. Linear correlation among metabolite concentrations and clinical data. 
 
 
 
 
 
 
 
 
 
Metabolite Age MMSE Abeta 42 t-tau p-tau Abeta 42/t-tau Abeta 42/p-tau 
2-hydroxybutyrate 0.082 
(4.68E-01) 
-0.088 
(4.33E-01) 
-0.177 
(1.15E-01) 
0.066 
(5.65E-01) 
-0.108 
(3.47E-01) 
-0.157  
(1.66E-01) 
-0.095  
(4.08E-01) 
leucine 0.246 
(2.65E-02) 
-0.288 
(9.22E-03) 
-0.216 
(5.32E-02) 
0.32 
(4.03E-03) 
0.134 
(2.44E-01) 
-0.235  
(3.68E-02) 
-0.193  
(9.11E-02) 
isoleucine 0.182 
(1.05E-01) 
-0.267 
(1.61E-02) 
-0.08 
(4.78E-01) 
0.33 
(2.93E-03) 
0.206 
(7.10E-02) 
-0.148  
(1.94E-01) 
-0.094  
(4.13E-01) 
valine 0.223 
(4.58E-02) 
-0.304 
(5.74E-03) 
-0.154 
(1.71E-01) 
0.397 
(2.88E-04) 
0.229 
(4.37E-02) 
-0.225  
(4.63E-02) 
-0.167  
(1.44E-01) 
isobutyrate 0.009 
(9.39E-01) 
-0.011 
(9.22E-01) 
-0.072 
(5.25E-01) 
-0.009 
(9.34E-01) 
-0.136 
(2.36E-01) 
-0.076  
(5.05E-01) 
0.006  
(9.59E-01) 
3-methyl-2-oxovalerate 0.04 
(7.21E-01) 
-0.274 
(1.33E-02) 
-0.346 
(1.55E-03) 
0.366 
(9.12E-04) 
0.151 
(1.88E-01) 
-0.46  
(1.97E-05) 
-0.45  
(3.64E-05) 
ethanol -0.075 
(5.06E-01) 
0.245 
(2.73E-02) 
0.161 
(1.50E-01) 
-0.147 
(1.95E-01) 
-0.052 
(6.50E-01) 
0.321  
(3.97E-03) 
0.322  
(3.99E-03) 
3-hydroxybutyrate 0.323 
(3.25E-03) 
-0.181 
(1.05E-01) 
-0.095 
(3.96E-01) 
0.286 
(1.05E-02) 
0.129 
(2.61E-01) 
-0.167 
(1.40E-01) 
-0.162  
(1.57E-01) 
3-hydroxyisovalerate 0.219 
(4.99E-02) 
-0.055 
(6.23E-01) 
0.04 
(7.22E-01) 
0.168 
(1.39E-01) 
0.106 
(3.54E-01) 
-0.008  
(9.41E-01) 
0.023  
(8.40E-01) 
alanine 0.141 
(2.11E-01) 
-0.208 
(6.20E-02) 
-0.066 
(5.60E-01) 
0.422 
(1.07E-04) 
0.325 
(3.68E-03) 
-0.149 
(1.90E-01) 
-0.138  
(2.29E-01) 
acetate 0.085 
(4.51E-01) 
0.088 
(4.37E-01) 
0.248 
(2.53E-02) 
-0.183 
(1.06E-01) 
-0.074 
(5.22E-01) 
0.356  
(1.27E-03) 
0.32  
(4.27E-03) 
acetone 0.321 
(3.52E-03) 
-0.071 
(5.30E-01) 
-0.006 
(9.59E-01) 
0.118 
(3.00E-01) 
0.022 
(8.49E-01) 
-0.057 
(6.17E-01) 
-0.034  
(7.66E-01) 
acetoacetate 0.31 
(4.81E-03) 
-0.222 
(4.65E-02) 
-0.176 
(1.17E-01) 
0.273 
(1.51E-02) 
0.066 
(5.68E-01) 
-0.237  
(3.54E-02) 
-0.193  
(8.96E-02) 
pyruvate -0.106 
(3.48E-01) 
-0.205 
(6.60E-02) 
-0.305 
(5.61E-03) 
0.284 
(1.11E-02) 
0.122 
(2.89E-01) 
-0.393  
(3.47E-04) 
-0.384  
(5.15E-04) 
glutamine 0.116 
(3.03E-01) 
-0.293 
(8.03E-03) 
-0.121 
(2.82E-01) 
0.157 
(1.66E-01) 
0.07  
(5.40E-01) 
-0.189  
(9.53E-02) 
-0.187  
(1.01E-01) 
citrate -0.013 
(9.11E-01) 
-0.306 
(5.40E-03) 
-0.2  
(7.34E-02) 
0.091 
(4.25E-01) 
-0.045 
(6.94E-01) 
-0.169  
(1.37E-01) 
-0.184  
(1.06E-01) 
choline 0.139 
(2.17E-01) 
-0.164 
(1.44E-01) 
-0.048 
(6.72E-01) 
0.27 
(1.62E-02) 
0.208 
(6.73E-02) 
-0.146  
(1.99E-01) 
-0.2  
(7.98E-02) 
myo-inositol -0.042 
(7.07E-01) 
0.052 
(6.47E-01) 
0.068 
(5.44E-01) 
0.016 
(8.87E-01) 
-0.182 
(1.11E-01) 
0.041  
(7.22E-01) 
0.101  
(3.79E-01) 
glucose 0.037 
(7.42E-01) 
-0.251 
(2.41E-02) 
-0.128 
(2.55E-01) 
0.31 
(5.51E-03) 
0.167 
(1.44E-01) 
-0.134  
(2.38E-01) 
-0.167  
(1.43E-01) 
glycine 0.107 
(3.41E-01) 
-0.361 
(9.24E-04) 
-0.104 
(3.54E-01) 
0.372 
(7.24E-04) 
0.166 
(1.47E-01) 
-0.155  
(1.73E-01) 
-0.16  
(1.62E-01) 
creatine 0.14 
(2.12E-01) 
-0.313 
(4.50E-03) 
-0.343 
(1.73E-03) 
0.132 
(2.46E-01) 
0.12  
(2.95E-01) 
-0.307 
 (5.93E-03) 
-0.299  
(7.78E-03) 
creatinine 0.28 
(1.13E-02) 
-0.183 
(1.01E-01) 
-0.013 
(9.08E-01) 
0.527 
(5.99E-07) 
0.406 
(2.24E-04) 
-0.197  
(8.15E-02) 
-0.188  
(9.93E-02) 
lactate -0.002 
(9.84E-01) 
-0.247 
(2.64E-02) 
-0.181 
(1.06E-01) 
0.185 
(1.02E-01) 
0.06  
(6.03E-01) 
-0.191  
(9.21E-02) 
-0.201  
(7.73E-02) 
mannose 0.05 
(6.58E-01) 
-0.189 
(9.04E-02) 
-0.085 
(4.49E-01) 
0.146 
(1.99E-01) 
0.022 
(8.46E-01) 
-0.081  
(4.78E-01) 
-0.198  
(8.18E-02) 
phenylalanine 0.165 
(1.41E-01) 
0.016 
(8.89E-01) 
0.077 
(4.96E-01) 
0.006 
(9.58E-01) 
-0.054 
(6.36E-01) 
0.015  
(8.97E-01) 
0.136  
(2.36E-01) 
formate 0.044 
(6.96E-01) 
-0.264 
(1.72E-02) 
-0.064 
(5.67E-01) 
-0.063 
(5.82E-01) 
-0.085 
(4.61E-01) 
-0.09  
(4.28E-01) 
-0.082  
(4.74E-01) 
tyrosine 0.125 
(2.66E-01) 
-0.101 
(3.69E-01) 
0.05 
(6.60E-01) 
0.267 
(1.72E-02) 
0.156 
(1.74E-01) 
-0.01  
(9.31E-01) 
-0.016  
(8.89E-01) 
pyruvate/lactate -0.064 
(5.70E-01) 
-0.193 
(8.51E-02) 
-0.279 
(1.15E-02) 
0.301 
(6.98E-03) 
0.158 
(1.68E-01) 
-0.392  
(3.55E-04) 
-0.379  
(6.20E-04) 
Coefficient of correlation (P-value) 
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Supplementary Table 2. CSF metabolite concentrations in ADdem, MCI-MCI, and MCI-AD 
patients. 
Metabolite 
ADdem 
(median ± MAD) 
MCI-MCI 
(median ± MAD) 
MCI-AD 
(median ± MAD) 
Creatine 989.57 ± 116.17 828.44 ± 70.57 934.63 + 107.34 
3-methyl-2-oxovalerate 98.21 ± 20.79 51.43 ± 44.92 86.81 + 26.91 
Pyruvate 1204.3 ± 427.97 243.24 ± 205.11 1123.22 + 466.71 
Pyruvate/lactate 0.3 ± 0.1 0.07 ± 0.06 0.33 + 0.08 
3-hydroxybutyrate 126.73 ± 27.03 82.17 ± 15.91 100.94 + 26.25 
Acetoacetate 129.52 ± 36.83 100.55 ± 22.28 104.26 + 30.90 
Valine 285.28 ± 52.64 234.84 ± 55.79 261.43 + 39.54 
Glycine 469.64 ± 79.16 383.07 ± 43.97 409.01 + 62.24 
Acetate 846.01 ± 462.16 1705.86 ± 811.89 854.96 + 369.88 
Citrate 2588.44 ± 373.32 2321.74 ± 369.48 2436.26 + 306.62 
Leucine 474.96 ± 87.73 426.87 ± 70.67 440 + 40.56 
Mannose 281.3 ± 53.11 232.88 ± 38.78 232.8 + 72.89 
Alanine 341.93 ± 74.68 306.9 ± 48.15 305.64 + 63.31 
Ethanol 32.36 ± 14.82 64.16 ± 51.76 45.39 + 32.90 
Glucose 9117.47 ± 811.19 8828.65 ± 558.32 8759.28 + 927.47 
Lactate 3862.04 ± 369.66 3568.53 ± 373.38 3632.1 + 322.84 
Acetone 347.05 ± 72.2 293.53 ± 52.73 287.63 + 60.04 
Glutamine 1248.17 ± 93.69 1179.44 ± 53.35 1197.66 + 80.21 
Isoleucine 88.53 ± 21.61 76.25 ± 22.3 76.75 + 15.33 
2-hydroxybutyrate 193.28 ± 40.31 162.2 ± 35.86 165.09 + 30.00 
Isobutyrate 182.28 ± 19.7 171.43 ± 18.37 170.95 + 22.86 
Creatinine 1257.53 ± 133.42 1196.19 ± 117.83 1262.72 + 126.58 
Formate 151.39 ± 25.38 139.47 ± 13.1 137.08 + 24.93 
Phenylalanine 202.29 ± 25.21 188.77 ± 32.72 179.31 + 23.59 
Myo-inositol 730.75 ± 136.96 763.61 ± 126.11 744.55 + 120.44 
3-hydroxyisovalerate 213.19 ± 39.93 213.37 ± 47.2 186.77 + 54.90 
Choline 240.14 ± 71.36 251.16 ± 74.75 250.49 + 51.26 
Tyrosine 138.08 ± 33.59 128.85 ± 30.11 131.95 + 27.36 
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4.2.2 NMR-based metabolomics approach to study urines of chronic 
inflammatory rheumatic diseases patients 
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Supplementary materials: 
Fig. S1 600 MHz, 1H spectrum at 300 K of: a, an urine control sample; b, urine sample with 
anomalous metabolite signals at 8.63 – 8.73 ppm, and 7.77 – 7.80 ppm, labelled by asterisks; c, 
urine sample containing an “anomalous” concentration of glucose 
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Fig. S2 1H and 13C NMR spectral assignments of isonicotinic acid derivatives in a urine sample 
a) 1H-1H COSY, b) 1H-13C HSQC, c) 1H-13C HMBC spectra with the assignments   
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Fig. S3 Metabolites with –Log2(FC) negative values had a higher concentrations in CIRDs 
patients with respect to healthy subjects. Metabolites with –Log2(FC) positive values had 
higher concentration in healthy subjects. Green bars represented metabolites whose 
concentration is significantly different (p-value<0.05) in the comparison, red bars represented 
metabolite values that were not statistically relevant 
 
 
 
Fig. S4 Metabolites with –Log2(FC) negative values had a higher concentrations in CIRDs 
patients with respect to MS patients. Metabolites with –Log2(FC) positive values had higher 
concentration in MS patients. Green bars represented metabolites whose concentration is 
significantly different (p-value<0.05) in the comparison, red bars represented metabolite 
values that were not statistically relevant 
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Table S1 Metabolites concentrations in CIRDs, MS and healthy subjects urine. In the table are 
reported the concentrations ± the standard deviation and the p-values of the two comparisons 
obtained using the univariate non-parametric Kruskal test and corrected with the Benjamini & 
Hochberg correction 
 
 
 
Table S2 Metabolites assigned in the 1H NMR spectra of urines 
Metabolite Group 1H, ppm Multiplicity, J Hz 13C, ppm 
Alanine CH3 1.49 d: 7.2 17.3 
CH 3.79  51.8 
Choline N(CH3)3 3.23 s 55.1 
β−CH2 3.52  68.5 
α−CH2 4.06  56.8 
Citric A α,γ-CH 2.55 d: 16.1 45.9 
α',γ'-CH 2.70 d: 16.1 45.9 
β−C   76.5 
COOH   179.7 
COOH   182.5 
Creatinine N-CH3 3.05 s 31.3 
N-CH2 4.07 s 57.4 
N=C   169.8 
COO   189.4 
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Dimethylamine N-CH3 2.74 s 35.8 
Glycine CH2 3.57 s 42.7 
COOH   173.5 
Hippuric A Phe, o-CH 7.83 d 128.17 
Phe, m-CH 7.55 t 129.9 
Phe, p-CH 7.63 t 133.2 
CH2-NH 3.97 d: 5.8 45.0 
3-Hydroxyisobutyric A  CH3 1.07 d:7.1  
CH 2.49 
  
CH2 3.55; 3.70  
3-Hydroxyisovaleric A CH3 1.27 s 29.1 
C(OH)   70.9 
CH2 2.37 s 50.5 
Isoleucine δCH3 0.94   
γCH3 1.01   
γCH2 1.23; 1.45  
βCH 1.98  
 
αCH 3.63   
Lactic A CH3 1.34 d: 6.8 21.2 
CH 4.12 q 69.7 
Leucine CH3 0.97   
γ-CH 1.68   
β-CH2 1.73   
α-CH 3.72 
  
1-Methylnicotinamide 2-CH 9.27 s  
4-CH 8.96 d: 6.1  
5-CH 8.18   
6-CH 8.89 d: 8.2  
N-CH3 4.48 s  
Phenylacetylglycine Phe, m-CH 7.42  130.0 
Phe, o-CH 7.36  130.2 
Phe, p-CH 7.36  128.3 
Phe, C-1   136.1 
CH2-Phe 3.66  43.4 
CH2-NH 3.79  44.5 
Pyruvic A CH3 2.37   
Threonine CH3 1.34 d: 6.8 20.6 
β−CH 4.28  67.1 
α−CH 3.60  61.6 
Trigonelline 2-CH 9.12 s 146.9 
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4-CH 8.83 d: 7.3 145.7 
5-CH 8.08 dd: 8.6; 7.3 128.7 
6-CH 8.84 d: 8.6 147 
N-CH3 4.44 s 49.3 
Valine γ-CH3 1.05 d  
γ'-CH3 0.97 d  
β-CH 2.27 
  
α-CH 3.62 
  
 
 
Table S3. Comparison of the trend of common metabolites among urine, serum and CSF for 
CIRDs patients, MS patients and healthy controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CIRDs vs Healthy MS vs Healthy 
Urine Serum (Priori et al. 
2013) 
Serum (Zabek et a. 
2016) 
CSF (Reinke et al. 
2014) 
Serum (Dickens et 
al. 2014;  
Tavazzi et al. 2011)
Alanine ↓ ↑ ↓   
Lactate ↓ ↑ ↓ ↓  
Leucine ↓ ↑ ↓   
Citrate ↓ ↑ ↑ ↓  
Creatinine ↓  ↓ ↑ ↑ 
Glycine ↓ ↑    
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4.2.3 The metabolic signature of Primary Biliary Cirrhosis and its comparison 
with Coeliac Disease 
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The metabolic signature of Primary Biliary Cirrhosis and its comparison with 
Coeliac Disease 
 
 
 
Abstract 
Background & Aims 
Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease characterized by 
ongoing inflammatory destruction of the interlobular bile ducts, eventually leading to 
chronic cholestasis and biliary cirrhosis. This study primarily aimed at defining the 
metabolomic signature of PBC comparing PBC patients and healthy controls (HC). The 
second study purpose was to evaluate the possible association between the 
metabolomic profile of patients with PBC and celiac disease (CD).  
Methods 
23 PBC patients, 21 CD patients and 19 sex-matched healthy controls (HC) participated 
in the study and both serum and urine samples were collected. Monodimensional 1H-
NMR spectra for all samples were acquired and multivariate statistical analyses were 
used to evaluate the differences among the three clusters’ spectra and provide 
information about the involved metabolites.  
Results 
The classification accuracies to discriminate PBC and HC groups were 76.9-83.1% for 
serum and 78.1% for urine. PBC patient sera were characterized by altered levels (P-
value <0.05) of citrate, lactate, lysine, phenylananine, proline, pyruvate, serine and 
tyrosine. Moreover, PBC patients urines showed lower levels (P-value <0.05) of 
hippuric acid, p-cresolsulfate, pyruvate and trigonelline with respect to HC. In this 
study, we compare for the first time, the NMR metabolomic profiles of patients with 
PBC and CD, revealing significant differences. 
Conclusions 
Our results show that PBC displays a unique metabolomic fingerprint, and it is possible 
to speculate about an impaired energy metabolism in PBC, probably associated with 
altered gut microbiota. These data could provide clues for the comprehension of the 
PBC pathogenetic mechanism and the detection of novel therapeutical targets.  
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Introduction 
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by a 
slowly progressive immune-mediated inflammation of the small intrahepatic bile ducts 
that leads to their destruction. Bile ducts loss decreases bile secretion and causes 
retention of several toxins, inducing hepatic damages that could proceed from fibrosis 
to cirrhosis and subsequent liver failure1–3. PBC mainly affects middle-aged women 
(female:male ratio is established as at least 9:1)3 and at the moment of diagnosis 
patients are frequently asymptomatic or suffer from fatigue and pruritus2.  
Associated autoimmune diseases are frequently reported in the literature (up to 84% 
of the cases), especially thyroiditis, rheumatoid arthritis, Sjögren’s syndrome and 
coeliac disease (CD)1,4. In a 1999 study5 the frequent combination between PBC and 
CD, an immune-mediated enteropathy triggered by the ingestion of gluten in 
genetically susceptible subjects, was reported. However, more insights on metabolic 
and pathophysiological mechanisms that are common or different in these two 
diseases are still needed.  
In this framework, metabolomics could be a powerful tool: metabolites are the most 
sensitive reporters of any disease status or phenotype, indeed, even slight alterations 
on metabolic fluxes have significant effects on metabolites concentrations6. As a 
consequence, metabolomics is already be applied extensively to develop personalized 
diagnostic, prognostic and therapeutic approaches7,8, to monitor disease progression, 
treatment efficacy or predisposition to drug-related side effects9–14. 
In this paper, we report the results obtained by applying the NMR-based metabolomic 
approach to determinate the serum and urine metabolic profile of PBC patients and, 
for the first time, to compare the serum and urine global metabolomic profiles of 
patients with PBC and CD. 
 
Methods 
Study Population and Sample Collections 
Twenty-three adults with a clinical and/or histological diagnosis of PBC (20 females, 3 
males, mean age 56 years) participated in the study.  Two of them suffered from 
potential coeliac disease (PCD), one from CD and one patient was diagnosed with PBC-
autoimmune hepatitis overlap syndrome. Two of the followings three criteria were 
required for PBC diagnosis: anti-mitochondrial antibodies (AMAs) ≥1:40, serum 
alkaline phosphatase (ALP) 1.5 times upper limit of normal, liver histology with 
nonsuppurative destructive cholangitis and destruction of interlobular bile ducts. CD 
diagnosis was based on positive serology, anti-endomysium (EMA) and anti-tissue 
transglutaminase antibodies (tTGA), and typical mucosal atrophy at the duodenal 
biopsies. Small intestinal mucosal damage was graduated according to the 
classification of Marsh modified by Oberhuber15. PCD diagnosis was considered when 
patients presented a positive serology, genetic susceptibility (i.e. DQ2 and/or DQ8 
haplotype) with normal (Marsh 1) or almost normal (Marsh 1 or 2) small intestinal 
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mucosal architecture. CD and PCD were analyzed at the time of diagnosis, before 
starting a gluten-free diet. Twenty-one adults with CD (17 females, 4 males, mean age 
56 years) were recruited for the study. Nineteen healthy controls (HC) (17 females, 2 
males, mean age 46) were selected, after confirmation of negative EMA, tTGA and silent 
medical history for gastrointestinal and autoimmune diseases.  
Serum and urine samples were collected from PBC, CD, PCD patients and HC. Each 
subject had fasted overnight, urine and serum were collected pre-prandial in the 
morning, and immediately frozen and stored at - 80 °C until used. All information about 
sample collections are detailed in depth in the Supplemental Materials.  
Written informed consent was obtained from all enrolled patients and healthy controls 
and the study protocol was approved by the local ethical committee. 
 
Patients Characteristics 
Characteristics of the 63 PBC, CD patients and HC patients were analyzed. A high female 
prevalence of PBC patients was noticed (86,9%), according to the previous data of the 
literature. PBC, CD patients and HC were matched for sex and age. The median age of 
patients was 56 years for PBC (interquartile range (IQR) 48-66 years) and CD (IQR 
48,5-59,6 years) patients, while HC were 46 year old (IQR 39-53 years). Biopsy was 
performed in 9 patients, two were diagnosed as stage I, one as stage II, five as stage IV. 
Based on clinical and transient elastography assessment (Fibroscan) three other 
patients were attributed to stage I, two patients to stage II-III and two to stage IV. PBC 
patient characteristics are summarized in Table 1.  
 
NMR analyses 
Serum and urine samples were prepared following the standard protocols detailed by 
Bernini et al.16. According to standard practice17,18, all serum spectra were acquired at 
310 K using a Bruker 600 MHz spectrometer, and for each serum sample three 
monodimensional 1H-NMR spectra, namely NOESY, CPMG and Diffusion-edited 
spectra, were acquired allowing the selective detection of different molecular weight 
metabolites. Instead, urine monodimensional 1H NMR spectra were acquired with 
presaturation water peak suppression using a standard NOESY 1Dpresat samples at 
300 K. A detailed description about sample preparation and experiments is presented 
in the Supplemental Materials. 
Each 1D spectrum in the range between 0.2 and 10.00 ppm was segmented into 0.02 
ppm chemical shift bins and the corresponding spectral areas were integrated using 
AMIX software (version 3.8.4, Bruker BioSpin). Binning is a means to reduce the 
number of total variables and to compensate for small shifts in the signals, making the 
analysis more robust and reproducible19,20. Regions between 6.5 and 4.2 ppm 
containing residual water signal were removed and the dimension of the system was 
reduced to 375 bins. The total spectral area was calculated on the remaining bins and 
total area normalization was carried out on the serum data prior to pattern 
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recognition; instead, for urine spectra probabilistic quotient normalization21 was 
chosen, because it performs well even when large variations of dilution occur. 
 
Statistical analyses 
All data analyses were performed using R, an open source software for statistical 
analysis22. Multivariate data analysis was conducted on processed data and univariate 
statistical analysis was carried out on whole spectra by combining established 
methods. 
Principal component analysis (PCA) was use as dimension reduction technique and as 
a preparation of the data table before further statistical analyses. Data reduction was 
carried out by means of projection into a PCA subspace, only the first 25 components, 
explaining 99.9% of the variance in the data, were retained in the model and the 
canonical analysis (CA) was applied to obtain the supervised separation of the analyzed 
groups.  
For the purpose of classification we used the K-nearest neighbors (k-NN) method (k=5) 
applied on the PCA-CA scores23. All the accuracies reported and the confusion matrix 
for the different classifications were assessed by means of 100 cycles of a Monte Carlo 
cross-validation scheme (MCCV, R script in-house developed). Briefly, 90% of the data 
were randomly chosen at each iteration as a training set to build the model. Then the 
remaining 10% was tested and sensitivity, specificity and accuracy for the 
classification were assessed. The procedure was repeated 100 times to derive an 
average discrimination accuracy for each group of subjects. 
The spectral regions related to the metabolites were assigned in the 1H-NMR profiles 
by using matching routines of AMIX 3.8.4 (Bruker BioSpin) in combination with the 
BBIOREFCODE (Bruker BioSpin), freely available database24, and published literature 
when available. These spectral regions were integrated to obtain the concentrations of 
metabolites in arbitrary units and the concentrations were analyzed to determine the 
discriminating metabolites among PBC patients, CD patients and healthy subjects. 
Wilcoxon–Mann–Whitney test25 was chosen to infer differences among the groups on 
the biological assumption that metabolite concentrations are not normally distributed, 
a P-value <0.05 was deemed significant.  
  
Results 
The clusterizations of PBC, CD patients and HC for the four sets of experiments (serum 
CPMG, NOESY, and Diffusion-edited, and urine NOESY) are shown in Figure 1 and 
Figure 2.  
The PCA-CA models applied demonstrated to be effective for the discrimination 
between the 19 PBC patients and the 20 HC using each set of experiment, even if the 
best clusterization was provided by serum CPMG spectra. The classification accuracies 
obtained for each experiment are reported in Table 2: the existence of a metabolic 
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fingerprint of primary biliary cirrhosis in both serum and urine is clearly 
demonstrated. 
In the comparison between the serum CPMG spectra of PBC patients and HC, higher 
levels of phenylalanine, tyrosine, serine, proline, lysine, lactate, citrate and pyruvate 
could be recorded in patients with PBC (P-value < 0.05) (Figure 3A). Lower levels of 
hippuric acid, trigonelline, p-cresolsulfate and pyruvate, instead, were demonstrated 
in PBC patients versus HC using urine samples (Figure 3B). 
To assess the capability of metabolomic profiles to discriminate between PBC and CD 
patients, the NMR data of 20 PBC samples and of 21 CD samples were analyzed using 
PCA-CA analysis, as previously described. The classification accuracies estimated for 
each of the four experiments are reported in Table 3. In this comparison, the serum 
Diffusion-edited spectra showed the best clusterization results. Data showed that PBC 
and CD have two different and distinguishable metabolic fingerprints on both serum 
and urine spectra. In particular, citrate, pyruvate, serine and phenylalanine levels were 
found to be higher in CD patients rather than PBC patients using CPMG spectra. 
In order to better understand the metabolic differences among PBC, CD and HC, the 
Diffusion-edited spectra was then analyzed, which is known to provide relevant 
information on lipoprotein lipids and subclasses (Supplemental Figure 1). PBC patients 
featured lower levels of cholesterol (C18) as compared with HC (P-value 0.0182). More 
relevant differences were remarkable comparing PBC and CD patients: cholesterol 
(C18) and –N(CH3)3 groups in molecules containing the choline moiety were found 
significantly higher in PBC patients (P-values are respectively 0.0027 and 0.0072). 
Interestingly, three patients suffering from both diseases (PBC and CD) were used as 
independent test set: on serum CPMG spectra using the classification model (PCA-CA-
kNN) applied to the three groups (PBC, CD, HC) these three patients with both diseases 
were placed in the metabolic region between PBC and CD (total discrimination 
accuracy of 71.9%) (Supplemental Figure 2). The same result was obtained with the 
other serum NMR spectra. With urine samples, instead, one patient was misclassified 
as healthy, confirming the evidence that the metabolic fingerprint of these two diseases 
is weaker in urine than in serum. 
  
Discussion 
The liver plays a critical role in human metabolism, regulating homeostasis and the 
synthesis, metabolism and catabolism of many products. For this reason, metabolomics 
has been used for detecting alterations of metabolic profiles in several liver diseases26–
28. In the present study, we applied NMR-based metabolomics to study serum and urine 
samples obtained from PBC patients, healthy controls and CD patients. To the best of 
our knowledge this is the first study analyzing systematically the metabolomic profile 
of PBC and CD patients. 
Our study shows that the 1H NMR metabolic profiles of PBC patients and healthy 
controls are definitely different, obtaining 83.1%, 79.6%, and 76.9% discrimination 
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accuracies with CPMG, NOESY, and Diffusion spectra respectively using serum, and 
78.1% accuracy using urine.   
Compared to healthy controls, the CPMG serum metabolic profiles of PBC patients 
show increased levels of phenylalanine, tyrosine, serine, proline, lysine, lactate, citrate 
and pyruvate. The lowest discrimination accuracy is obtained from urine NOESY 
spectra, as expected from the higher day-to-day variability of the urine metabolic 
profiles29,30. Despite this, a PBC urine fingerprint can be defined, characterized by 
lower levels of hippuric acid, trigonelline, p-cresolsulfate and pyruvate. Even if there is 
not a unique possible interpretation, several hypotheses can be proposed to explain 
these results. 
1) The liver plays a central role in the aromatic amino-acid catabolism and in our study 
PBC patients present increased level of two of these amino-acids: phenylalanine and 
tyrosine. These aminoacids are metabolically closely related, indeed, phenylalanine is 
converted to tyrosine by the hepatic enzyme phenylalanine hydroxylase31. The 
observed imbalance in serum amino-acids levels, as highlighted by the decrease in the 
ratio between branched chain amino acids and aromatic amino acids (BCAA/AAA ratio 
in PBC and healthy controls respectively: 2.18 and 3.11) could be related to the hepatic 
function impairment. These results are consistent with previous studies32,33, which 
revealed that during a hepatic failure BCAA blood levels decrease while the levels of 
AAA increase, and hypothesized that the cause of these abnormalities is a reduction in 
the insulin/glucagon ratio disturbing the balance between anabolism and catabolism.  
2) The increased serum levels of lactate and pyruvate could be explained with an 
impairment of the mitochondrial respiratory chain. As described in a previous study, 
the autoantibodies AMAs typical of PBC, seem to have direct effects in muscle 
metabolism leading to an excessive use of the anaerobic respiration34. The inability to 
adapt and compensate acidosis possibly induces systemic lactic acidosis that 
potentially correlated with fatigue, a frequent symptom in PBC patients. The 
hypothesis of a peripheral mechanism in the development of fatigue in PBC patients is 
further supported by the high levels of tyrosine found in serum; indeed, tyrosine is a 
key precursor in the biosynthesis of neurotransmitters (like dopa, dopamine, 
epinephrine and norepinephrine) and its reduction is associated with fatigue35. 
Moreover, fatigue symptoms improve only marginally after liver transplantation, most 
likely indicating that the cognitive symptoms operate outside the liver36.  
3) It is interesting to underline that PBC patients show a reduction in the urinary 
excretion levels of three metabolites directly produced  by the intestinal microbiota: p-
cresol, a uremic toxin that represents the end-product of the catabolism of tyrosine and 
phenylalanine37,38, hippuric acid, obtained by the conjugation of benzoic acid with 
glycine39, and trigonelline. This evidence could indicate an alteration of the gut 
microbiota metabolism. Previous studies reported changes in colonic/fecal microbiota 
of cirrhotic patients40, and immune responses involving the microbiota have been 
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proposed as relevant in the pathogenesis of PBC41; therefore, our results could be 
considered as a sort of direct consequences of these processes. 
Bertini et al.9,10,42 have extensively described the metabolic signature of CD (overt and 
potential) applying the same NMR-metabolomic approach here described, and 
identifying important alterations of the metabolic profiles of patients with respect to 
controls, especially for what concerns energy and ketone body metabolism, and gut 
microbiota alterations. In this study, we established a significant differential clustering 
comparing PBC and CD metabolic profiles. Interestingly, the discrimination accuracy in 
this comparison using serum samples increases upon going from CMPG to NOESY, to 
Diffusion-edited spectra, a trend opposed of what emerged comparing PBC with HC. 
Actually, Diffusion-edited spectra model ensures the highest accuracy in 
discriminating PBC and CD, and from the spectra analysis emerged that PBC patients 
feature higher levels of cholesterol and high-density lipoprotein-cholesterol (HDL-C) 
with respect to CD patients. These differences are a clear result of an opposite 
alterations in the lipid metabolism: PBC, indeed, is characterized by a marked 
increment of the enterohepatic circulation of various compounds, especially of lipid 
moieties, and several studies have demonstrated that cholesterol metabolism is 
markedly impaired both for synthesis and biliary elimination in PBC patients1,43. 
Conversely, not only untreated coeliac disease patients are associated with lower 
concentrations of total cholesterol and high-density lipoprotein-cholesterol, but it 
seems that a reduction in serum HDL-C level is present even in the absence of 
gastrointestinal symptoms44,45. Therefore, HDL-C could be a key biomarker for the 
early diagnosis of CD and for the follow-up of the patients after gluten free diet 
treatment44–46. Nonetheless, the underlying mechanisms remain still poorly 
understood: intestinal malabsorption, reduction of the cholesterogenesis, reduction in 
cholesterol-transporting lipoproteins, decreased apolipoprotein (Apo)-AI secretion 
from the altered small bowel mucosa, increased biliary secretion and high fecal 
elimination of cholesterol have all been proposed as explanations of this 
phenomenon45,46. 
Nevertheless, it was possible to identify differences also analyzing low molecular 
weight metabolites: the serum concentrations of citrate, pyruvate, serine and 
phenylalanine resulted appreciably higher in PBC patients with respect to CD. In 
particular, the differences related to pyruvate and citrate could indicate a different 
impairment in the energetic metabolism in the two diseases.  
In conclusion, in the present work we have demonstrated the presence of a clear 
metabolic fingerprint in serum and urine of PBC patients that is able to discriminate 
them from healthy controls. Our results show that the PBC NMR metabolomic profiles 
differ markedly from those of CD patients, indicating that these two pathologies, whose 
association is well established4, are characterized by different metabolic alterations. 
Undoubtedly, our results require validation in a larger independent cohort of patients 
to confirm their reproducibility. Moreover, all PBC patients in this study received 
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systemic therapy, making it impossible to know whether the therapy was directly 
responsible for changes in PBC metabolic fingerprint. An ideal series would have an 
arm with no intervention, although this is unlikely to be feasible because patients are 
often treated also before the final diagnosis. 
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Figure 1. PCA-CA-kNN score plots, discrimination between PBC (red dots, n = 20) and 
healthy controls (blue dots, n = 19). A) CPMG serum samples; B) NOESY1D serum 
samples; C) Diffusion-edited serum samples; D) NOESY1D urine samples. 
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Figure 2. PCA-CA-kNN score plots, discrimination between PBC patients (red dots, n = 
20) and CD patients (blue dots, n = 21). A) CPMG serum samples; B) NOESY1D serum 
samples; C) Diffusion-edited serum samples; D) NOESY1D urine samples. 
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Figure 3. Metabolites with –Log2(FC) negative values had higher concentrations in PBC 
patients with respect to healthy subjects. Green bars represented metabolites whose 
concentration is significantly different (P-value <0.05) in the comparison, red bars 
represented metabolite values that were not statistically relevant. A) serum analysis; 
B) urine analysis. 
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Table 1. PBC patients and their characteristics. IQR= interquartile range; GGT = 
gamma-glutamyl transferase, ALP= alkaline phosphatase; AST= 
aspartate transaminase, ALT= alanine transaminase, anti-mitochondrial antibodies 
  
PBC (n = 23) 
 
Sex (M/F) (n) 
4/19 
Age (median, IQR) (years) 56 (48-66) 
Haemoglobin (median IQR) (g/dL) 12,45 (11,175-13,45) 
Total Bilirubin (median, IQR) (mg/dL) 0,985 (0,52-1,685) 
Conjugated Bilirubin (median, IQR) 
(mg/dL) 
0,325 (0,2-1,14) 
γGT (median, IQR) (U/L) 128 (40-194) 
ALP (median, IQR) (U/L) 217,5 (151-323,75) 
AST (median, IQR) (UI/L) 56 (25-120) 
ALT (median, IQR) (UI/L) 67 (25-110) 
AMAs (median, IQR) (n) 1/320 (1/240-1/480) 
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Table 2. Cross-validation classification results obtained using CPMG, NOESY, 
Diffusion-edited serum spectra and NOESY urine spectra of PBC patients and healthy 
controls (HC). 
 
 Sensitivity Specificity Accuracy 
  
PBC - HC 
Serum CPMG spectra 
77.3% 
(95% CI 76.7-
78.0%) 
89.3% 
(95% CI 88.8-
89.8%) 
83.1% 
(95% CI 82.7-
83.6%) 
 
Serum NOESY spectra 
75.4% 
(95% CI 74.8-
76.0%) 
84.2% 
(95% CI 83.5-
84.8%) 
79.6% 
(95% CI 79.3-
80.1%) 
 
Serum Diffusion-edited spectra 
70.5% 
(95% CI 69.7-
71.2%) 
83.7% 
(95% CI 83.1-
84.2%) 
76.9% 
(95% CI 76.4-
77.4%) 
 
Urine NOESY spectra 
74.8% 
(95% CI 74.2-
75.4%) 
81.6% 
(95% CI 81.0-
82.2%) 
78.1% 
(95% CI 77.7-
78.6%) 
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Table 3. Cross-validation classification results obtained using CPMG, NOESY, 
Diffusion-edited serum spectra and NOESY urine spectra of PBC patients and CD 
patients. 
 
 Sensitivity Specificity Accuracy 
  
PBC - CD 
Serum CPMG spectra 
91.8% 
(95% CI 91.4-
92.2%) 
65.2% 
(95% CI 64.4-
66.0%) 
78.2% 
(95% CI 77.8-
78.6%) 
 
Serum NOESY spectra 
85.3% 
(95% CI 84.8-
85.8%) 
84.3% 
(95% CI 83.7-
84.8%) 
84.8% 
(95% CI 84.4-
85.2%) 
 
Serum Diffusion-edited spectra 
89.3% 
(95% CI 88.8-
89.8%) 
87.3% 
(95% CI 86.8-
87.8%) 
88.3% 
(95% CI 88.0-
88.6%) 
 
Urine NOESY spectra 
87.3% 
(95% CI 86.8-
87.8%) 
69.4% 
(95% CI 68.7-
70.1%) 
78.1% 
(95% CI 77.7-
78.7%) 
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Supplementary materials 
Sample Collections 
Venous blood samples were collected into plastic serum tube (6 mL), with increased silica act 
clot activator, silicone-coated interior (Becton Dickinson, Plymouth, U.K.). Clotting was 
obtained by standing tubes vertically at room temperature (22 °C) for 60 min. Tubes were 
centrifuged at 1,800 RCF for 10 min at room temperature. Within 15 min of centrifugation, the 
supernatant (serum) was transferred in 500 μL aliquots to prelabeled 1 mL cryovials (Bruker 
BioSpin, Milan, Italy). Three aliquots per patient were immediately frozen and stored at - 80 °C 
until used.  
First morning pre-prandial urine void was used for the collection period. Patients were 
supplied with appropriate collection instructions and information on fasting, diet and 
medication restrictions when necessary. The urine samples were collected into prelabeled 
sterile collections cups. One milliliter of urine sample was transferred into prelabeled 1 mL 
sterile cryovials (Nalgene, Rochester, NY). Three aliquots per patient were immediately frozen 
and stored at - 80 °C until used.  
 
NMR samples preparation 
Frozen urine and serum samples were thawed at room temperature and shaken before use, 
both kinds of biological specimens were prepared according to standard operating 
procedures1.  A total of 300 µL of a phosphate sodium buffer (10.05 g Na2HPO4·7H2O; 0.2 g 
NaN3; 0.4 g sodium trimethylsilyl [2,2,3,3-2H4]propionate (TMSP) in 500 mL of H2O with 20% 
(v/v) 2H2O;  pH 7.4) was added to 300 µL of each serum sample, and the mixture was 
homogenized by vortexing for 30 s. A total of 450 µL of this mixture was transferred into a 4.25 
mm NMR tube (Bruker BioSpin srl) for analysis. 
Urine NMR samples were prepared centrifuging 630 µL of each sample at 14,000 RCF for 5 
minutes. 540 µL of the supernatant were added to 60 µL of phosphate potassium buffer (1.5 M 
K2HPO4, 100% (v/v) 2H2O, 10 mM sodium trimethylsilyl [2,2,3,3-2H4]propionate (TMSP) pH 
7.4). A total of 450 µL of each of the mixtures was transferred into a 4.25 mm NMR tube (Bruker 
BioSpin srl) for analysis. 
 
NMR analyses 
Monodimensional 1H NMR spectra for all samples were acquired using a Bruker 600 MHz 
spectrometer (Bruker BioSpin) operating at 600.13 MHz proton Larmor frequency and 
equipped with a 5mm CPTCI 1H-13C-31P and 2H-decoupling cryoprobe including a z axis 
gradient coil, an automatic tuning-matching (ATM) and an automatic sample changer. A BTO 
2000 thermocouple served for temperature stabilization at the level of approximately 0.1 K at 
the sample. Before measurement, samples were kept for at least 3 minutes inside the NMR 
probehead, for temperature equilibration (310 K for serum samples, 300 K for urine samples).  
According to common practices2,3, for each serum samples three monodimensional 1H NMR 
spectra with different pulse sequences were acquired allowing the selective detection of 
different molecular components: 
(i) a standard nuclear Overhauser effect spectroscopy pulse sequence NOESY 1Dpresat 
(noesygppr1d.comp; Bruker BioSpin) pulse sequence, using 64 scans, 98,304 data points, 
a spectral width of 18,028 Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s and a 
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mixing time of 0.1 s, was applied to obtain a spectrum in which both signals of metabolites 
and high molecular weight macromolecules (lipids and lipoproteins) are visible. 
(ii) a standard spin echo Carr-Purcell-Meiboom-Gill (CPMG)4 (cpmgpr1d.comp; Bruker 
BioSpin) pulse sequence applied to a standard 1D sequence, with 64 scans, 73,728 data 
points, a spectral width of 12,019 Hz and a relaxation delay of 4 s, was used for the 
selective observation of low molecular weight metabolites, suppressing signals arising 
from macromolecules.  
(iii) a standard Diffusion-edited5 (ledbgppr2s1d.comp; Bruker BioSpin) pulse sequence, using 
64 scans, 98,304 data points, a spectral width of 18,028 Hz and a relaxation delay of 4 s, 
was applied to suppress metabolites signals.   
For each urine sample, one monodimensional 1H NMR spectra was acquired with presaturation 
water peak suppression using a standard NOESY 1Dpresat pulse sequences 
(noesygppr1d.comp; Bruker BioSpin), using 64 scans, 64k data points, a spectral width of 
12019 Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s and a mixing time of 100 ms.  
 
Spectral Processing 
Free induction decays were multiplied by an exponential function equivalent to a 1.0 Hz line-
broadening factor before applying Fourier transform. Transformed spectra were automatically 
corrected for phase and baseline distortions and calibrated (glucose doublet at 5.24 ppm for 
serum, and TMSP singlet at 0.00 ppm for urine) using TopSpin 3.2 (Bruker Biospin srl). Each 
1D spectrum in the range between 0.2 and 10.00 ppm was segmented into 0.02 ppm chemical 
shift bins and the corresponding spectral areas were integrated using AMIX software (version 
3.8.4, Bruker BioSpin). Binning is a means to reduce the number of total variables and to 
compensate for small shifts in the signals, making the analysis more robust and reproducible6,7. 
Regions between 6.5 and 4.2 ppm containing residual water signal were removed and the 
dimension of the system was reduced to 375 bins. The total spectral area was calculated on the 
remaining bins and total area normalization was carried out on the data of serum prior to 
pattern recognition, instead for urine spectra probabilistic quotient normalization (PQN)8 was 
chosen, because it performs well even when large variations of dilution occur. 
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Supplemental Figure 1. The Diffusion-edited NMR spectral characteristics and the metabolic 
contents of a serum sample. Despite the broad overall peaks and the overlap of the resonances, 
the spectra provide information on lipoproteins as indicated in figure. In red are highlighted 
the signals whose values are statistically relevant in the comparison between PBC and CD 
patients. 
 
 
Supplemental Figure 2. PCA-CA-kNN score plots using CPMG spectra as input variables 
considering all the three groups: PBC patients (red), CD patients (green) and healthy controls 
(blue). Yellow triangles represent the patients that suffer for both diseases, these samples are 
placed in the PCA-CA-kNN subspace in the region between PBC and CD samples. 
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4.3 Metabolomics as a tool for precision medicine 
The goal of precision medicine is to customize disease prevention and clinical care 
strategies base on individual variability in response to environment, lifestyle, genetics, 
and molecular phenotype. Since metabolomics through biofluid analysis monitors the 
global outcome of all factors influencing the individual phenotype, it represents a 
valuable and promising tool for that goal. This kind of metabolomics application has 
been investigated in two different ways in this thesis: the first two studies proposed in 
this section contribute to the characterization of the human metabolic phenotype; 
while, the second two studies demonstrate how it is possible to use metabolomics to 
monitor patient responses to drug administrations and life interventions. 
The comprehension of how common variables affect the expression of the individual 
metabolic phenotype is of paramount importance for development of metabolomics as 
a population screening and precision medicine platform. In the first study here 
presented, in a cohort of 844 adult healthy volunteers age and sex effects on plasma 
metabolic phenotype and on the probabilistic network constructions of an array of 22 
quantified metabolites have been investigated (see paragraph 4.3.1). Our results show 
not only that is possible to discriminate individuals upon sex and age with a classical 
multivariate approach, but also that plasma-metabolite networks can be associated 
with sex and age differences. Statistically significant sex differences in metabolite 
concentrations and connections were observed, implying variations in many metabolic 
pathways (aminoacyl-tRNA biosynthesis, nitrogen, valine, leucine and isoleucine, 
arginine and proline, D-Glutamine and D-glutamate metabolisms). Moreover, 
alterations of the aminoacyl-tRNA metabolism and the shrinkage of the number of 
network connectivities were found to be associated with age in both sex groups. 
Furthermore, in the second study here proposed, we explored how strong and 
prolonged stressful conditions can affect the plasma metabolomic phenotype (see 
paragraph 4.3.2). This metabolomic investigation is part of the Sarcolab study66, 
designed to disentangle the various constituents of muscle weakness, elucidate the 
myotendinous and neuromuscular adaptations to long-term spaceflight, and address 
the molecular metabolic pathways in skeletal muscle and in the blood affected in 
astronauts during their missions on the international space station (ISS). We analyzed 
the plasma samples of two astronauts collected prior to the mission, immediately after 
the spaceflight and two weeks after the mission, and we could identify pronounced 
differences between them for what concern aminoacidic and energetic metabolisms. 
Crew member A, who was under a milder physical activity plan than crew member B, 
showed increased levels of glucose, pyruvate and pyruvate/lactate ratio, which can be 
understood as the metabolic consequences of muscle wasting, since it has been 
proposed that muscle disuse atrophy shifts metabolism towards glycolysis and 
gluconeogenesis.  Interestingly, the metabolic profiles of the two individuals appeared 
distinct already before launch; then, they responded to the space mission stress, even 
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if in two different ways, moving toward different metabolic positions, and finally both 
reverted to their initial metabolic spaces two weeks after the spaceflights. This 
behavior is consistent with the resilience of the individual metabolic phenotype 
already described in urine11. 
The third study presented in this section showed how a breathomic approach can be 
successfully combined with classic diagnostic techniques to monitor the effects of 
steroid treatment and withdrawal in chronic obstructive pulmonary disease (COPD) 
patients (see paragraph 4.3.3). Exhaled breath condensate (EBC) metabolomics in 
combination with exhaled breath analysis with two different e-noses, sputum cell 
counts, prostaglandin-E2 and 15-F2t-isoprostane in sputum supernatants and EBC, 
fraction of exhaled nitric oxide, and spirometry were used to follow 14 COPD patients 
at 4 visits in a timeframe of 10 weeks. At visit 1 patients were administered for at least 
8 weeks with a combination of inhaled fluticasone propionate (steroid drug formulated 
in microparticles) and salmeterol, the therapy was then changed in a combination of 
inhaled beclomethasone (steroid drug formulated in nanoparticles) and formoterol for 
two weeks (visit 2). The steroid drug was then suspended for 4 weeks (visit 3) and 
finally the combination of inhaled beclomethasone/formoterol was reintroduced once 
again for 4 weeks (visit 4). Three independent breathomic techniques (carbon polymer 
sensor e-nose, quartz crystal sensor e-nose, NMR-based metabolomics) showed that 
extrafine beclomethasone/formoterol short-term treatment was associated with 
different breathprints compared with regular fluticasone propionate/formoterol, and 
a multidimensional, integrated, model including all analyses performed improves the 
ability of identifying pharmacological treatment-induced effects compared with a 
monodimensional model based on standard pulmonary function testing. Therefore, 
this study provides the first prospective evidence of the effects of pharmacological 
treatment and steroid withdrawal on breathomics in COPD patients, and it represents 
a rational basis for large, randomized, controlled, pharmacological trials. 
Finally, NMR-based metabolomic analysis has been performed to evaluate the impact 
of the effects of specific life style interventions, inspired by The European Code Against 
Cancer, in a cohort of women with high mammographic density, and therefore, higher 
risk to develop breast cancer (see paragraph 4.3.4). Plasma samples of 321 women 
were collected and analyzed at baseline and at follow up after four different life style 
interventions (diet, physical activity, diet + physical activity, control). Each 
intervention arm was compared at baseline and at follow up using two approaches: 
PCA-CA models to discover interindividual variations and mPLS to unravel 
intraindividual variability at the two-time points, obtaining statistically significant 
accuracies. Furthermore, our data demonstrated for the first time that the information 
of the mammographic density in a certain way is included in the plasma metabolic 
fingerprint. Indeed, we discriminated high and low breast density with 70% accuracy 
and 4 metabolites (leucine, isoleucine, valine and glucose) correlated with the density 
in a statistically relevant way. 
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4.3.1 Age and sex effects on plasma metabolite association networks in healthy 
subjects 
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Age and sex effects on plasma metabolite association networks in healthy 
subjects 
 
 
 
Abstract 
In the era of precision medicine, the analysis of simple information like sex and age can 
increase the potential to better diagnose and treat conditions that occur more 
frequently in one of the two sexes, present sex-specific symptoms and outcomes, or are 
characteristic of a specific age group. In this framework metabolomics and networks 
analyses could be important instruments for the molecular characterization of sex and 
age differences. We investigate the probabilistic network constructions of 
experimentally identified relationships within an array of 22 plasma metabolites, and 
applied a differential network approach to analyze sex and age differences in a cohort 
of 844 adult healthy volunteers.  
Our results show that plasma-metabolite networks can be associated with sex and age 
differences. Significant sex differences in whole-spectrum fingerprints, metabolite 
concentrations and connections were observed implying variations in many metabolic 
pathways (aminoacyl-tRNA biosynthesis, nitrogen, valine, leucine and isoleucine, 
arginine and proline, D-Glutamine and D-glutamate metabolisms). Alterations of the 
aminoacyl-tRNA metabolism and the shrinkage of the number of network 
connectivities were found to be associated with age in both sex groups.  
Our results demonstrate that the characterization of metabolite–metabolite 
association networks is a powerful tool to characterize the human phenotype at a 
molecular level. 
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INTRODUCTION 
Simple type information like sex and age can prove valuable information within a 
precision medicine approach to investigate and to define disease risk and susceptibility 
in the human population. Although the molecular mechanisms may be not fully 
understood, it has been long known that differences between the two sexes affect 
manifestation, epidemiology and pathophysiology of many widespread diseases and, 
therefore, require different approaches to health care1: for instance,  drug efficacy and 
toxicity profiles are affected by sexual dimorphisms2.   
Age differences in the metabolic phenotype have been previously explored:  Chiu et al.3 
investigated the age-related metabolic changes in healthy children throughout early 
childhood; Yu et. al analyzed the serum metabolome and its association with age4. 
Moreover, the metabolic effects of chronological and physiological aging in correlation 
with blood leukocyte telomere length and epigenetic data were also investigated5–7. 
Age-related considerations are increasingly being taken into account in medical 
therapy, such as in the case of cancer treatment8; but while sexual dimorphisms is a 
dichotomic variable providing a clear discrimination of the groups of interest, age and 
ageing are elusive concepts and new insight into systemic metabolic patterns 
associated with this variable are needed. Indeed, not only the definition of young and 
old and the discriminant among them depends on socioeconomic and geographical 
considerations, but the metabolomics study of aging requires large-scale longitudinal 
studies with replication due to the high variability observed among subjects in term of 
metabolic phenotypes8–13.  
In this study, we take a systems biology approach to investigate sex and age-specific 
differences in the plasma metabolite profiles of healthy subjects by considering a group 
of young and middle aged healthy subjects of both sexes derived from a larger cohort 
of healthy blood donor volunteers who were analyzed for their plasma metabolite 
concentration profiles using Nuclear Magnetic Resonance (NMR) spectroscopy. 
Consistent with previous observations of sex specific differences at the metabolic 
level14 we performed the analysis separately for males and females to minimize 
confounding effects.  
In contrast with other age-related metabolomics studies, our data analysis strategy 
combines standard univariate and multivariate analysis15 to explore the patterns of 
variation of metabolites among the two age classes together with advanced metabolite-
metabolite association network analysis and inference.  
Networks and network analysis are fundamental tools in systems biology and are being 
exploited more and more often to analyze, understand and interpret the complex 
patterns observed in metabolomics data13,14,16,17. The rationale is that metabolite 
concentrations change in an orchestrated fashion in such a way that the association 
among metabolite inferred from measured concentrations in biofluids can be 
considered, to some extent, related to the underlying structure of the biological 
networks. Moreover, since metabolite concentrations can change rapidly in response 
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to perturbations of the system, they can be considered proximal reporters of a 
pathophysiological status.   
The utility of network-based approaches to analyze metabolomics data relies on these 
two key concepts, and networks are best exploited when compared across different 
conditions in a so called differential-network analysis approach: different network 
characteristics and different patterns of association between metabolites can highlight 
possibly affected molecular mechanisms, such as those that can be expected to be 
altered when considering young and old subjects.  
 
 
MATERIALS AND METHODS  
Data description 
The study population consists of 844 adult healthy volunteers (661 males, 183 females, 
median age 41±12 years) recruited in collaboration with the Tuscany section of the 
Italian Association of Blood Donors (AVIS) in the Transfusion Service of the Pistoia 
Hospital (Ospedale del Ceppo, AUSL 3 - Pistoia, Italy). NMR spectra, and associated 
clinical data were retrieved from the Open-Access Database Repository MetaboLights18 
with the accession number MTBLS147 (http://www.ebi.ac.uk/metabolights). Twenty 
samples from the original dataset were excluded from this analysis because sex or age 
information were missing. Age distributions for both sexes are reported as histograms 
in the Supplementary Figure 1. 
 
Statistical analysis 
All data analyses were performed using the open source software R19. Multivariate 
analysis was conducted on both spectral bins and integrated peak area corresponding 
to metabolite concentrations; instead, univariate analysis was performed only on 
metabolite concentrations.  
Data reduction was carried out by means of projection into a PCA subspace, the 
minimum number of components that maximized the accuracy was retained in the 
model and the canonical analysis (CA) was applied to obtain the supervised separation 
of the groups of interest.  
The k-Nearest Neighbors (k-NN) method (k=9) applied on the PCA-CA scores was used 
for classification20. All the accuracies reported and the confusion matrix for the 
different classifications were assessed by means of 100 cycles of a Monte Carlo cross-
validation scheme (MCCV, R script in-house developed). Briefly, 90% of the data were 
randomly chosen at each iteration as a training set to build the model. Then the 
remaining 10% was tested and sensitivity, specificity and accuracy for the 
classification were assessed. The procedure was repeated 100 times to derive an 
average discrimination accuracy for each group of interest. Sensitivity, specificity and 
accuracy are given together with the standard error calculated over 102 repetitions of 
the Monte Carlo samplings. Moreover, the accuracies calculated were assessed for 
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significance against the null hypothesis of no prediction accuracy in the data, by means 
of 102 randomized class-permutation test. 
The spectral regions related to the metabolites were assigned in the spectra by using 
matching routines of AMIX 3.8.4 (Bruker BioSpin) in combination with the 
BBIOREFCODE (Bruker BioSpin), freely available dataset i.e. Human Metabolome 
DataBase (HMDB)21,22 and published literature when available. The metabolites 
quantification was determined by an in-house developed software in MATLAB 
programming suite (Mathworks, MATLAB version R2014b).  Our algorithm is based 
upon the unconstrained non-linear minimization (fitting) of the metabolites NMR 
signals, employing a combination of lorentzian-gaussian functions.  By this approach, 
each NMR region of interest is decomposed and deconvoluted into its component parts, 
and then integrated to obtain the metabolite concentrations in arbitrary units. These 
concentrations were analyzed to determine the discriminating metabolites between 
the groups of interest. Wilcoxon signed-rank test23 was chosen to infer differences 
between the groups on the biological  assumption that metabolite concentrations are 
not normally distributed, and false discovery rate correction was applied using the 
Bonferroni method24. An adjusted P-value < 0.05 was deemed significant. Cliff’s delta25 
was calculated using the R package “effsize”. 
 
Network Analysis 
Network reconstruction 
Three different methods were used to infer metabolite-metabolite association 
networks together with the standard correlation approach A brief description of the 
methods is presented here: we refer to the original publications for more details17,26,27. 
All methods were applied using default parameters. 
 
Method based on correlations (CORR) 
The association between any pair of metabolites is measured through the absolute 
value of Pearson’s correlation.  
 
The CLR algorithm 
The CLR (Context Likelihood of Relatedness) algorithm28 uses mutual information (MI) 
as a measure of the similarity between the profiles of any two metabolites   in the data 
which is then compared against the local context for each possible interaction: in this 
way possible spurious (indirect) associations are removed.  This result in a weighted 
adjacency matrix that can be transformed into a binary adjacency matrix imposing a 
threshold of 0 on its entries.                                                       
 
The ARACNE algorithm 
As CLR, ARACNE (Algorithm for the Reconstruction of Accurate Cellular Networks)29 
uses MI as a measure of the similarity between two chosen variables. The properties of 
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MI are used to prune the network of spurious interactions. Specifically, edges for which 
the null hypothesis of mutual independence cannot be ruled out at a given confidence 
level are removed from the network. 
 
The PCLRC algorithm 
PCLRC17 is based on a modification of the CLR algorithm (using correlation instead of 
MI to measure similarity between metabolite profiles) and on iteratively sampling the 
dataset resulting in a weighted adjacency matrix containing an estimate of the 
association likeliness between any two metabolites. An R implementation of this 
algorithm is available at semantics.systemsbiology.nl. 
 
Construction of plasma metabolite networks 
The plasma metabolite-metabolite association networker taking a wisdom of crowd 
approach as detailed in reference13. For each set of samples (Males, Females, Old M, 
Young M, Old F, Young F) adjacency matrices (aij)m (with m=1,2 ,... 4) were obtained 
using the above described methods. The entries of such matrices matrix are real 
numbers in the range [-1, 1] for correlation matrices, in the [0, +∞] range for mutual 
information matrices, or [0, 1] for probabilistic networks, indicating the strength or the 
likelihood of the metabolite-metabolite associations. These matrices are binarized to 0 
and 1 imposing a threshold on the values9–11,13: 
 
                                                   
1    if  { }
0     otherwise
ij m
ij
a
a
τ>
→ 
                                                                 (1) 
The values of mτ  tm depends on the method considered: 0 for ARACNE and CLR, 0.95 
for PCLRC, and 0.6 for the correlation map, as previously detailed26. The four networks 
were then superimposed 
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The final adjacency matrix, representing the metabolite network was defined by 
retaining only those links inferred by three or more methods, as suggested in ref 26 
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In total, six networks were defined: Males, Females, Old M, Young M, Old F, and Young 
F. Network vertexes are colored according to their modularity calculated using the R 
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package "igraph”. The modularity of each graph with respect to vertex types measures 
how separated are the different vertex types from each other. It defined as 
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here m is the number of edges, Aij is the element of the A adjacency matrix in row i and 
column j, ki is the degree of i, kj is the degree of j, ci is the type (or component) of i, cj 
that of j, the sum goes over all i and j pairs of vertices, and delta(x,y) is 1 if x=y and 0 
otherwise. 
 
Enrichment analysis 
Metabolic pathway analysis (MetPA) was performed using MetaboAnalyst 3.030 server 
(http://www.metaboanalyst.ca/): this tool combines functional enrichment analysis 
and network topology analysis to help identify metabolic pathways that are most likely 
to be associated with the condition under study. For the over-representation analysis, 
hypergeometric test was chosen and the pathway topology analysis was based on the 
relative-betweeness centrality.  
 
Ethical Issues 
The original data were collected in accordance with the 1964 Helsinki declaration and 
its later amendments. 
 
 
RESULTS AND DISCUSSION 
Sex related effects on blood metabolite profiles 
Discrimination analysis among the NMR profiles of males and females was performed 
using PCA-CA-kNN (Figure 1A).   The data set was unbalanced, with far more males (n 
= 661) than females (n = 163). This is not surprising and it reflects the sex bias 
observed in Italy among blood donors where more males than females donate blood31. 
To avoid the bias resulting from different sample size, analysis was performed by 
resampling n = 150 subjects from both the male and female groups and taking the 
average over 102 repetitions. 
We obtained excellent discrimination between the plasma profiles of males and 
females (see Table 1), a result in line with previous observations14.  Discrimination 
accuracy was also high when only a reduced set of 22 quantified metabolites was used, 
indicating that sex-specific biological information is thoroughly represented by a 
limited number of metabolites, consistently to what observed in the case of metabolite 
and metabolic profiling in urines13.  
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Upon univariate analysis, the concentration levels of several metabolites were found 
to be statistically different between males and female (P-value<0.05 after Bonferroni 
correction): creatine showed higher levels in females; instead, phenylalanine, 
glutamine, proline, histidine, glutamate, tyrosine, valine, propylene glycol, leucine, 
isoleucine, creatinine, and acetone were higher in males (Table 2). Higher levels of 
creatinine in males has been reported since long time and has been found to relate to 
muscle mass. Overall we observed systematic higher plasma concentrations of amino 
acids in males which may be linked to differences in muscle mass metabolism32.  
We also performed metabolic pathway analysis on the metabolites whose 
concentration were observed to be different in males and females and we found 
statistically significant P-values for the aminoacyl-tRNA biosynthesis, nitrogen, valine, 
leucine and isoleucine, arginine and proline, D-Glutamine and D-glutamate 
metabolisms (Table 3). Variation in amino acids levels is consistent with differential 
regulation and activity of the aminoacyl-tRNA biosynthesis, a metabolic pathway 
directly involved in the protein synthesis. 
Our results are in line with those of  Krumsiek and coworkers14, who addressed sex-
specific differences in the metabolism of healthy subjects, although two different 
analytical approach were applied (Mass Spectrometry vs NMR spectroscopy) and the 
study sizes were different.  Interestingly, in the present work creatinine and tyrosine 
trends are consistent with their findings but in contrast with what reported by Dunn 
et al. in their UK population study33 where they observed lower levels of creatinine and 
tyrosine in males. Moreover, we did not observe sex-related differences in glucose and 
lactate plasma levels. 
 
Sex related effects on plasma metabolite association networks 
Plasma metabolite-metabolite association networks were estimated taking a so called 
“wisdom of crowd” approach, i.e. combing the results of four different methods to avoid 
bias induced by the choice of a particular method, following an established 
practice13,26,34. Sex specific networks are shown in Figure 2A (males) and 2B (females). 
Networks were arranged and colored according to metabolite modularity. In both sex-
specific networks two aminoacidic clusters are visible; moreover, in males also 
metabolites related to glucose/energetic metabolism formed a cluster. These 
evidences are in line with those observed by Krumsiek and coworkers14. 
We observed that, in general, the female-specific network is less densely connected 
that the males-specific network (Figure 3) and this different topology is likely to reflect 
underlying metabolic differences but it could be also affected by the differences in the 
sample size. Highly connected metabolites, the so called “hubs” play a special role in 
biological network and network analysis since in many cases, for example in gene co-
expression and regulatory networks35,36, metabolic networks, protein−protein 
interaction networks37–39, and cell−cell interaction networks40, there is evidence of few 
highly connected nodes (in this case metabolites) that are considered to play crucial 
 
158| 
biological roles; for instance it has been shown that, in yeast, proteins that are highly 
connected are essential for survival35,37.  
Consistently with previous approaches41, at a first stage,  we considered as hubs those 
metabolites with degree larger than 5 and clustering coefficient <0.03.   In male-specific 
networks only leucine, glucose, lactate, valine, acetoacetate, and creatinine satisfied 
these selection criterion, while in the female-specific network only valine was found to 
be a hub according to this classification. Interestingly, valine is a hub metabolite in both 
networks, yet it resulted more connected in males than in females (9 vs 5 connections); 
4 connections are in common (Ile, Leu, Phe, and Tyr) while citrate is a connection found 
only in females, and acetoacetate, creatinine, creatine, acetone, and histidine are 
connected with valine only in males. It is worth of noting that citrate excretion levels 
differ significantly in males and females, and in particular the sex differences increase 
with age42. We used high connectivity and low clustering coefficient to exclude 
metabolites that could be highly interconnected because participating to same 
molecular machine, such as amino acids deriving from protein metabolism and 
catabolism, while focus on metabolites that could be pivotal in discriminating between 
males and females network topology. Indeed, according to this criterion BCAA such as 
isoleucine and leucine, whose levels are also dependent of protein intake, are excluded.  
The hub metabolites in the male-specific network are enriched for propanoate 
metabolism and for the valine, leucine and isoleucine degradation. Branched chain 
amino acids (BCAA) cannot be synthesized de novo, so their homeostasis is maintained 
by degradation and dietary intake only43, which we speculate may be differentially 
regulated in males and females given the different connectivity observed in the sex-
specific networks.  Whether protein metabolism and degradation is different in males 
and females is an open question, and there are conflicting results given also the 
different methodologies used in such studies. However, the present results seem to 
suggest the existence of sex-specific differences in protein metabolism: whether these 
differences are due to different body mass composition or being attributable to sex 
hormones as suggested44,45 has to be ascertained.   
Propionate and BCAA metabolism overlap at the gene level with BCAA metabolic genes 
contributing to propanoate pathway enrichment; propanoate is involved in BCAA 
metabolism but is also involved in the short-chain fatty acid metabolism, and this result 
can be reconciled with the hypothesis of sexual dimorphism in human lipid 
metabolism46.   
Similarly to41 we also analyzed the networks using a hub definition of connectivity 
greater than 5 without considering the clustering coefficient, and we focused solely on 
those metabolites for which the difference  Δ between a metabolite connectivity in the 
male and female specific network was larger than 2. In addition to the valine, leucine 
and isoleucine catabolism and propanoate metabolism we found three other pathways 
associated with sex-specific metabolite connectivity differences, namely synthesis and 
degradation of ketone bodies, aminoacyl-tRNA biosynthesis, and pyruvate metabolism. 
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That ketone bodies catabolism emerges as a discriminant between males and females 
is interesting;  blood samples  have been collected after overnight fasting, and it is 
known that during short term fasting the decrease of plasma glucose and the increase 
of ketone body levels are greater in females than in males47–51 and evidences have been 
given for the existence of sexual dimorphism for what concerns lipid metabolism in 
response to short-term fasting47. However, as for the case of protein metabolism, the 
causes are not known and a role of sexual hormones has been proposed47. Since 
aminoacyl-tRNA is the obligatory precursor of protein synthesis52, the sexual 
dimorphism highlighted by sex- specific network analysis further supports the 
hypothesis that protein metabolism and degradation is different in males and females. 
Pyruvate is produced during glycolysis and it has been suggested that females have a 
significantly lower overall capacity for aerobic oxidation and for anaerobic glycolysis 
than males53,54. 
 
Age effects on blood metabolite networks 
While sexual dimorphism provides a clear discriminant for a comparative analysis, 
dividing the population under investigation in age groups is less straightforward. 
According to the World Health Organization55, the chronological age of 65 years is used 
for the definition of 'elderly' or older person. However, in this study the cohort is made 
of blood donor volunteers, and in Italy the maximum age for blood donation is set to 
65. Here, the average age is 41±11 years for males and 42±12 years for females; we are 
thus in the presence of a relatively young, healthy, and homogenous population. To set 
boundaries for discriminant analysis we take a pragmatic approach, by taking the 
lower (L) and upper (U) tertiles of the age distribution and labelling as Old those 
individual with age > U and as YOUNG those with age < L. For males we had L  = 35  and 
U = 45 years, and for females L = 37  and U =48 .  
Discriminant analysis was performed using PCA-CA-kNN on these age-defined groups 
(Figure 1C-F). As shown in Table 1 we found good discrimination accuracy between 
the two age classes, with discrimination higher in males than in females. This can be 
due to the smaller sample size in the case of females (661 males vs 183 females) which 
can affect the discrimination power of the statistical model, or reflecting the fact that 
males age faster than females56 resulting in larger age related differences in males in 
respect with females.  
The univariate analysis of the metabolite concentrations (arbitrary units) was also 
presented for both age-comparisons: acetate, and histidine exhibited statistically 
higher concentrations in Young males; conversely, alanine and creatine were elevated 
in Old males (Table 5). These metabolites were associated with the aminoacyl-tRNA 
biosynthesis (Table 3). For the female cohort, glucose, glutamine, glycine, tyrosine, and 
creatine presented statistically higher concentrations in Old females (Table 6) and 
these metabolites were related with aminoacyl-tRNA biosynthesis and nitrogen 
metabolism (Table 3). The role of the aminoacyl-tRNA metabolic pathway in 
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individuals with different age, independent of sex, could be related to the so called 
codon restriction theory of aging57,58. This theory is based on the hypothesis that the 
readability of codons progressively decreases with the age, resulting in inefficient and 
inaccurate protein synthesis. 
The analysis of the metabolite connectivity (Δ degree) was also performed for the 
comparison Young males vs Old males, and Young females vs Old females. For males 3-
hydroxybutyrate, proline, citrate, and creatinine showed increased connectivity in the 
young cohort (Δ ≥ 2); instead, acetone, leucine, and propylene glycol decreased their 
connectivity with age (Figure 3B). Isoleucine, phenylalanine, glycine, glutamine, 
glutamate, formate, creatine, and acetoacetate did not display any connectivity 
variations in the male cohort (Δ = 0). MetPA results suggested that changing in 
metabolite connectivities were associated with the synthesis and degradation of 
ketone bodies and arginine and proline metabolism; instead, glutamine and glutamate 
metabolism was associated with the metabolites with Δ = 0 (Table 4).  
For females, isoleucine, alanine, tyrosine, 3-hydroxybutyrate, proline, leucine and 
glucose were found to be more connected in the young cohort (Δ ≥ 2); instead, 
glutamine and creatine did not exhibit any changes in connectivity (Figure 3C). MetPA 
showed statistically significant results only for the metabolites that changed in 
connectivity. Indeed, they resulted associated with the valine, leucine and isoleucine 
biosynthesis and degradation, and with the aminoacyl-tRNA biosynthesis (Table 4). 
As a general remark, we can observe a shrinkage of the number of connections in the 
older individuals, both for males (Figure 2C and E) and females (Figure 2D and F). Older 
males showed two hubs (valine and acetone) that are not present in younger ones; 
conversely, no hubs were found in females independent of age.  Interestingly, Soltow 
et al.59 in their study on metabolism and ageing in common marmosets (Callithrix 
jacchus, a premiere primate model for studies of aging) reported that metabolite 
connectivity decreases with age and this result is line with what we are reporting in 
this paper. These evidences could indicate that further efforts in this direction and 
using these types of analyses (global metabolic profiling combined with network 
analysis) in well-designed models may reveal biomarkers associated with age-related 
phenotype and disease. 
 
 
CONCLUSIONS 
In conclusion, we have presented the network constructions of experimentally 
identified relationships between metabolites, and applied a differential network 
approach to analyze sex and age differences in a cohort of healthy subjects. Our results 
show significant differences between males and females for what concerns both 
metabolite concentrations and connections implying variations in the metabolic 
pathways, especially for what concerns the aminoacyl-tRNA biosynthesis, nitrogen, 
valine, leucine and isoleucine, arginine and proline, D-Glutamine and D-glutamate 
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metabolisms. Moreover, we found an alteration of the aminoacyl-tRNA metabolism, 
and a decrease of the connectivity with age in both sex groups, demonstrating that this 
evidence is peculiar of ageing even if the biological meaning of our result needs to be 
further investigated.  
Although the age range is limited and sex is unequally biased towards males, this study 
provides important information on how common variables influence expression of the 
metabolic phenotype. Both age and sex are recognized confounders, understanding 
these differences will be a critical component for development of metabolomics as a 
population screening and precision medicine platform.  
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Figure. 1 Clustering in the first two components of the PCA-CA models on NMR plasma 
metabolite concentration profiles of: A) male (blue dots) and female (pink dots); B) 
young (light blue) and old (dark blue) male subjects; C) young (light pink) and old (dark 
pink) female subjects. Discrimination accuracy obtained using kNN for each different 
model are given in table 1. 
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Figure. 2 Metabolite-metabolite association networks reconstructed from the plasma 
metabolite concentration profiles of: A) males; B) females; C) Young males; D) Young 
females; E) Old males and F) Old females. Vertexes are colored according to metabolite 
modularity. 
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Figure. 3 Differences in metabolite connectivity (node degree) between A) males and 
females; B) young and old males and C) young and old females 
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Table 1. The average Accuracy, Sensitivity and Specificity are given together with the 
standard error calculated over 102 repetitions of the Monte Carlo samplings. The 
significance (P-value) is assessed by mean of permutation test. 
 
 
 
 
Table 2. Pairwise comparison of plasma metabolite concentration in males and 
females using Wilcoxon test. A positive log2(FC) indicates higher concentrations in 
females. 
  P-value Adjusted P-value Cliff's Δ log2(FC) 
3-hydroxybutyrate 5.83E-02 1.00E+00 -6.75E-02 0.00E+00 
Acetate 3.30E-01 1.00E+00 -4.70E-02 -7.12E-02 
Acetoacetate 8.50E-01 1.00E+00 -9.12E-03 7.29E-02 
Acetone 1.65E-11 3.62E-10 -3.25E-01 -6.04E-01 
Alanine 5.23E-03 1.15E-01 -1.35E-01 -8.61E-02 
Citrate 3.80E-01 1.00E+00 4.24E-02 6.27E-02 
Creatine 2.95E-23 6.48E-22 4.79E-01 9.33E-01 
Creatinine 2.08E-52 4.58E-51 -7.35E-01 -4.40E-01 
Formate 3.05E-02 6.70E-01 -1.04E-01 -5.18E-02 
Glucose 7.96E-01 1.00E+00 -1.25E-02 -1.34E-03 
Glutamate 1.77E-03 3.90E-02 -1.51E-01 -1.92E-01 
Glutamine 3.93E-04 8.64E-03 -1.71E-01 -1.26E-01 
Glycine 7.19E-01 1.00E+00 1.74E-02 8.34E-03 
Histidine 1.58E-04 3.48E-03 -1.82E-01 -1.67E-01 
Isoleucine 7.07E-29 1.55E-27 -5.38E-01 -3.48E-01 
Lactate 9.91E-01 1.00E+00 5.54E-04 9.93E-03 
Leucine 2.11E-29 4.65E-28 -5.43E-01 -3.19E-01 
Phenylalanine 3.38E-05 7.45E-04 -2.00E-01 -8.79E-02 
Proline 6.44E-05 1.42E-03 -1.93E-01 -1.59E-01 
Propylene glycol 4.87E-10 1.07E-08 -3.00E-01 -2.41E-01 
Tyrosine 4.41E-10 9.70E-09 -3.01E-01 -1.99E-01 
Valine 1.05E-14 2.32E-13 -3.73E-01 -2.28E-01 
PCA-CA-kNN Model Accuracy Sensitivity Specificity P-value 
Full CPMG NMR spectra 
Males vs Females 0.90±0.01 0.90±0.02 0.89±0.02 <0.01 
Young vs Old Males 0.70±0.01 0.70±0.02 0.71±0.02 <0.01 
Young vs Old Females 0.60±0.04 0.56±0.05 0.64±0.05 0.02 
Quantified metabolites in CPMG NMR spectra 
Males vs Females 0.79±0.03 0.81±0.03 0.78±0.02 <0.01 
Young vs Old Males 0.65±0.01 0.64±0.02 0.66±0.02 <0.01 
Young vs Old Females 0.65±0.03 0.68±0.03 0.62±0.04 <0.01 
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Table 3. Significant results for pathway analysis performed on the sets of metabolites 
whose adjusted P-value were find statically significant between the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathway Name Match Status P-value Adjusted P-value FDR 
Males vs Females     
Aminoacyl-tRNA biosynthesis 8/75 6.93E-10 5.55E-08 5.55E-08 
Nitrogen metabolism 4/39 3.79E-05 3.00E-03 1.52E-03 
Valine, leucine and isoleucine biosynthesis 3/27 3.34E-04 2.61E-02 8.91E-03 
Arginine and proline metabolism 4/77 5.56E-04 4.28E-02 1.11E-02 
Valine, leucine and isoleucine degradation 3/40 1.08E-03 8.24E-02 1.73E-02 
D-Glutamine and D-glutamate metabolism 2/11 1.44E-03 1.08E-01 1.92E-02 
     
Young vs Old Males     
Aminoacyl-tRNA biosynthesis 3/75 2.78E-04 2.22E-02 2.09E-02 
     
Young vs Old Females     
Nitrogen metabolism 3/39 3.85E-05 3.08E-03 3.08E-03 
Aminoacyl-tRNA biosynthesis 3/75 2.78E-04 2.20E-02 1.11E-02 
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Table 4. Significant results for pathway analysis performed on the sets of metabolites 
whose connectivity was found to vary (Δ ≥ 2) or being the same (Δ = 0) in the 
differential network analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Match 
Status 
P-value 
Adjusted 
P-value 
FDR 
Δ ≥ 2 Males vs Females     
Propanoate metabolism 4/35 1.71E-05 1.37E-03 1.37E-03 
Synthesis and degradation of ketone bodies 2/6 3.38E-04 2.67E-02 8.66E-03 
Aminoacyl-tRNA biosynthesis 4/75 3.56E-04 2.78E-02 8.66E-03 
Pyruvate metabolism 3/32 4.33E-04 3.34E-02 8.66E-03 
Valine, leucine and isoleucine degradation 3/40 8.44E-04 6.41E-02 1.35E-02 
 
Δ ≥ 2 Young vs Old Males     
Synthesis and degradation of ketone bodies 2/6 7.74E-05 6.19E-03 6.19E-03 
Arginine and proline metabolism 2/77 1.39E-02 1.00E+00 5.58E-01 
 
Δ = 0 Young vs Old Males     
D-Glutamine and D-glutamate metabolism 2/11 5.24E-04 4.09E-02 1.40E-02 
 
Δ ≥ 2 Young vs Old Females     
Aminoacyl-tRNA biosynthesis 5/75 5.15E-07 4.12E-05 4.12E-05 
Valine, leucine and isoleucine biosynthesis 2/27 2.46E-03 1.94E-01 9.83E-02 
Valine, leucine and isoleucine degradation 2/40 5.37E-03 4.19E-01 1.43E-01 
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Table 5. Pairwise comparison of plasma metabolite concentration in young and old 
male subjects using Wilcoxon test. A positive log2(FC) indicates higher concentrations 
in young male. 
 
 
P-value Adjusted P-value Cliff's Δ log2(FC) 
3-hydroxybutyrate 1.97E-01 1.00E+00 -5.21E-02 0.00E+00 
Acetate 1.15E-03 2.53E-02 1.72E-01 1.60E-01 
Acetoacetate 5.32E-01 1.00E+00 -3.32E-02 4.33E-02 
Acetone 5.25E-02 1.00E+00 -1.03E-01 -2.26E-01 
Alanine 1.15E-04 2.54E-03 -2.04E-01 -1.27E-01 
Citrate 1.00E-02 2.20E-01 -1.36E-01 -9.21E-02 
Creatine 1.88E-05 4.13E-04 -2.27E-01 -3.91E-01 
Creatinine 2.98E-01 1.00E+00 5.51E-02 4.07E-02 
Formate 2.10E-01 1.00E+00 6.64E-02 3.74E-02 
Glucose 3.07E-03 6.76E-02 -1.57E-01 -5.91E-02 
Glutamate 3.09E-01 1.00E+00 5.39E-02 1.01E-01 
Glutamine 7.12E-02 1.00E+00 -9.56E-02 -7.56E-02 
Glycine 4.00E-02 8.80E-01 1.09E-01 6.69E-02 
Histidine 1.98E-04 4.36E-03 1.97E-01 1.65E-01 
Isoleucine 9.44E-01 1.00E+00 3.71E-03 4.63E-04 
Lactate 5.78E-01 1.00E+00 -2.95E-02 -2.73E-03 
Leucine 1.26E-01 1.00E+00 8.12E-02 2.88E-03 
Phenylalanine 9.38E-01 1.00E+00 -4.13E-03 -2.17E-02 
Proline 5.28E-01 1.00E+00 3.34E-02 7.14E-03 
Propylene_glycol 8.33E-02 1.00E+00 9.18E-02 6.71E-02 
Tyrosine 1.99E-04 4.38E-03 -1.97E-01 -1.24E-01 
Valine 1.82E-01 1.00E+00 7.07E-02 3.50E-02 
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Table 6. Pairwise comparison of plasma metabolite concentration in young and old 
female subjects using Wilcoxon test. A positive log2(FC) indicates higher 
concentrations in young female. 
 
 P-value Adjusted P-value Cliff's Δ log2(FC) 
3-hydroxybutyrate 7.52E-01 1.00E+00 2.14E-02 0.00E+00 
Acetate 1.72E-01 1.00E+00 -1.41E-01 -1.96E-01 
Acetoacetate 5.42E-03 1.19E-01 -2.87E-01 -3.43E-01 
Acetone 6.57E-01 1.00E+00 -4.61E-02 -4.77E-02 
Alanine 3.31E-03 7.28E-02 -3.04E-01 -2.40E-01 
Citrate 2.74E-02 6.03E-01 -2.28E-01 -9.92E-02 
Creatine 3.33E-07 7.33E-06 -5.27E-01 -7.54E-01 
Creatinine 7.55E-01 1.00E+00 -3.25E-02 2.62E-02 
Formate 7.77E-01 1.00E+00 -2.95E-02 -7.13E-02 
Glucose 6.60E-04 1.45E-02 -3.52E-01 -1.49E-01 
Glutamate 9.69E-01 1.00E+00 4.28E-03 1.69E-01 
Glutamine 1.26E-03 2.77E-02 -3.33E-01 -2.21E-01 
Glycine 7.00E-06 1.54E-04 -4.64E-01 -2.58E-01 
Histidine 6.03E-02 1.00E+00 -1.94E-01 -1.75E-01 
Isoleucine 7.33E-01 1.00E+00 3.55E-02 7.60E-03 
Lactate 3.01E-01 1.00E+00 -1.07E-01 -1.72E-01 
Leucine 3.27E-01 1.00E+00 -1.02E-01 -6.79E-02 
Phenylalanine 1.93E-01 1.00E+00 -1.35E-01 -9.14E-02 
Proline 4.32E-01 1.00E+00 -8.14E-02 -1.53E-02 
Propylene glycol 3.59E-01 1.00E+00 -9.50E-02 -6.36E-02 
Tyrosine 1.57E-03 3.45E-02 -3.27E-01 -3.19E-01 
Valine 2.99E-01 1.00E+00 -1.08E-01 -7.38E-02 
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Supplementary materials 
 
Supplementary Figure 1. Age distribution for: A) Female; B) Male. Median age, mean age and 
standard deviation are also reported. 
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4.3.2 Muscle in Space – Shall the Force be with Us?  
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Muscles in Space – Shall the Force be with Us? 
 
 
  
Introduction 
Physical deconditioning has been known to occur as a result of space flight since the 
days of Skylab and Mir studies.  Lower limb muscles, in particular, undergo rapid 
wasting (1) and loss of function (2). Most affected is the triceps surae muscle (3), where 
20% fiber atrophy occur after 6 months of space flight (4). In the ground-based models 
of spaceflight (e.g. bedrest), this muscle wasting is associated with decreases in the 
fascicles’ pennation angle and length (5, 6). Alterations of muscle architecture directly 
affect the mechanical output and therefore are potential contributors to muscle 
weakness. Moreover, immobilization is also leading to reductions in the muscle fibers’ 
specific force and power, and to reductions in myosin heavy chain (MCH) concentration 
(7). All of these factors can independently alter the mechanical characteristics of the 
lower limb muscles and hamper force output.  
Countermeasure exercises on board the international space station (ISS) are nowadays 
mandatory for the crew. Countermeasures aiming at muscle involve exercises with the 
advanced resistive exercise device (aRED) and the treadmill with vibration isolation 
system (TVIS).  Effects of strength training upon skeletal muscle on Earth have been 
studied extensively (8), but relatively little is known about the molecular events in 
disuse or in spaceflight. It is therefore an open question in how far the training loads in 
space are helpful to maintain the lower limb musculature. As a window into the 
muscle’s loading history, we were interested in the behavior of the costameric proteins 
(9-15), which anchor the sarcomeres to extracellular matrix (ECM) receptors (16-18). 
Integrin-linked focal adhesion kinase (FAK) is a mechanically regulated costamere 
component that controls the turnover of focal adhesion in a fiber type-specific manner 
together with its natural inhibitor FRNK (13, 16, 19). Herein, the content of post-
translation modification of tyrosine 397 (Y397) is a critical event, which is affecting the 
activity of FAK (20-22). 
Thus, the Sarcolab study has been designed to 1) disentangle the various constituents 
of muscle weakness, to 2) elucidate the myotendinous and neuromuscular adaptations 
to long-term spaceflight, and to 3) address the molecular and metabolic pathways in 
skeletal muscle and in the blood affected in astronauts during their missions on the 
international space station (ISS). The general hypothesis of the Sarcolab study is that 
both alterations in the physiological cross section as well as in single fiber mechanics 
are involved in the space-related muscle weakness. Moreover, the study also aims to 
assess messenger RNA and proteomic data in order to generate new hypotheses, and 
to screen for systemic consequences related to muscle metabolism. After initial data 
assessment in two astronauts, the study has now been enlarged into a 3-agency study 
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(Sarcolab-3). The present paper now highlights the salient findings from the two 
astronauts of the Sarcolab pilot study.   
 
 
Results 
Analyses on the two astronaut enrolled in this study (crew member A and B) were 
performed at three time points: before the space flight (baseline), at post-flight 1 (PF-
1, at 0 to 4 days after landing) and at post-flight 2 (PF-2, at 15 days after landing). 
 
On-board Exercise Training: Crew member A performed fewer treadmill sessions than 
B (90 vs. 114), ran with lower pull-down force (median of 55.9% vs 85.6% of body 
weight), ran at slower speed (median 11.3 vs. 12.9 km/hr), and covered a shorter 
distance than B, both per running session (median 4.7 vs. 5.8 km) as well as cumulated 
for the 6-month space sojourn (442 vs. 572 km, Figure 1). Crew member A also trained 
less with the aRED, performing fewer heel raise sessions (54 vs. 98) with fewer 
repetitions (median 30 vs. 48) and at lower resistive load (median 122% vs. 221% of 
body weight). Thus, B was generally training more vigorously than A, which was in 
particular true for the resistive elements of the countermeasure exercises. 
 
Muscle function: During post-flight session 1 (PF-1, performed 0 to 4 days after return 
to Earth), plantar flexor muscle strength was reduced by 30.6% in crew member A, 
whereas B depicted little or no change from baseline (Figure 2). However, very notably, 
the rate of force development was profoundly compromised in both crew members, 
and perhaps even more so in B, during both post-flight testing sessions. 
Muscle size and architecture: Volume, pennation angle and fascicle length were all 
substantially reduced in the medial gastrocnemius (GM) muscle at PF-1 in crew 
member A (Table 1). Such changes were much less pronounced in B. However, the 
physiological cross-sectional area (pCSA) was affected to comparable extent in both 
crew members at PF-1 (Table 1). At PF-2, pCSA of the GM muscle had recovered in B, 
but not in A.  
 
Fiber type, fiber size & fiber mechanics: As expected for soleus muscles, the analysis of 
myosin heavy chain isoform (MHC) distribution showed almost homogeneous MHC-1 
content in the samples of both crew members. No shift in MHC relative content was 
observed post flight. Cross sectional area of individual muscle fibers (CSA_SF) declined 
at PF-1 in crew member A by -45%, but only by -23% in B (Figure 2).  
Functional analysis could be performed pre- and post-flight in crew member A only. All 
fibers analyzed contained MHC-1, i.e. were type 1 fibers. As expected, specific force 
(Po/CSA) was lower post-flight than pre-flight (-27%), but unloaded shortening 
velocity (Vo) was unchanged. Interestingly, actin sliding velocity (Vf) on myosin 
extracted from single muscle fibers of crew member A was not different pre- vs post-
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flight. Taken together, Vo and Vf finding suggest no alteration in the acto-myosin 
kinetics post-flight and no alteration of myosin at molecular level. 
 
Skeletal muscle proteomic analysis:  From 1100 spots detected in the 2D-DIGE gel, 900 
were included in the base set for statistical analysis. The Principal Component Analysis 
(PCA) of the muscle tissue from both crew members provided an overview of spot 
distributions and yielded two components (PCA1 and PCA2) that explain 59.2%  and 
25.9%, respectively, of the global variation (supplementary Figure 1). Interestingly, 
differences between baseline and PF-1 are concordant for both crew members with 
regards to PCA2. However, the differences between baseline and PF-2 were discordant 
between crew members with regards to PCA1; the protein data set at PF-2 appears 
more similar to baseline in crew member B.  
Proteomic analyses followed by paired one-way ANOVA and Tukey tests (α= 0.01) 
indicated significant differences between baseline and PF-1 in 32 and 39 spots in crew 
member A and B, respectively. When comparing baseline to PF-2, 37 spots were 
changed in crew member A and 24 spots were changed in crew member B (Figure 3).  
Concerning contractile proteins, PF-1 samples revealed alterations in troponin I and 
troponin T in both crew members, but only crew member B revealed some moderate 
changes in Actin and tropomyosin. More specifically, crew member A demonstrated 
distinct increases in troponin I fast (TNNI2) and in two proteoforms of troponin T fast 
(TNNT3), and decreases in two proteoforms of troponin T slow (TNNT1). Notably, 
where PF-1 changes in the troponins were observed in B, they were in the opposite 
direction in crew member A. At PF-2, some moderate decreases in Actin proteoforms 
(ACTA1) were observed in both crew members. 
Proteins involved in anaerobic metabolism were also affected by space flight. In crew 
member A there were decreases in four different proteoforms of glycogen 
phosphorylase (PYGM) at PF-1, as well as increases in glycerol-3-phosphate 
dehydrogenase (GPDI) and one beta-enolase proteoform (ENO3). By contrast, B 
depicted increases in glyceraldehyde-3-phosphatase dehydrogenase (GAPDH), 
phosphoglycerate mutase 2 (PGAM2), alpha-enolase (ENO1), three proteoforms of 
ENO3  and pyruvate kinase (PKM). At PF-2, two of the PYGM proteoforms were 
recovered in A, but decreases in two proteoforms of fructose-bisphosphate aldolase A 
(ALDOA) and L-lactate dehydrogenase A chain (LDHA) occurred at that time. Thus, 
dysregulation of glycogen metabolism and accumulation of specific enolase 
proteoforms appeared and persisted post-flight in crew member A, whereas crew 
member B adapted metabolically to space flight by increasing anaerobic metabolism.  
Concerning aerobic metabolism, enzymes involved in malate shuttle, in oxidative 
phosphorylation and in lipid metabolism were down-regulated in both crew members 
at PF-1 and persisting at PF-2. In crew member A, this encompassed virtually all 
enzymes, except for NADH dehydrogenase iron-sulfur protein 3 (NDUFS3) was up-
regulated. Crew member B depicted a very similar response as A, except that NDUFS3 
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was down- rather than up-regulated.  Thus, aerobic metabolism seemed comparably 
compromised in both crew members. 
Enzymes involved in high energy phosphate transfer likewise depicted a down-
regulation in both crew members post-flight. This was more pronounced in crew 
member A than B, and A also tended to better recover these changes at PF-2. The 
enzymes affected involved four proteoforms of creatine kinase M-type (CKM) and 
creatine kinase S-type (CKMT2). Thus, the dysregulation of enzymes involved in high 
energy phosphate production appeared to be a consequence of the severe impairment 
of aerobic metabolism. 
 
Costameric protein expression: All costameric proteins of interest were detectable in 
soleus muscle at baseline (Supplementary Figures 2 to 4). Gamma-vinculin was more 
abundant than meta-vinculin (Supplementary Figure 2). At PF-1, protein 
concentrations of FAK (normalized to actin) was reduced in crew members A and B by 
-60% and -44%, respectively, and FRNK by -60% and -67 (Table 2, Supplementary 
Figure 3). By contrast, FAK and FRNK concentrations were both increased above 
baseline levels at PF-2 (Table 2, Supplementary Figure 3). Importantly, FAK-pY397 
concentration was reduced in crew member A at PF-1, but increased in B 
(Supplementary Figure 3). These findings suggest that loading forces in space were 
near-normal in crew member B, but substantially reduced in A. 
Concentration of the meta-vinculin proteoform and tenascin-C was increased at PF-1 
in crew member A by 786% and 2781% respectively, but both were slightly reduced 
in crew member B (Supplementary Figures 2 and 4). At PF-2, these proteins resumed 
to near baseline levels in crew member A, but were increased in crew member B 
(Supplementary Figure 2). The concentration of gamma-vinculin was only marginally 
affected by space flight (Table 2).  
The meta-vinculin:gamma-vinculin ratio was comparable in crew members A and B at 
baseline (0.06 vs. 0.06). It depicted 8-fold and 5-fold increases in crew member A at 
PF-1 and PF-2, respectively, but no changes in crew member B (Supplementary Table 
1). The FRNK:FAK ratio, by contrast, was greater at baseline in crew member A than in 
crew member B (2.01 vs. 0.58). It was unchanged in crew member A after spaceflight, 
but depicted a moderate decrement in B.  
 
Intracellular signaling pathways controlling muscle mass and metabolism: The 
response to spaceflight of the two major catabolic systems was studied on mRNA level 
in both crew members by assessing expression of MuRF-1 and atrogin-1, the two major 
markers of the ubiquitin proteasome activity, and of p62 and Beclin-1, two of the 
markers of activity of autophagy. Whereas atrogin-1 expression was upregulated post-
flight in both crew members, MuRF-1 expression was highly up-regulated in crew 
member A, but not in crew member B. Beclin-1 was upregulated in both crew members 
post-flight, whereas p62 was up-regulated in crew member A only.  
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At PF-2, expression of all of these markers was lower than at PF-1. In crew member A, 
recovery towards normal activation was somewhat less complete, especially for Murf-
1. The results suggest a higher activation of both catabolic systems and a slower 
recovery towards normal values in crew member A. 
PGC-1alpha is a master controller of mitochondrial biosynthesis and oxidative 
metabolism. It was surprisingly up-regulated post flight in both crew members and did 
not go back to normal expression even at PF-2. SREBP-1 is a transcription factor 
controlling lipid synthesis. It was upregulated in crew member B only.  
NRF2 is a transcription factor involved in the response to injury and inflammation, and 
thus also in sensing the level of intracellular ROS and stimulates synthesis of 
antioxidant defense systems. Its increase occurred in crew member B only. No 
complete recovery of pre-flight expression was observed at PF-2. 
 
Plasma Metabolomics:  Twenty metabolites were assigned and quantified in the 
spectra, the levels of the statistically significant metabolites (plasma amino acids, 
glucose, lactate, pyruvate, and pyruvate/lactate ratio) are reported along with their P-
values in Figure 4, compared with a cohort of control subjects. All metabolite levels 
investigated at baseline were comparable with the control group, except for isoleucine 
that was elevated and alanine that was at the upper control margin at PF-1 in crew 
member A. Serum alanine was increased in this crew member post flight (in both PF-1 
and PF-2 P < 0.01), but, conversely from isoleucine, was not normalized at PF-2. 
Moreover, crew member A depicted elevated serum levels of glucose and pyruvate, as 
well as an elevated pyruvate-lactate ratio on day PF-1 (all P < 0.01).  
In crew member B, serum levels were generally within the control margins. The only 
exceptions were alanine, phenylalanine and tyrosine, which were all increased at PF-1 
(P < 0.01), but not at PF-2.    
 
 
Discussion 
The present study provides a comprehensive account of how different two different 
individuals can respond to the same stimulus of spaceflight. Whilst crew member A 
exhibited the expected neuromuscular responses, namely decrements in plantar flexor 
muscle volume, altered architecture, reductions in contractile protein composition, 
downgraded fiber contractility, and thus overall muscle strength, crew member B was 
much less affected after 6 months in Space. It has to be considered here that the loading 
levels achieved by crew member B are rarely achieved by other crew members in 
Space. It is therefore tempting to ascribe the salient differences between A and B to the 
loading forces. Moreover, it seems reasonable to ascribe the divergent muscle 
proteomic responses in both crew members (contractile proteins & aerobic 
metabolism affected in crew member A, but almost not in B), as well as differences in 
the systemic metabolic profiles (greater effects upon energy and protein metabolism 
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in A than in B) to the different countermeasure regimens. These findings therefore 
demonstrate the partial effectiveness of current ISS countermeasures. However, the 
23% decrement in muscle fiber CSA that was still occurring in crew member B, the fact 
that rate of torque development, aerobic metabolism as well as high phosphate energy 
transfer were still compromised in crew member B suggest that complete preservation 
of the musculature in Space is not yet achievable. 
It is also intriguing that the response of the two load-dependent parameters, pY397-
FAK and meta-vinculin concentration (12, 13) reflected the diverging responses of the 
two crew members in muscle mass and strength, but not FAK or FRNK. Explaining 
these differences by the loading during on-board countermeasure exercises seems 
straightforward, and thereby corroborate the idea of a load-regulated costamere 
turnover that is mediated by the FAK system. 
By contrast, expression of FAK and FRNK proteins demonstrated a consistent down-
regulation at PF-1. These replicates earlier findings in anti-gravity muscles of rats and 
human (11-13), implicating a requirement of gravitational loading for maintaining the 
expression of the gene products of the FAK gene (i.e. PTK2). It has been previously 
demonstrated that immobilization-related decrement in pY397-FAK is related to a 
reduction of FAK content at the sarcolemma (12), while pY397-FAK concentration 
during recovery from immobilization remains low independent of alterations in FAK 
protein (12). The present novel observations support that the phenomenon of muscle 
unloading is associated with a net reduction in the capacity for regulation of costamere 
turnover (10).  Consistently with this notion, the concentration of both FAK and FRNK, 
in vastus lateralis muscle increased two weeks after return to Earth being indicative of 
regulation towards a reestablishment of adhesion sites in the sarcolemma with return 
of load-bearing muscle activity. 
Alterations in the costameric factors FAK-pY397 and meta-vinculin were associated 
with alterations in tenascin-c expression, which typically is up-regulated by muscle 
loading (23, 24) (compare supplementary Figures 2 to 4). All these factors were 
considerably less affected in crew member B, who experienced greater loading during 
on-board exercising (Figure 1). Collectively the tenascin-C alterations suggest a 
protection of the soleus muscle in crew member one    to the injuring consequence of 
high forces during reentry into the gravitational field of the Earth .  
Surprisingly, the present results did not show a shift in MHC isoform content  toward 
a fast phenotype, and likewise no increase in Vo of individual muscle fibers. Thus, no 
compensation for the lost muscle mass could be provided by these mechanisms. 
Notably, the muscle wasting appears to be at least partly due to activation of muscle 
proteolysis, i.e. through activation of ubiquitine proteasome and autophagy. This 
interpretation is also supported by the observation that crew member A had greater 
activation of these catabolic pathways than crew member B after spaceflight.  
It is a bit surprising to see that muscular aerobic metabolism was affected in both crew 
members, given the time and distance covered during treadmill exercise. Moreover, the 
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increase in pGC-1alpha expression in both crew members is somewhat 
counterintuitive, as a down-regulation following disuse in soleus muscle of mice (25) 
and in VL muscle of humans (26) have been previously observed. The lower expression 
of PGC-1alpha has been considered a relevant cause of muscle atrophy in disuse (25-
27). The origin of the higher expression of PGC-1alpha following space-flight is unclear. 
It could be due to reloading after flight and before biopsy. An alternative possibility is 
that the countermeasures in flight successfully prevented PGC-1alpha down-
regulation, possibly preventing metabolic alterations in muscle too.  PGC-1alpha is 
believed to be responsible for the metabolic response to endurance training. 
It is also of interest that SREBP1 expression was increased in the soleus muscle in both 
crew members after space flight. As SREBP1 is a master control of lipid metabolism 
and increases lipid synthesis, it seems possible that weightlessness may increase 
intramuscular lipid accumulation. Furthermore, it is interesting that NRF2, a 
transcription factor sensitive to intracellular ROS and simultaneously a stimulator of 
antioxidant defense systems, was elevated in crew member B but not in crew member 
A.  Redox imbalance could be expected on the basis of previous observations in humans 
(Dalla Libera et al) (26) and mice (25). However, to see the NRF2 increment in crew 
member B only speaks against a higher redox imbalance as a side-effect of muscle 
atrophy. An alternative explanation might be that NRF2 increase is a compensatory 
antioxidant response in crew member B, which does not occur in crew member A.  
Pronounced differences between the two crew members were also present in their 
metabolomic profiles. Whilst post-flight changes in crew member B can be related 
more to energy metabolism than to aminoacids metabolism, the opposite was true for 
crew member A.  Previous reports suggest that myofibrillar breakdown (assessed via 
urine 3-methylhistidine) is un-affected by spaceflight (28), which was also confirmed 
in the present study (data not shown). Moreover, the increases of glucose, pyruvate 
and pyruvate/lactate ratio in crew member A can be understood as the metabolic 
consequences of muscle wasting, and it has been proposed that muscle disuse atrophy 
shifts metabolism towards glycolysis and gluconeogenesis (29). Interestingly, both 
crew members’ metabolic profiles appeared distinct already before launch: PCA 
showed that the two crew members were located in different regions of the metabolic 
distribution space before the space mission; then, they responded to the space mission 
stress, even if in two different ways, moving toward different positions at PF-1, and 
finally both reverted to their initial metabolic spaces at PF-2 (Supplementary Figure 5). 
This behavior is consistent with the observed metabolic resilience already described 
in urine of healthy controls (30). 
In conclusion, this observational study in two ISS crew members has shown that single 
fiber mechanics seems to be a better explanation for post-flight muscle weakness than 
muscle architecture. However, the present data still support an important contribution 
to muscle strength by muscle size and architecture. Countermeasure exercises seem to 
have been remarkably effective in crew member B, albeit not fully. Altogether, results 
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indicate a crucial role for force loading to constitute effective on-board exercises. 
Finally, proteomic assessment of muscle tissue and metabolomic blood analyses have 
greatly helped to widen the view in this study, and to understand that exercise may 
have benefits in space that go far beyond mere maintenance of muscle mass. 
 
 
Methods 
Subjects and testing schedule: Two crew members of equal sex, A and B, were tested 
pre-flight and post-flight (Supplementary Table 2), and in between accomplished their 
ISS mission of 6 months, respectively. Information on in-flight countermeasure 
exercise performance on advanced resistive exercise device (aRED) and on the T2 
Colbert treadmill was obtained via data sharing with NASA. For the heel raise exercises 
on aRED, the total number of repetitions was computed, and the peak and average load 
during each session was selected and normalized to body weight. For T2 treadmill 
exercises, the distance, speed, exercise time and the bungee load at rest were extracted. 
Two-way ANOVA was performed to test for time effects and differences between 
astronauts. 
 
Metabolomic profiles: for the control cohort, plasma samples were collected from 79 
healthy volunteers from two centers, 56 of which collected in collaboration with the 
Tuscanian section of the Italian Association of Blood Donors (AVIS) in the Transfusion 
Service of Pistoia Hospital (Ospedale del Ceppo, AUSL 3 - Pistoia, Italy), and 23 samples 
were from young healthy subjects collected in Bologna (in the framework of the project 
PRIN2009CB4C9F with ethical approval EM 157/2011/U at S.Orsola-Malpighi 
hospital, Bologna). Specifically, 6 healthy volunteers were recruited at 4 different times 
(up to 7 months, one dropped out at a specific time, thus 23 samples were obtained). 
No differences in the time series were evidenced (data not shown) and all samples 
were merged to obtain a more heterogenous population.  
 
Muscle biopsy: Approximately 50 mg of tissue were harvested from the soleus muscle 
with a 11G ACECUT automatic biopsy system (TSK Laboratory, Oisterwijk, the 
Netherlands). A lateral approach was chosen approximately 2 cm below the distal end 
of the lateral gastrocnemius muscle. Before the incision, the skin was razed and 
disinfected appropriately, and 2 mL of local anesthetic (Lidocain 1%) was injected into 
the skin and the fascia. Samples were divided, shock-frozen in liquid nitrogen and 
aliquoted within 10 min after the biopsy. 
 
Costameric protein biochemistry: Biopsies were sectioned and protein was extracted 
with the help of a rotorstat mixer (Kinematica, Lucerne, Switzerland) using RIPA 
buffer, and total protein quantified essentially as described (13). Homogenate 
corresponding to 10 microgram total protein was separated on 7.5% SDS-PAGE gels, 
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blotted onto nitrocellulose membrane and subjected to immunological protein 
detection as described (13) using the following antibodies: 1: 1000 dilution of 
polyclonal FAK antiserum Lulu (16), 1:500 of monoclonal Tenascin-C serum B28:13 
(31), 1:100 of monoclonal antiserum against gamma-vinculin and meta-vinculin (gift 
of Dr. M. A. Glukhova, Paris, France) (13). Detection of pY397-FAK content was carried 
out based on immune-precipitation of soluble proteins in homogenate corresponding 
to 1 mg total protein essentially as described (13). Samples being derived from the 
three samples of each subject were analyzed in adjacent lanes of the same SDS-PAGE 
gel. Equal loading and blotting was verified based on the signal intensity of the actin 
band on the Ponceau S-stained nitrocellulose membrane after blotting signal intensity 
was assessed from background-corrected band intensities using PxI system (Syngene) 
as described (32). 
 
Skeletal muscle proteomics: Protein extraction: for 2-dimensional difference in gel 
electrophoresis (2D-DIGE) and immunoblot assays, each sample from each subject was 
suspended in lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, and 1 mM 
PMSF) and solubilized by sonication on ice. Proteins were selectively precipitated 
using PlusOne 2D-Clean up Kit (GE Healthcare, Little Chalfont, UK) in order to remove 
non protein impurities, and re-suspended in lysis buffer. The pH of the protein extracts 
was adjusted to pH 8.5 by addition of 1 M NaOH. Protein concentrations were 
determined by PlusOne 2D-Quant Kit (GE Healthcare). 2D-DIGE: Protein minimal 
labeling with cyanine dyes (Cy3 and Cy5), 2D separation, and analyses were performed 
as described previously (for crew members A and B; SOL biopsy pre-flight, immediately 
post-flight and 15 days post-flight) (15). Briefly, proteins extracted (50 µg) from each 
individual samples were labeled with Cy5, while internal standards were generated by 
pooling (50 µg) individual samples that were Cy3-labeled. Samples were separated on 
3–10 nonlinear immobilized pH gradient (IPG) strips; the adopted gradient enables 
separation of protein isoforms in the first dimension, providing a detailed pattern of 
the muscle proteome. Each individual sample was run in triplicate (analytical 
replicates) to minimize the inter-gel variability and to increase the reliability of the 
results. Image analysis was performed using DeCyder 7.0 software (GE Healthcare). 
Statistically significant differences of 2D-DIGE data were computed by paired one-way 
ANOVA coupled to Tukey’s multiple group comparison test; the significance level was 
set at p < 0.01. In addition, the false discovery rate (FDR) was applied as a multiple 
testing correction method to keep the overall error rate as low as possible (Hochberg, 
Y. B. Y. (2000). Educ. Behav. Stat. 25, 60–83). Two independent analyses were 
performed. Proteins of interest were identified by mass spectrometry. Protein 
identification by mass spectrometry: proteins were identified by peptide mass 
fingerprinting (PMF) utilizing a matrix-assisted laser desorption/ionization (MALDI) 
time-of-flight (ToF) mass spectrometer (Ultraflex III ToF/ToF; Bruker Daltonics, 
Bremen, Germany), as previously described (33). In particular, search was carried out 
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by correlation of uninterpreted spectra to Mammalia entries in NCBInr 20090430 
database (8 483 808 sequences; 2 914 572 939 residues). In cases where this approach 
was unsuccessful, additional searches were performed using electrospray ionization-
MS/MS, as previously described (34). 
 
Metabolomics: Blood sampling was obtained both from astronauts and control cohort. 
Ethylenediaminetetraacetic acid (EDTA) was always used as anticoagulant, but the 
effects of its presence were eliminated as previously described (35). Frozen plasma 
samples were thawed at room temperature, shaken before use, and NMR samples were 
prepared according to the standard operating procedures (36) . A total of 300 µL of a 
sodium phosphate buffer (10.05 g Na2HPO4·7H2O; 0.2 g NaN3; 0.4 g sodium 
trimethylsilyl [2,2,3,3-2H4]propionate (TMSP) in 500 mL of H2O with 20% (v/v) 2H2O;  
pH 7.4) was added to 300 µL of each plasma sample, and the mixture was homogenized 
by vortexing for 30 s. A total of 450 µL of this mixture was transferred into a 4.25 mm 
NMR tube for the analysis. 
1H NMR spectra were acquired at 310 K using a Bruker 600 MHz spectrometer (Bruker 
BioSpin): water suppressed Carr–Purcell–Meiboom–Gill (CPMG) (37) spin echo pulse 
sequence (RD-90°-(τ-180°-τ)n-acq) with a total spin echo (2nτ) of 80 ms was used in 
order to obtain monodimensional 1H NMR spectra in which broad signals from high 
molecular weight metabolites (i.e. proteins and lipoproteins) are attenuated. 64 FID 
were collected into 73728 data points over a spectral width of 12019 Hz, with a 
relaxation delay of 4 s and acquisition time of 3.1 s. Free induction decays were 
multiplied by an exponential function equivalent to a 1.0 Hz line-broadening factor 
before applying Fourier transformation. Transformed spectra were automatically 
corrected for phase and baseline distortions and calibrated (anomeric glucose doublet 
at 5.24 ppm) using TopSpin 3.2 (Bruker Biospin GmbH, Germany).  
All metabolomic data analyses were performed using R (40). The spectral regions 
related to metabolites were assigned in the 1H-NMR profiles by using matching 
routines of AMIX 3.8.4 in combination with the BBIOREFCODE (Bruker BioSpin GmbH, 
Germany), freely available datasets (e.g. the Human Metabolome DataBase -HMDB- 
Wishart et al.,(41, 42)), and published literature when available. Metabolite 
concentrations in arbitrary units were obtained integrating the related spectral 
regions. Principal component analysis (PCA) was used as a first unsupervised 
exploratory analysis to compare metabolic profiles of astronauts and healthy 
volunteers, monitoring how the two astronaut profiles move in the PCA metabolic 
space at the three different time points; moreover, PCA enables the assessment of the 
homogeneity or the presence of any outliers in plasma samples of volunteers that come 
from two different collection centers.  
For the univariate statistical analysis, the concentrations of each metabolite in the 
astronaut samples were compared with the healthy volunteers distributions using a 
modified Z-score calculated on Median Absolute Deviation (MAD), on the biological 
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assumption that metabolite concentrations are not parametrically distributed (43). P-
values < 0.01 were deemed significant and P-values < 0.05 near-significant. 
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Figure 1: Survey of the load and distance per treadmill session, and the load and 
number of heel raise exercise with aRED for crew member A (red) and B (green) during 
their sojourn on the ISS. 
 
 
Figure 2: Effects of spaceflight upon muscle function, given in percent changes from 
baseline, for crew member A and B. 
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Figure 3: Proteomic analysis in human skeletal muscle. Histograms of differential 
protein expression in soleus muscle between baseline versus PF-1 (colored bars) and 
baseline versus PF-2 (striped bars) in crew member A (green bars) and B (red bars), 
as detected by 2D DIGE analysis. Proteins significantly altered (paired one-way ANOVA 
and Tukey, α=0.01) are indicated by their gene name and expressed as a percent of 
spot volume variation. (A) Contractile proteins; (B) Metabolism. 
 
 
 
Figure 4: Metabolomic analysis. Panels (A,B) show amino acid and energetic 
metabolites, respectively, in box plot analysis and in arbitrary units (C.A.U.) 
concentrations of the most significant metabolites. Astronaut A and B are represented 
by green and red colors, respectively. Circle, triangle and square represent baseline, 
PF-1 and PF-2, respectively. Gray circles represent the control cohort (76 volunteers). 
Significant (p<0.01) and barely significant (p<0.05) p-values are also reported. 
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Table 1: Changes in muscle size and architecture for testing sessions post-flight 1 (PF-
1, at 0 to 4 days after landing) and post-flight session 2 (PF-2, at 15 days after landing) 
  Crew 
Member 
PF-1 PF-2 
Medial 
Gastrocnemius 
Muscle 
Volume A -18.1% -10.7% 
B -11.8% -1.2% 
Pennation angle A -23.2% -13.1% 
B +3.7% +3.3% 
Fascicle length A -7.6% -0.6% 
B -1.3% -0.6% 
Physiological CSA A -11.4% -10.2% 
B -10.7% -0.6% 
Soleus Muscle Volume A -21.1% -16.6% 
B -9.4% -7.4% 
Pennation Angle A   
B -2.9% +6.2% 
Fascicle length A   
B +0.6% +1.7% 
Physiological CSA A   
B -9.9% -8.9% 
 
 
Table 2: Summary of expressional alterations in costameric proteins. 
 PF-1 PF-2 
Parameter 
Crew 
member A 
Crew 
member B 
Crew 
member A 
Crew 
member B 
FAK-pY397 -92% 11% -54% 28% 
FAK -60% -44% 112% 88% 
FRNK -60% -67% 124% 26% 
FAK-p85 -75% -35% 257% 5% 
Gamma-vinculin 5% -17% 4% 23% 
Meta-vinculin 786% -26% -24% 116% 
Tenascin-C 2781% -14% -40% 64% 
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Supplementary materials: 
 
Supplementary Table 1: Relationships between costameric gene products, which relate to fast 
fiber types. Note the considerable increase in meta- per gamma-vinculin content in crew 
member A after space flight, and the relative stability of this ratio in crew member B.   
 
 Baseline PF-1 PF-2 
FRNK per FAK    
Crew member A 2.01 1.98 2.09 
Crew member B 0.58 0.34 0.23 
     
meta-vinculin per gamma-vinculin    
Crew member A 0.06 0.47 0.34 
Crew member B 0.05 0.05 0.08 
 
Supplementary Table 2: Testing schedule. Baseline dates are relative to launch (L), and post-
flight dates are relative to return to Earth (R+0 = landing day). 
 
Crew Member Test Baseline  
 
Post-Flight 1 
(PF-1) 
Post-Flight 2 
(PF-2) 
A Blood Sample & 
Biopsy 
L-79 R+0 R+15 
Magnetic 
Resonance 
Imaging  
L-79 R+3 R+15 
Plantar flexor 
testing 
L-79 R+1 R+15 
B Blood Sample & 
Biopsy 
L-76 R+0 R+15 
Magnetic 
Resonance 
Imaging 
L-76 R+3 R+15 
Plantar flexor 
testing 
L-76 R+4 R+15 
 
 
Supplementary Figure 1:  
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Supplementary figure 2: 
 
 
Supplementary figure 3: 
 
 
Supplementary figure 4: 
 
 
Supplementary figure 5: 
 
 
RESULTS | 195 
4.3.3 Breathomics for assessing the effects of treatment and withdrawal with 
inhaled Beclomethasone/Formoterol in patients with COPD 
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BREATHOMICS FOR ASSESSING THE EFFECTS OF TREATMENT AND 
WITHDRAWAL WITH INHALED BECLOMETHASONE/FORMOTEROL IN PATIENTS 
WITH COPD  
 
 
 
ABSTRACT 
Prospective pharmacological studies on breathomics in COPD are not available. We 
assessed the effects of steroid treatment and withdrawal of an extrafine inhaled 
corticosteroid (ICS)- long-acting β2-agonist (LABA) fixed dose combination (FDC) in a 
multidimensional classification model including breathomics. 
A pilot study was undertaken in 14 COPD patients on inhaled fluticasone 
propionate/salmeterol FDC (500/50 µg b.i.d.) maintenance treatment (visit 1). 
Patients received 2-week inhaled beclomethasone dipropionate/formoterol FDC 
(100/6 µg b.i.d.) (visit 2), 4-week formoterol (6 µg b.i.d.) (visit 3), and 4-week 
beclomethasone/formoterol (100/6 µg b.i.d.) (visit 4). Exhaled breath analysis with 
two different e-noses and exhaled breath condensate (EBC) NMR-based metabolomics 
were performed. Sputum cell counts, sputum supernatant and EBC prostaglandin-E2 
and 15-F2t-isoprostane, fraction of exhaled nitric oxide, and spirometry were 
measured. 
Three independent breathomic techniques showed that extrafine 
beclomethasone/formoterol short-term treatment was associated with different 
breathprints compared with regular fluticasone propionate/formoterol. Either 
ICS/LABA FDC treatment versus formoterol alone was associated with increased 
FEF25%-75% and FEV1/FVC (P=0.008-0.029). The multidimensional model distinguished 
fluticasone propionate/salmeterol versus beclomethasone/formoterol, fluticasone 
propionate/salmeterol versus formoterol, and formoterol versus 
beclomethasone/formoterol (accuracy>70%, P<0.01). 
Breathomics could be used for assessing ICS treatment and withdrawal in COPD 
patients. Large, controlled trials are required to clarify the biological implications of 
breathomic changes. 
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INTRODUCTION 
Respiratory inflammation has a central role in the pathophysiology of COPD. Inhaled 
corticosteroids (ICS) are the principal anti-inflammatory treatment for COPD [1], but 
little is known about the pattern of inflammatory markers which are affected by this 
pharmacotherapy. While ICS are generally effective in asthma, their anti-inflammatory 
efficacy in COPD is not clearly established [2]. 
Electronic noses (e-noses), consisting of cross-reactive chemical sensor arrays 
for the detection of volatile chemical species [3], discriminate between patients with 
COPD, asthmatic patients, healthy smokers and healthy non-smokers [4], and predict 
oral corticosteroid responsiveness in patients with asthma [5]. E-nose breathprints are 
associated with airway inflammatory markers, including sputum eosinophils and 
neutrophils, in COPD patients and can be useful for subphenotyping [6,7]. 
Metabolomics is a global approach to understanding regulation of metabolic pathways 
and metabolic networks of a biological system [7]. Nuclear magnetic resonance (NMR)-
based metabolomic analysis of exhaled breath condensate (EBC), the liquid fraction of 
exhaled breath, is suitable for identifying and quantifying semi-volatile/non-volatile 
small molecular weight metabolites and has been applied to the assessment of airway 
inflammation in COPD patients [9-11]. Published prospective clinical studies on effects 
of pharmacological treatment on e-nose breathprints in COPD patients are not 
available. 
We aimed to assess the effects of treatment and steroid withdrawal of an 
extrafine ICS/long-acting β2-agonist (LABA) fixed dose combination (FDC) on 
breathprints and non-invasive inflammatory outcomes in COPD patients; to compare 
accuracy of a multidimensional classification model versus a standard spirometry-
based model. 
 
 
METHODS 
Study subjects 
Fourteen COPD non-smokers or ex-smokers diagnosed for at least one year with stable 
mild, moderate or severe airflow limitation (GOLD stage I-III, baseline forced 
expiratory volume in one second (FEV1) > 30% predicted value, FEV1/forced vital 
capacity (FVC) < 70%), who were on a fixed dose combination (FDC) of fluticasone 
propionate/salmeterol delivered via a dry powder inhaler [DPI] at a constant dose of 
500/50 µg b.i.d. for at least 8 weeks, were studied. Diagnosis of COPD was based on 
GOLD guideline criteria [1].  
COPD patients had negative reversibility test to 400 µg of inhaled salbutamol 
(<12% or 200 mL increase in FEV1), no history of asthma and atopic disease, negative 
skin prick test results, no upper respiratory tract infections in the previous 3 weeks, 
and were excluded from the study if they had used systemic corticosteroids in the 
previous 4 weeks. 
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Study design 
This was a single centre, prospective, open label, pilot, proof-of-concept, 
pharmacological study of steroid withdrawal and treatment in COPD patients on 
maintenance treatment with inhaled fluticasone propionate/salmeterol at full doses 
(visit 1). Study duration was 10 weeks including 4 visits (Figure 1). Patients received 
inhaled beclomethasone/formoterol FDC for 2 weeks (100/6 µg 2 puffs b.i.d. via 
pressurized metered dose inhaler [pMDI]) (visit 2), inhaled formoterol alone for 4 
weeks (6 µg 2 puffs b.i.d. via pMDI) (visit 3), and inhaled beclomethasone/formoterol 
FDC for 4 weeks (visit 4) (Figure 1). Breathomics included analysis of exhaled breath 
gaseous phase with two different e-noses, and NMR-based metabolomics of exhaled 
breath condensate (EBC). Sputum cell counts, prostaglandin (PG)-E2 and 15-F2t-
isoprostane in sputum supernatants and EBC, and fraction of exhaled nitric oxide 
(FENO) were also measured (see also online supplementary material). 
Informed consent was obtained from patients. The study was approved by the 
Ethics Committee of the Catholic University of the Sacred Heart, Rome, Italy (EudraCT: 
2012-001749-42). 
 
Pulmonary function 
Spirometry was performed with a Pony FX spirometer (Cosmed, Rome, Italy) and the 
best of three consecutive maneuvers chosen. 
 
FENO measurement 
FENO was measured with the NIOX system (Aerocrine, Stockholm, Sweden) with a 
single breath on-line method at constant flow of 50 mL/sec according to American 
Thoracic Society guidelines [12,13]. FENO measurements were obtained before 
spirometry. 
 
Collection of exhaled breath 
Exhaled breath was collected from each subject at 8.30 a.m. No food or drinks were 
allowed at least 12 hours prior to collection of exhaled breath.  
Exhaled breath was collected as previously described [4,14] and based on 
recent ERS technical standard [3]. Subjects were asked to breathe tidally volatile 
organic compound (VOC)-filtered air for 5 minutes, while wearing a nose-clip, into a 2-
way non-rebreathing valve with an inspiratory VOC filter and an expiratory silica 
reservoir to reduce sample water vapor [15]. Then, subjects were asked to inhale to 
maximal inspiration and perform a FVC maneuver into a Tedlar bag. Two consecutive 
samples were collected 15 min apart and immediately analyzed. 
 
Electronic noses 
The first sample was analyzed with a commercially available e-nose (Cyranose 320, 
Sensigent, Baldwin Park, USA) [4,16], which consists of an array of 32 cross-reactive 
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carbon black polymer composite sensors and detects resistance variations; the second 
sample was analyzed with an e-nose prototype (Ten 2011, University of Rome Tor 
Vergata, Italy) [17] which consists of an array of 8 cross-reactive quartz microbalance 
gas sensors coated by molecular films of metallo-porphyrins and detects frequency 
variations [17]. Breathprints were analyzed by pattern recognition algorithms (see 
supplementary material) [18].  
Ambient VOCs were subtracted from measures and results were automatically 
adjusted for ambient VOCs. 
 
EBC sampling 
Before EBC collection, subjects refrained from eating for at least 3 h. EBC was collected 
using a condenser (Ecoscreen, Jaeger, Hoechberg, Germany) [9], in a windowless clinic 
facility without disinfectant dispensers (see online supplementary material) [9]. 
Samples were snap frozen in liquid nitrogen to immediately ‘quench’ metabolism and 
preserve the metabolite concentrations. 
 
Metabolomic analysis of EBC with NMR spectroscopy 
1H-NMR spectra for EBC samples were acquired using a Bruker 600 MHz spectrometer 
operating at 600.13 MHz using standard nuclear Overhauser effect spectroscopy 
(NOESY) experiments and standard protocols for sample preparation [19]. Signals of 
interest were assigned on template one-dimensional NMR profiles and integrated to 
calculate their relative concentrations [10,19,20]. Multilevel partial least square (PLS) 
analysis was used to analyze EBC spectra from the same subject obtained at paired 
visits. (see also online supplementary material). 
 
Measurement of PGE2 and 15-F2t-isoprostane in sputum supernatants and EBC 
PGE2 and 15-F2t-isoprostane concentrations in sputum supernatants and EBC were 
measured with radioimmunoassays developed in our laboratory, previously validated 
and compared with gas chromatography/mass spectrometry and high performance 
liquid chromatography [21,22].  
 
Skin testing 
Atopy was assessed by skin prick tests for common aeroallergens (Stallergenes, 
Antony, France) [23]. 
 
Multivariate data analysis 
E-nose and NMR spectroscopy data analysis requires multivariate statistical 
algorithms [18,24]. Multilevel partial least square analysis was used for data reduction; 
the K-nearest neighbors method, applied on the multilevel PLS scores, was used for 
classification purposes [18,24]. The global classification accuracy was assessed by 
means of Monte Carlo cross-validation scheme. The threshold for significant 
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classification was set at a value of 70% [25]. Correlations among multidimensional 
data, shown as a heatmap, were calculated using the algorithm implemented in the R-
library “psych” [26,27], based on a correlation matrix built using the R-function 
“heatmap.2”, implemented in the “gplots” package [28]. (see online supplementary 
material). 
 
Statistical analysis 
Data were expressed as mean ± SEM or medians and interquartile ranges (25th and 75th 
percentiles), after assessing for normality with the D’Agostino-Pearson omnibus 
normality test. Depending on data distribution, repeated-measures ANOVA or 
Friedman test or Wilcoxon test were used for assessing within-group pharmacological 
treatment effect. Correlation was expressed as a Pearson coefficient. Significance was 
defined as a value of P < 0.05. 
 
 
RESULTS 
Study subjects 
The mean age of the subjects (2 females and 12 males) enrolled in this study was 73.6 
± 1.8 years. Patients smoke a mean of 64.3 ± 1.8 pack-year and, according to the 
airflow limitation severity, were classified as GOLD I (4 patients), II (5 patients), and 
III (5 patients). Information about common aeroallergens, history of atopy, sputum 
eosinophils at visit 1 are detailed in Table 1.  
 
Pulmonary function testing 
Higher mean percentage of predicted pre-bronchodilator (forced expiratory flow at 
25% to 75% of forced vital capacity (FEF25%-75%) and absolute values were observed 
after 2-week inhaled beclomethasone/formoterol FDC treatment (visit 2) compared 
with 4-week treatment with inhaled formoterol alone (visit 3) (P = 0.029 and P = 0.026, 
respectively) (Figure 2A and 2B; Supplementary Table 1).  
Mean pre-bronchodilator FEV1/FVC ratio was higher on maintenance treatment 
with inhaled fluticasone propionate/salmeterol FDC (visit 1) compared with post-
treatment with inhaled formoterol alone (visit 3) (P = 0.008) (Supplementary Table 1). 
Higher mean pre-bronchodilator peak expiratory flow (PEF) percentage 
predicted and absolute values were observed after 2-week 
beclomethasone/formoterol FDC (visit 2) compared with those observed after 4-week 
treatment with formoterol alone (visit 1) (P = 0.044 and P = 0.033, respectively) 
(Figure 2C and 2D; Supplementary Table 1). No within-group differences in post-
bronchodilator functional parameters were observed (Supplementary Table 2). 
 
Electronic nose 
E-nose analysis with either e-nose  was successfully performed in all 14 subjects  at all  
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visits. A total of 56 breathprints for each e-nose was collected. Fifteen out of 32 carbon 
polymer sensors showed significant mean differences between maintenance treatment 
with inhaled fluticasone propionate/salmeterol FDC (visit 1) and after 4-week 
treatment with beclomethasone/formoterol FDC (visit 4), whereas 7 sensors showed 
significant mean differences between fluticasone propionate/salmeterol maintenance 
treatment (visit 1) and 2-week treatment with beclomethasone/formoterol (visit 2) 
(Table 2).  
Consistent with carbon polymer sensor behaviour, two quartz crystal sensors 
showed significant differences between maintenance treatment with fluticasone 
propionate/salmeterol (visit 1) and 4-week beclomethasone/formoterol treatment 
(visit 4); sensor 3 and 4 showed significant differences between fluticasone 
propionate/salmeterol maintenance treatment (visit 1) and 2-week treatment with 
beclomethasone/formoterol (visit 2) (Table 3). 
There was no difference in sensor response using either e-nose when other 
paired visits were compared (Table 2 and 3). 
 
Metabolomic analysis of EBC with NMR spectroscopy 
A total of 56 EBC NMR spectra obtained from 14 study subjects across visits were 
analyzed (Supplementary Figure 1). EBC metabolomics with NMR spectroscopy 
discriminated between maintenance treatment with fluticasone 
propionate/salmeterol FDC (visit 1) and treatment with beclomethasone/formoterol 
FDC for 4 weeks (visit 4) (accuracy = 72%, P = 0.01) (Supplementary Figure 2). 
Formate levels were higher at visit 1 (694.9 ± 360.5 arbitrary units, median ± median 
absolute deviation [MAD]) than at visit 4 (409.2 ± 224.8 arbitrary units, P = 0.029) 
(Supplementary Figure 3A and 3B, s-Table 3). Other paired comparisons showed 
accuracy below the significant threshold set at 70% (s-Table 4). After 4-week 
treatment with beclomethasone/formoterol FDC (visit 4), EBC acetate levels were 
lower than those measured after 4-week treatment with formoterol alone (visit 3) (P 
= 0.009) (s-Table 3). Several EBC metabolites, including formate, phenol, methanol, 
trimethylamine, acetone, acetoine, acetate, n-butyrate, lactate, 3-hydroxyisovalerate, 
ethanol, propionate, and leucine-o-butyrate were identified (Figure 3). Apart from 
formate and acetate, their levels were similar across visits (s-Table 3).  
 
Fraction of exhaled nitric oxide (FENO) 
There was no within-group difference in FENO concentrations in patients with COPD 
(overall P = 0.35) (s-Table 5).  
 
Measurement of PGE2 and 15-F2t-isoprostane in sputum supernatants and EBC 
PGE2 concentrations were detected in 49 out of a total of 56 sputum supernatant 
samples. Compared with formoterol alone post-treatment values (visit 3), lower 
sputum PGE2 concentrations were observed after 4-week treatment with 
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beclomethasone/formoterol FDC (visit 4) (P = 0.008) and on maintenance treatment 
with fluticasone propionate/salmeterol FDC (visit 1) (P = 0.021) (Supplementary Table 
6). These data suggest that treatment with ICS FDC, containing either fluticasone 
propionate or beclomethasone, reduces PGE2 sputum concentrations. There was no 
between-visit differences in EBC PGE2 or sputum and EBC 15-F2t-isoprostane 
concentrations (Supplementary Table 6). 
 
Sputum cell analysis 
Eight patients with COPD had a complete set of sputum slides (visit 1 to visit 4) 
(Supplementary Table 7). No patient with COPD had sputum eosinophilia, as defined 
by sputum cell counts > 3%, at visit 1 (screening visit). There was no within-group 
difference in sputum cell counts (Supplementary Table 7). Percentage sputum cell 
counts in all valid sputum slides are shown in Supplementary Table 8. 
 
Correlations  
Responses within each individual e-nose and between e-noses were correlated, 
whereas EBC metabolites detected by NMR spectroscopy were not correlated with 
either e-noses, except EBC phenol which was correlated with 16 carbon polymer 
sensors (Figure 4, and online supplementary material). In EBC, there was a correlation 
between PGE2 and formate (r = 0.78, P = 5.06-11), acetone (r = 0.63, P = 1.64-6), lactate 
(r = 0.64, P = 6.03-7), n-butyrate (r = 0.82, P = 5.89-13), propionate (r = 0.59, P = 8.26-6), 
and acetate (r = 0.71, P = 1.23-8) (Figure 4). Quartz crystal sensor 4 (r = -0.35, P = 0.023) 
and 7 (r = -0.31, P = 0.041) negatively correlated with sputum neutrophils. These 
showed negative correlation with FEV1/FVC (r = -0.34; P = 0.028) (Figure 4, and online 
supplementary material). 
 
Multidimensional integrated model for assessment of pharmacological treatment 
In the 14 COPD study subjects, multidimensional pairwise discrimination models were 
built. The models discriminated between maintenance treatment with fluticasone 
propionate/salmeterol (visit 1) versus 4-week treatment with formoterol alone (visit 
3) (accuracy = 71.5%, P < 0.01); the univariate analysis showed differences in sputum 
supernatant PGE2 and FEV1/FVC ratio (Table 4); between maintenance treatment with 
fluticasone propionate/salmeterol (visit 1) versus 4-week treatment with 
beclomethasone/formoterol (visit 4) (accuracy = 82.5%, P < 0.01); the univariate 
analysis showed differences in EBC formate, e-noses, and EBC PGE2 (Table 4); between 
4-week treatment with formoterol alone (visit 3) versus 4-week treatment with 
beclomethasone/formoterol (visit 4) (accuracy = 74.6%, P < 0.01); the univariate 
analysis showed differences in sputum PGE2 and EBC acetate (Table 4). The 
multidimensional models showed higher accuracies than the models based on 
spirometry alone (s-Table 9). 
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DISCUSSION 
The principal messages of the present study are: 1) breathomics can be successfully 
applied to assessment of effects of treatment and steroid withdrawal with ICS/LABA 
in patients with COPD; 2) breathomic results are confirmed by the concordance of 
three different breathomic techniques (carbon polymer sensor e-nose, quartz crystal 
sensor e-nose, NMR-based metabolomics) applied to the gaseous and aerosol particle 
(EBC) phase of the exhaled breath. These techniques provide complementary 
information; 3) a multidimensional, integrated, model including breathomics, 
improves the ability of identifying pharmacological treatment-induced effects 
compared with a monodimensional model based on standard pulmonary function 
testing. 
We show that short-term treatment with extrafine beclomethasone/formoterol 
FDC pMDI is associated with different breathprints as compared with regular 
fluticasone propionate/formoterol FDC DPI in patients with COPD. These results might 
suggest that various ICS/LABA formulations have different effects on breathomic 
outcomes, although the biological implications of these findings are unknown and have 
to be defined.  
Treatment with either ICS/LABA FDC versus inhaled formoterol alone was 
associated with a slight, but significant, increase in small airway function as reflected 
by FEF25%-75% and FEV1/FVC values, whereas higher PEF values were observed after 
beclomethasone/formoterol (visit 2) than on regular fluticasone 
propionate/salmeterol (visit 1), suggesting that treatment-induced e-nose breathprint 
variations parallel the observed functional changes only to a limited extent.      
Interestingly, functional effects were observed after only 4-week treatment with 
inhaled beclomethasone/formoterol, a relatively short duration of treatment for COPD 
trials, and in patients with COPD who had normal sputum eosinophils, negative 
reversibility test to bronchodilators, negative skin prick tests, and no history of atopy, 
thus, excluding an asthma component, on which ICS are generally more effective. 
            The strong correlation between most sensors within each individual e-nose 
indicates a high degree of sensor redundancy, whereas a similar behaviour of e-nose 
based on different technologies confirms the results of the exhaled breath analysis. Of 
note, quartz crystal sensors, but not carbon polymer sensors, showed correlation with 
sputum neutrophils. On the other hand, the lack of correlation between EBC 
metabolites detected by NMR spectroscopy and either e-noses suggests that a 
comprehensive breathomics approach might be complementary and increase the 
level of information. In EBC, there was a correlation between PGE2, an eicosanoid 
which can have potent pro-inflammatory effects in the airways [29,30], and formate 
(r = 0.78), acetone (r = 0.63), lactate (r = 0.64), n-butyrate (r = 0.82), propionate (r = 
0.59), and acetate (r = 0.71) suggesting that these EBC metabolites might reflect 
respiratory inflammation.  
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          Unlike a standard model based on spirometry, the multidimensional model used 
in our study was able to distinguish between pharmacological treatments (accuracy > 
70%) in 3 out of 6 possible paired comparisons. This might increase the chance of 
detecting drug effects in COPD patients. In line with an anti-inflammatory effect of ICS, 
sputum concentrations of PGE2, the key between-treatment discriminating outcome 
measure, were lower after treatment with either ICS/LABA FDC compared with 
formoterol alone. By contrast, other inflammatory outcomes, including sputum 
neutrophil cell counts, EBC PGE2, and sputum and EBC 15-F2t-isoprostane, showed 
steroid resistance. Elevated EBC formate and acetate levels have been reported in 
COPD patients compared with healthy subjects [9,31]. Interestingly, we found reduced 
EBC levels of these metabolites after beclomethasone/formoterol treatment.  
           Study strengths rely on the fact that this is the first prospective evidence of the 
effects of pharmacological treatment and steroid withdrawal on breathomics in COPD 
patients, the multidimensional, non-invasive, approach to drug assessment requiring 
a systems medicine-based data analysis, and the use of complementary breathomics 
techniques. The limited number of study subjects, the open-label, uncontrolled, design 
of the pharmacological study, the short duration of treatment/withdrawal phases, the 
lack of training and testing validation and external validation cohorts, represent 
limitations which preclude definitive conclusions.  
In conclusion, breathomics can be used for assessing the effects of treatment and 
steroid withdrawal with ICS/LABA in patients with COPD. The present pilot, proof-of-
concept, study provides a rational basis for large, randomized, controlled, 
pharmacological trials in patients with COPD using a similar multidimensional 
approach. 
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Table 1. Subject characteristics* 
 COPD patients 
n 14 
Age, years 73.6 ± 1.8 
Gender, females/males 2/14 
Pack-years 64.3 ± 8.1 
GOLD I/II/III, airflow limitation 
severity 
4/5/5 
§Skin prick tests, positive/negative 0/14 
History of atopy, positive/negative 0/14 
#Sputum eosinophils ≥ 3% at visit 1 0/14 
*Data are expressed as numbers or mean ± SEM. §Common aeroallergens were tested. #Expressed as percentage of 
total non-squamous cells. 
 
 
Table 2. Carbon polymer sensor e-nose response*. The behaviour of each sensor 
(sensor 1 - sensor 32) is shown. Sensors whose mean values differ across visits are 
shown in bold. 
 
Sensor 1 
V1 V2 V3 V4 P value 
2.507±0.2171 2.843±0.1636 2.891±0.2411 3.208±0.1857 0.0480 
V1 vs V4    0.0055 
Sensor 2 
V1 V2 V3 V4 P value  
1.664±0.1427 
 
1.891±0.0979 
 
1.934±0.1537 
 
2.181±0.1260 
 
0.0212 
V1 vs V2    0.0364 
V1 vs V4    0.0053 
Sensor 3 
V1 V2 V3 V4 P value  
2.527±0.2057 2.768±0.1549 2.868±0.2432 3.183±0.1993 n.s. 
Sensor 4 
V1 V2 V3 V4 P 
1.447±0.1191 1.640±0.0891 1.693±0.1378 1.926±0.1249 0.0209 
V1 vs V4    0.0040 
Sensor 5 
V1 V2 V3 V4 P value 
11.27±1.195 12.86±0.8729 13.38±1.261 16.70±2.785 n.s. 
Sensor 6 
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V1 V2 V3 V4 P value  
6.574±0.7314 7.547±0.5477 7.757±0.8441 8.510±0.6821 n.s. 
Sensor 7 
V1 V2 V3 V4 P value  
0.001109±0.0962 0.001253±0.0678 0.001265±0.1008 0.001409±0.0763 0.0409 
V1 vs V4    0.0053 
Sensor 8 
V1 V2 V3 V4 P value  
0.6803±0.05038 0.7709±0.03499 0.7732±0.05597 0.8569±0.05064 0.0259 
V1 vs V2    0.0216 
V1 vs V4    0.0058 
Sensor 9 
V1 V2 V3 V4 P value  
2.154±0.2058 2.462±0.1496 2.542±0.2280 2.811±0.1892 n.s. 
Sensor 10 
V1 V2 V3 V4 P value  
1.283±0.1128 1.474±0.08070 1.492±0.1259 1.649±0.1020 n.s. 
Sensor 11 
V1 V2 V3 V4 P value  
1.277±0.1155 1.429±0.0759 1.460±0.1267 1.607±0.0973 n.s. 
Sensor 12 
V1 V2 V3 V4 P value  
1.321±0.1193 1.487±0.0781 1.559±0.1282 1.715±0.0970 0.0300 
V1 vs V4    0.0046 
Sensor 13 
V1 V2 V3 V4 P value  
1.036±0.0877 1.185±0.0624 1.196±0.0981 1.315±0.0757 n.s. 
Sensor 14 
V1 V2 V3 V4 P value  
0.8994±0.0752 1.014±0.0542 1.048±0.0820 1.163±0.0604 0.0258 
V1 vs V4    0.0051 
Sensor 15 
V1 V2 V3 V4 P value  
2.225±0.1933 2.513±0.1338 2.577±0.2234 2.881±0.1799 0.045 
V1 vs V4    0.0071 
Sensor 16 
V1 V2 V3 V4 P value  
1.241±0.1085 1.405±0.0809 1.447±0.1203 1.577±0.0962 0.0100 
V1 vs V4    0.0094 
Sensor 17 
V1 V2 V3 V4 P value  
1.430±0.1237 1.603±0.0880 1.637±0.1437 1.804±0.1222 n.s. 
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Sensor 18 
V1 V2 V3 V4 P 
2.643±0.2480 3.000±0.1781 3.093±0.2729 3.385±0.2228 n.s. 
Sensor 19 
V1 V2 V3 V4 P value 
0.9070±0.0727 1.033±0.0569 1.075±0.0908 1.172±0.0648 0.0273 
V1 vs V2    0.0320 
V1 vs V4    0.0052 
Sensor 20 
V1 V2 V3 V4 P 
2.341±0.2267 2.658±0.1648 2.702±0.2400 2.910±0.1990 n.s. 
Sensor 21 
V1 V2 V3 V4 P 
0.8288±0.0683 0.9423±0.0510 0.9509±0.0762 1.057±0.0597 0.0362 
V1 vs V2    0.0307 
V1 vs V4    0.0062 
Sensor 22 
V1 V2 V3 V4 P value  
1.004±0.0863 1.132±0.0594 1.132±0.0935 1.233±0.0767 n.s. 
Sensor 23 
V1 V2 V3 V4 P value  
9.586±0.9759 10.94±0.7091 11.47±1.157 13.26±1.443 n.s. 
Sensor 24 
V1 V2 V3 V4 P value  
1.403±0.1185 1.597±0.0943 1.704±0.1439 1.904±0.0872 0.0084 
V1 vs V2    0.0404 
V1 vs V4    0.0030 
V2 vs V4    0.0365 
Sensor 25 
V1 V2 V3 V4 P value  
1.426±0.1198 1.618±0.0865 1.635±0.1300 1.849±0.1003 0.0286 
V1 vs V2     0.0494 
V1 vs V4    0.0051 
Sensor 26 
V1 V2 V3 V4 P value  
0.003672±0.3577 0.004201±0.2878 0.004370±0.4194 0.004926±0.4143 n.s. 
Sensor 27 
V1 V2 V3 V4 P value  
0.0005989± 
0.0456 
0.0006938± 
0.0359 
0.0007088± 
0.0597 
0.0007838± 
0.0412 
0.0182 
V1 vs V2    0.0170 
V1 vs V4    0.0013 
Sensor 28 
 
210| 
V1 V2 V3 V4 P value  
0.004238±0.4047 0.004810±0.2025 0.004937±0.4320 0.005434±0.3809 n.s. 
Sensor 29 
V1 V2 V3 V4 P value  
2.228±0.2167 2.521±0.1581 2.573±0.2285 2.890±0.2030 n.s. 
Sensor 30 
V1 V2 V3 V4 P value  
0.9987±0.0863 1.151±0.0666 1.170±0.0987 1.301±0.0946 
 
n.s. 
Sensor 31 
V1 V2 V3 V4 P value  
15.13±1.761 17.41±1.240 18.35±2.133 24.58±6.076 n.s. 
Sensor 32 
V1 V2 V3 V4 P value  
0.6599±0.0538 0.7333±0.0397 0.7486±0.0599 0.8363±0.0437 0.0426 
V1 vs V4    0.0066 
*Data, expressed as mean ± SEM, are relative changes in sensor resistance [(Rmax-R0)/R0] (µOhms). Intra-group, 
between-visit comparisons were performed with ANOVA for repeated measures. If overall P was lower than 0.05, 
considered significant, paired t test was performed. Abbreviations: n.s., not significant; V, visit. 
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Table 3. Quartz crystal sensor e-nose response*. The behavior of each sensor (sensor 
1 - sensor 8) is shown. Sensors whose mean values differ across visits are shown in 
bold. 
Sensor 1 
V1 V2 V3 V4 P value 
21.5 (14.75-31) 30 (19-38) 27.5 (21.75-36.75) 30.5 (22.75-
38.25) 
n.s. 
Sensor 2 
V1 V2 V3 V4 P value 
19 (14-29) 27.5 (20.5-
32.75) 
25 (21.5-35.25) 30.5 (25.5-38) 0.0092 
V1 vs V4    0.0329 
Sensor 3 
V1 V2 V3 V4 P value 
49 (38.25-
76.25) 
79.5 (57-105.8) 66.5 (53.5-106.5) 89 (65.5-101) n.s. 
V1 vs V2    0.0279 
Sensor 4 
V1 V2 V3 V4 P value 
31 (26.75-48) 48.5 (37.25-
58.25) 
44 (36-66.75) 54.4 (43.5-67) 0.0523 
V1 vs V2    0.0445 
V1 vs V4    0.0413 
Sensor 5 
V1 V2 V3 V4 P value 
12.5 (9-16.8) 19 (13.3-22.5) 15.5 (12.5-25.5) 19.5 (15.8-24.3) n.s. 
Sensor 6 
V1 V2 V3 V4 P value 
24 (18.8-33.3) 29.5 (23.3-43.8) 36 (25-41) 32 (24.8-45) n.s. 
Sensor 7 
V1 V2 V3 V4 P value 
20.5 (15.3-32) 29 (22.3-38) 29 (25.8-41.3) 32.5 (29-36.8) n.s. 
Sensor 8 
V1 V2 V3 V4 P value 
30.5 (20.3-44.5) 42 (32.5-55.3) 30 (27.5-48.3) 41.5 (29.5-49.5) n.s. 
     
*Data, expressed as median and interquartile range, are relative changes in sensor frequency [(ƒmax-
ƒ0)/ƒ0] (Hz). Intra-group, between-visit comparisons were performed with Friedman’s test. If overall P 
was lower than 0.05, considered significant, Wilcoxon matched-pairs signed rank test was performed. 
Abbreviation: n.s., not significant; V, visit. 
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Table 4. Classification accuracies with 95% confidence interval and P values among 
different pharmacological treatments from visit 1 to visit 4 based on multidimensional 
PLS models in 14 patients with COPD. The significant variables in the univariate 
analysis of each experimental technique are also reported (Wilcoxon signed-rank test 
P values). 
 
Abbreviations: AUC, area under the curve; EBC, exhaled breath condensate; FEF25%-75%, forced expiratory flow at 
25%-75% of the forced vital capacity; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; NMR, 
nuclear magnetic resonance; PEF, peak expiratory flow; PGE2, prostaglandin E2; % pred, percentage of predicted 
value; PLS, partial least squares.  
Comparison 
Overall accuracy 
(P value) 
Model quality Variable P value 
Visit 1 vs. Visit 2 
66.4% (CI 95% 
66.0-66.9%) 
(P = 0.12)   
AUC 0.714 
Youden's J 0.294 
Carbon 
polymer sensor 
e-nose 
Sensor2 0.036 
Sensor8 0.021 
Sensor19 0.032 
Sensor21 0.031 
Sensor24 0.040 
Sensor25 0.049 
Sensor27 0.017 
Quartz crystal 
sensor e-nose 
Sensor 3 0.028 
Sensor 4 0.044 
Spirometry 
PEF, % pred 0.033 
PEF 0.044 
Visit 1 vs. Visit 3 
71.5% (CI 95% 
71.1-72.0%) (P < 
0.01) 
AUC 0.704 
Youden's J 0.446 
Eicosanoids 
PGE2 in 
sputum 
supernatants 
0.021 
Spirometry FEV1/FVC, % 0.008 
Visit 1 vs. Visit 4 
82.5% (CI 95% 
82.0-83.0%) (P < 
0.01) 
AUC 0.857 
Youden's J 0.666 
NMR 
spectroscopy 
Formate in 
EBC 
0.029 
Carbon 
polymer sensor 
e-nose 
Sensor1 0.006 
Sensor2 0.005 
Sensor4 0.004 
Sensor7 0.005 
Sensor8 0.006 
Sensor12 0.005 
Sensor14 0.005 
Sensor15 0.007 
Sensor16 0.009 
Sensor19 0.005 
Sensor21 0.006 
Sensor24 0.003 
Sensor25 0.005 
Sensor27 0.001 
Sensor32 0.007 
Quartz crystal 
sensor e-nose 
Sensor 2 0.032 
Sensor 4 0.041 
Visit 2 vs. Visit 3 
59.9% (CI 95% 
58.8-61.1%) (P = 
0.23) 
AUC 0.571 
Youden's J 0.134 
Spirometry 
FEF25%-75%, L 0.029 
FEF25%-75%, % 
pred 
0.026 
Visit 2 vs. Visit 4 
59.8% (CI 95% 
58.2-61.3%) (P = 
0.12) 
AUC 0.556 
Youden's J 0.214 
Carbon 
polymer sensor 
e-nose 
Sensor 24 0.037 
Visit 3 vs. Visit 4 
74.6% (CI 95% 
73.9-75.2%) (P < 
0.01) 
AUC 0.760 
Youden's J 0.454 
Eicosanoids 
PGE2 in 
sputum 
supernatants 
0.008 
NMR 
spectroscopy 
Acetate 0.009 
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Figure 1. Study design and detail of interventions. At screening visit (visit 1), treatment 
with a constant dose of inhaled fluticasone propionate/salmeterol xinafoate fixed dose 
combination (FDC) (500/50 µg b.i.d. via a dry powder inhaler) for at least 8 weeks was 
switched to an extrafine formulation of inhaled beclomethasone dipropionate 
(BDP)/formoterol fumarate (FOR) FDC (100/6 µg 2 puffs b.i.d. via a pressurized 
metered dose inhaler [pMDI]). After a run-in phase of 2 weeks, the FDC containing 
beclomethasone was suspended (visit 2, baseline visit), while maintaining formoterol 
alone (6 µg 2 puffs b.i.d. via pMDI). After 4 weeks of beclomethasone withdrawal (visit 
3, post-withdrawal visit), treatment with inhaled beclomethasone/formoterol FDC at 
the same dose (100/6 µg 2 puffs b.i.d. via pMDI) was reintroduced. Exhaled breath 
sampling for e-nose analysis, measurement of fraction of exhaled nitric oxide (FENO), 
exhaled breath condensate (EBC) collection, pulmonary function tests (PFT), and 
sputum induction were performed at each visit. Study duration was 10 weeks. 
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Figure 2. Pre-bronchodilator forced expiratory flow at the 25%-75% of the forced vital 
capacity (FEF25%-75%) and peak expiratory flow (PEF) values in 14 patients with COPD 
at visit 1 (V1) to visit 4 (V4). A) FEF25%-75% percentage predicted values; B) absolute 
FEF25%-75% values; C) PEF percentage predicted values; D) absolute PEF values. Mean 
values ± SEM are shown. 
 
 
Figure 3. An example of EBC NMR spectrum at 600 MHz. All metabolites assigned and 
quantified are reported in figure. 
 
 
RESULTS | 215 
Figure 4. Heatmap showing correlations between study outcome measures in 14 
patients with COPD at visit 1 to visit 4 (n = 56). R values are shown as different degree 
of colour intensity (red, positive correlations; blue, negative correlation). 
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Supplementary materials: 
 
SUPPLEMENTARY METHODS 
Study subjects 
Subjects were on maintenance treatment with inhaled fluticasone propionate/salmeterol at a 
constant dose of 500/50 µg b.i.d. delivered via a dry powder inhaler (DPI) for at least 8 weeks.  
Patients were recruited at the outpatient clinic, Respiratory Medicine Unit, and Clinical 
Pharmacology Unit, Catholic University of the Sacred Heart, University Hospital Agostino 
Gemelli Foundation, Rome, Italy. 
 
Study design 
Treatment with an extrafine beclomethasone/formoterol fixed dose combination (FDC) was 
suspended and reintroduced as described in Figure 1 (main manuscript).  
At visit 1, patient treatment, consisting of a constant dose of inhaled fluticasone 
propionate/salmeterol xynafoate FDC (500/50 µg b.i.d. via DPI) for at least 8 weeks, was 
switched to an extrafine formulation of inhaled beclomethasone/formoterol FDC (100/6 µg 2 
puffs b.i.d. via pressurized metered dose inhaler [pMDI]). After 2-week treatment (visit 2), FDC 
containing beclomethasone was suspended, while maintaining formoterol alone (6 µg 2 puffs 
b.i.d. via pMDI). After 4 weeks of beclomethasone withdrawal (visit 3), treatment with inhaled 
extrafine beclomethasone/formoterol FDC at the same dose (100/6 µg 2 puffs b.i.d. via pMDI) 
was reintroduced and maintained for 4 weeks (visit 4). Study duration was 10 weeks. Study 
design and details of intervention are shown in Figure 1 (main manuscript). At each visit, 
interventions were performed in the following order: fraction of exhaled nitric oxide (FENO) 
measurement, exhaled breath sampling for e-nose analysis, exhaled breath condensate (EBC) 
collection, pulmonary function tests, and sputum induction. Skin prick testing was performed 
at visit 1. 
Before breath sampling, subjects were asked to refrain from eating and drinking (except water) 
for at least 12 h and to stop short-acting bronchodilators for at least 12 h and long-acting 
bronchodilators for at least 24 h. Breath sampling and e-nose analysis was performed in a 
windowless conference facility in the Clinical Pharmacology Unit, University Hospital Agostino 
Gemelli Foundation, Catholic University of the Sacred Heart, controlled by a central ventilation 
system and without disinfectant dispensers or person traffic.  
 
Collection of exhaled breath 
Exhaled breath was collected through mixed expiratory sampling in which total breath, 
including dead space air, is collected. An equilibration phase (wash-in) with volatile organic 
compound (VOC)-filtered room air was performed before breath sampling to reduce the 
interference of ambient VOCs [1,2]. Subjects were asked to breathe tidally VOC-filtered air for 
5 minutes, while wearing a nose-clip, into a 2-way non-rebreathing valve with an inspiratory 
VOC filter and an expiratory silica reservoir to reduce sample water vapor as this could affect 
sensor response [3,4]. Then, subjects were asked to inhale to maximal inspiration and perform 
a FVC manoeuvre into a Tedlar bag against an expiratory resistance of 20 cmH2O to close the 
soft palate and obtain an expiratory flow of 0.1-0.2 L/s [1,2]. This breath sampling procedure 
minimizes the effect of ambient VOCs on e-nose analysis. 
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Electronic nose analysis 
The setup for e-nose analysis used in this study consists of a commercially available e-nose 
(Cyranose 320, Sensigent, Baldwin Park, USA, formerly manufactured by Smiths Detection, 
Pasadena, USA) [1,5] and a prototype e-nose (Ten 2011, University of Rome Tor Vergata, Italy) 
[6]. The commercially available e-nose consists of an array of 32 chemical sensors made from 
composites of an inorganic conductor (carbon black) and insulating organic polymers [5]. The 
measurement is based on a resistance variation in each chemical sensor when exposed to 
breath VOCs. E-nose analysis was performed immediately after breath sample collection. Each 
breath sample was analyzed 5 times with the same e-nose. Data from the first measure were 
discarded as suggested by the manufacturer and reported in previous studies [1,7]; the second 
e-nose measure was used for data analysis [2]. E-nose responses for each sensor (changes in 
resistance) were stored in the e-nose in-built database, copied into a Matlab file and analyzed 
offline with a pattern recognition algorithm [2]. Algorithms were created using principle 
component analysis (PCA) and multilevel partial least square (PLS) analysis. The K-nearest 
neighbours method, applied on the multilevel PLS scores, was used for classification purposes. 
Only the first few principal components were used to avoid errors of the first degree. 
Component number was chosen based on those required to describe 99.9% of the dataset 
variance. T-test was used to identify discriminating principle components, with a P value < 0.1 
considered significant, which were then analyzed with canonical discriminant analysis. The 
Monte Carlo cross-validation scheme was used to calculate the cross-validated sensitivity, 
specificity and global classification accuracy of the algorithm as the limited sample size 
precluded training and testing validation. The analysis was performed with SPSS (version 17.0, 
SPSS Inc., Chicago, IL, USA). 
The second e-nose, which detects frequency variations, contains an array of eight quartz 
microbalance (QMB) gas sensors coated by molecular films of metallo-porphyrins [6]. Sensors 
detect the amount of molecules absorbed in a sensitive film through the changes of resonant 
frequency that is proportional to the absorbed mass [6]. 
 
EBC sampling 
The condenser has a saliva trap to reduce the chance of salivary contamination [8]. Under our 
experimental conditions, no effect of salivary contamination or cleaning solution on EBC 
profiles has been observed [8-10]. Subjects were asked to wash their mouth thoroughly before 
collecting EBC, to breathe tidally through a mouthpiece into a two-way non-rebreathing valve 
for 15 minutes wearing a nose-clip, and to stop breathing into the mouthpiece and swallow 
every time they felt salivation. An average of 1.5 ± 0.2 mL (mean ± SD) of EBC was collected in 
15 minutes of tidal breathing. EBC sampling was performed as previously described [8]. EBC 
was immediately transferred into 10 mL glass vials, closed with 20 mm butyl rubber lined with 
polytetrafluoroethylene septa and crimped with perforated aluminum seals [8]. Before sealing, 
volatile substances were removed from samples by a gentle nitrogen gas flow for 3 min [8]. 
Previous experiments showed no difference with spectra acquired after a variable time of 
nitrogen exposure (1, 3, 5, 10, 15 and 20 min) [9]. However, as 1-min interval appeared to be 
too short to avoid systematic errors, a 3-min interval was chosen.  Samples were not dried out 
to avoid their precipitation, with a possible loss of nonvolatile compounds, and/or formation 
of aggregates upon dissolving the dried condensate for NMR measurements. Sealed samples 
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were then frozen in liquid nitrogen, so as to immediately “quench” metabolism and preserve 
the metabolite concentrations [6,9]. Samples were stored at -80°C until metabolomic analysis.  
 
Metabolomic analysis of EBC with NMR spectroscopy 
EBC samples, stored at -80°C, were thawed at room temperature. Sample aliquots (630 μL) 
were then centrifuged at 14000 rpm for 10 minutes. Sample aliquots of the supernatant (540 
μL) were mixed with 55 μL of 2H2O and 5 μL of buffer phosphate (0.2 M Na2HPO4, 0.2 M 
NaH2PO4 in 100% 2H2O, pH 7) containing 30 mM NaN3 and 10 mM sodium 3-trimethylsilyl 
[2,2,3,3-2H4] propionate (TMSP). Then, 450 μL of mixture were pipetted into 4.25 mm NMR 
tube (Bruker BioSpin) [11]. 
1H-NMR spectra were acquired using a Bruker 600 MHz spectrometer (Bruker BioSpin) 
operating at 600.13 MHz proton Larmor frequency and equipped with a 5 mm CPTCI 1H-
13C/31P-2H cryo-probe including a z-axis gradient coil, an automatic tuning-matching (ATM), 
and an automatic sample changer [11].  
A PT 100 thermocouple served for temperature stabilization at the level of approximately 0.1 
K at the sample. Before measurement, samples were kept for at least 3 min inside the NMR 
probe head for temperature equilibration (300 K). For each sample, a one-dimensional NMR 
spectrum was acquired with water peak suppression using a standard pulse sequence (NOESY 
presat), using 512 free induction decays (FIDs), 64 k data points, a spectral width of 12019 Hz, 
an acquisition time of 2.7 s, a relaxation delay of 4 s, and a mixing time of 100 ms [11]. 
Free induction decays were multiplied by an exponential function equivalent to 1.0 Hz line-
broadening factor before applying Fourier transform. Transformed spectra were manually 
corrected for phase and baseline distortions, and calibrated (TMSP peak at 0.00 ppm) using 
TopSpin (Bruker). Each one-dimensional spectrum in the range of 0.02–10 ppm was 
segmented into 0.02-ppm chemical shift buckets, and the corresponding spectral areas, after 
scaling, were used as input variables for the subsequent statistical analysis [11]. Regions 
between 6.0 and 4.5 ppm, containing residual water signals, were removed. Probabilistic 
quotient normalization (PQN) algorithm [12] was chosen to normalize the spectra, because it 
is a more accurate and robust alternative to the total area scaling, and PQN performs well even 
when large variations of dilution occur. Signals were assigned on template one dimensional 
NMR profiles by using matching routines of AMIX 3.8.4 (Bruker BioSpin) in combination with 
the BIOREFCODE reference database (Bruker BioSpin), and publicly available databases like 
HMDB (Human Metabolome DataBase) [13].  
All data analyses were performed using R, an open source software for the analysis of statistical 
data [14]. Multivariate data analyses were conducted on processed data by combining 
established methods. Data reduction was obtained by means of multilevel Partial Least Square 
Analysis (mPLS) using the algorithm implemented in the R-library “plsgenomics” and the 
standard R function “cancor”.  
For the purpose of classification, we used the K-nearest neighbors (k-NN) method (k = 3) 
applied on the multilevel PLS scores [16]. All the accuracies reported and the confusion matrix 
for the different classifications were assessed by means of 100 cycles of a Monte Carlo cross-
validation scheme (MCCV, R script in-house developed) [17]. Briefly, 90% of the data were 
randomly chosen at each iteration as a training set to build the model. Then the remaining 10% 
was tested and sensitivity, specificity and accuracy for the classification were assessed.  
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For the univariate analysis, after PQN normalization of the spectra, each spectral region related 
to the metabolites assigned in the 1H NMR profiles was aligned, by a simple horizontal rigid 
shift, in a way that the corresponding peaks of interest resulted superimposed. Then, they were 
integrated reducing the selected ppm intervals, and improving the precision in the integration 
by compensating the variations in peaks position in the different EBC samples. The obtained 
integrals represent the metabolite concentrations in arbitrary units. The whole procedure was 
performed using a R script developed in house. EBC metabolite concentrations at each visit 
were determined. Statistical significance was assessed using the univariate non-parametric 
Wilcoxon signed-rank test [18]. A P value < 0.05 was deemed statistically significant. 
To evaluate the discrimination power of the integrated model containing all the different 
analytical approaches used in this study, paired visit comparisons were performed using data 
matrices created by binding together all the different variables obtained from the various 
techniques (EBC NMR-spectroscopy, spirometry, carbon polymer sensor e-nose, quartz crystal 
sensor e-nose, eicosanoids and FeNO measurements). On this dataset, the same multivariate 
statistical approach previously described was applied (multilevel PLS and cross-validation 
using kNN). Furthermore, the accuracies calculated were assessed for significance against the 
null hypothesis of no prediction accuracy in the data by means of 102 randomized class-
permutations test [19]. 
 
Measurement of PGE2 and 8-isoprostane in sputum supernatants and EBC 
PGE2 and 8-isoprostane concentrations in sputum supernatants and EBC were measured with 
radioimmunoassays developed in our laboratory that were previously validated and compared 
with gas chromatography/mass spectrometry (GC/MS) and high performance liquid 
chromatography (HPLC) [20,21].  
 
Multivariate data analysis 
To investigate the correlations among the different analytical approaches used in this study, a 
matrix with data from all techniques was created and then its correlation matrix was calculated 
using the algorithm implemented in the R-library “psych” [22,23]. The heatmap of the 
correlation matrix was built using the R-function “heatmap.2”, implemented in the “gplots” 
package [24]. This function reordered the rows and columns of the correlation matrix 
according to the restrictions imposed by the dendrogram, calculated on the basis of the 
Euclidean distance among the data and using the R-function “hclust”. 
 
Statistical analysis 
Data were expressed as mean ± SEM or medians and interquartile ranges (25th and 75th 
percentiles), after assessing for normality with the D’Agostino-Pearson omnibus normality 
test. Depending on data distribution, repeated-measures ANOVA or Friedman test were used 
for assessing within-group pharmacological treatment effect. If overall statistical significance 
was observed, unpaired t test and Mann-Whitney U test were used for comparing groups for 
normally distributed and nonparametric data, respectively. Correlation was expressed as a 
Pearson coefficient. Significance was defined as a value of P value < 0.05. 
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RESULTS 
Pulmonary function testing 
All patients with COPD performed spirometry at all visits. There was no missing data. Results 
of pulmonary function tests show higher mean absolute and percentage of predicted pre-
bronchodilator FEF25%-75% values after treatment with inhaled beclomethasone/formoterol 
FDC in microparticle formulation (visit 2) compared with inhaled formoterol alone in 
microparticle formulation (visit 3) (Figure 2A and 2B). These data suggest that inhaled 
ultrafine beclomethasone/formoterol FDC improves small airway function as reflected by 
FEF25%-75% values. This might be particularly relevant as this functional effect is observed after 
only 4-week treatment with inhaled beclomethasone/formoterol, a relatively short duration of 
treatment for COPD trials, and in view of the fact that all patients with COPD included in our 
study had normal sputum eosinophils, negative reversibility test to bronchodilators, negative 
skin prick tests, and no history of atopy, thus, excluding an asthma component, on which ICS 
are generally more effective. 
An effect of ICS on small airway function is also suggested by a higher mean pre-bronchodilator 
FEV1/FVC ratio at visit 1 (COPD patients were on inhaled fluticasone/salmeterol FDC at full 
doses) compared with visit 3 (post-treatment with inhaled formoterol alone) (s-Table 1). 
Higher mean absolute and percentage of pre-bronchodilator PEF predicted values were 
observed after 4-week treatment with inhaled beclomethasone/formoterol (visit 2) compared 
with visit 1 (s-Table 1, Supplementary Figure 2C and 2D). These data might be the consequence 
of a higher lung deposition of the ultrafine drug formulation delivered through pMDI, resulting 
in a greater anti-inflammatory and/or bronchodilating effect of inhaled 
beclomethasone/formoterol combination in the small airways compared with inhaled 
fluticasone/salmeterol in standard formulation delivered through DPI (s-Table 1). 
 
Electronic nose 
E-nose analysis with carbon polymer sensor e-nose and quartz crystal sensor e-nose was 
performed in all 14 subjects at all 4 visits for a total of 56 breathprints for each e-nose. Results 
are shown in Table 2 and 3. Data were normally distributed and expressed as mean ± SEM. 
Mean values (n = 14) for each single sensor at each visit (V1-V4) are shown. Within- group 
differences were assessed by ANOVA for repeated measures and paired t test using GraphPad 
Prism software.  
Regarding analysis with carbon polymer sensor e-nose, mean ∆R values in 15 out of 32 sensors 
showed significant differences between visit 1 (screening visit) and visit 4 (post-treatment 
visit) (sensor 1, 2, 4, 7, 8, 12, 14, 15, 16, 19, 21, 24, 25, 27, 32) and mean ∆R values in 7 sensors 
showed significant differences between visit 1 and visit 2 (sensor 2, 8, 19, 21, 24, 25, 27).  
As all patients with COPD were on a constant dose of a FDC of inhaled fluticasone/salmeterol 
500/50 µg one puff b.i.d. via DPI (Seretide or Aliflus Diskus) for at least 8 weeks before study 
enrolment, these data indicate that the FDC of inhaled beclomethasone/formoterol (Foster) 
via pMDI at a dose of two puffs of 100/6 µg b.i.d. has a different effect on carbon polymer sensor 
e-nose breathprints. However, the pathophysiological and clinical implications of these 
differences are currently unknown and require further study. 
There was no difference in the relative change in resistance [(Rmax-R0)/R0] of any sensor 
between visit 2 (baseline visit) and visit 3 (post-withdrawal visit). These data suggest a similar 
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effect of inhaled ultrafine beclomethasone/formoterol and inhaled ultrafine formoterol alone 
on e-nose breathprints in patients with mild to severe COPD. This evidence is reinforced by 
similar results obtained with the quartz crystal sensor e-nose, based on a different technology 
(see below). 
There was no difference in the behaviour of all sensors between visit 2 (baseline visit) and visit 
4 (post-treatment visit). 
Consistent with carbon polymer sensor behaviour, two quartz crystal sensors showed 
significant differences between visit 1 and visit 4, whereas between-visit difference in sensor 
3 (P = 0.056) and 5 (P = 0.059) response was close to statistical significance. Sensor 3 and 4 
showed significant differences between visit 1 and visit 2, whereas between-visit differences 
in sensor 2 (P = 0.054) and 5 (P = 0.093) approached statistical significance (Table 3). 
These results are consistent with and confirm those obtained with the carbon polymer sensor 
array, an e-nose based on a different technology (see above), indicating a robust methodology. 
 
Metabolomic analysis of EBC with NMR spectroscopy 
EBC samples obtained from 14 patients with COPD at visit 1 to visit 4 for a total of 56 EBC 
samples were analyzed with NMR spectroscopy as described in Methods. There was no missing 
data. 
When EBC spectra were analyzed with multilevel PLS, that is analysis of pairs of spectra from 
the same subject at two different visits, comparison between visit 1 and visit 4 showed a 
classification accuracy of 72% (Supplementary Figure 2). 
These data indicate that regular treatment with inhaled fluticasone/salmeterol (COPD patients 
were on this FDC at a constant full dose, delivered through DPI, for at least 8 weeks) is 
associated with a different EBC metabolite profile compared with that observed after 4-week 
treatment with inhaled beclomethasone/formoterol in microparticle formulation delivered 
through pMDI. The pathophysiological meaning and possible implications of these results 
require further research. 
Regarding the other paired comparisons, classification accuracy was below 70% (s-Table 4). 
The lack of between visit differences in EBC metabolite profiles, apart from visit 1 vs visit 4, 
could be due to high intragroup inter-individual variability in EBC metabolites which might 
mask pharmacological treatment-induced differences. 
Among metabolites responsible for discrimination between visit 1 and visit 4, formate was the 
only one with a P-value < 0.05. EBC formate levels were lower at visit 4 (409.1551 ± 333.2239, 
relative intensity) compared with those observed at visit 1 (694.9539 ± 534.4349, relative 
intensity; P = 0.029) (Supplementary Figure 3A and 3B). EBC formate levels were also lower at 
visit 4 (409.1551 ± 333.2239, relative intensity) compared with those observed at visit 2 
(695.1441 ± 770.2066, relative intensity; P = 0.049), although accuracy of classification 
between visit 2 and visit 4 based on EBC NMR spectroscopy did not reach the significant 
threshold of 0.7 (0.63) (s-Table 4).  Moreover, at visit 4 EBC acetate levels were lower than 
those measured at visit 3 (P = 0.01) (s-Table 3). The pathophysiological meaning and possible 
implications of these findings require further research. 
 
Measurement of fraction of exhaled nitric oxide (FENO) 
Measurement of FENO was performed in all subjects at each visit. There was no missing data.  
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There was no within-group difference in FENO concentrations in patients with COPD (overall 
P = 0.3529)  (s-Table 5).  
However, in the 8 patients with COPD who had elevated FENO concentrations (> 20 ppb), 
median FENO was lower after treatment with beclomethasone/formoterol FDC (visit 4) than 
after treatment with formoterol alone (visit 3) (26.6 (12.8-34.) ppb vs 14.9 (13.1-25.7) ppb), 
although this difference was not statistically significant (P = 0.2334).  
In the same group of patients with COPD and elevated FENO, the difference in median FENO 
concentrations after treatment with fluticasone/salmeterol FDC (visit 1) (27.2 (23.2-29.3) 
ppb) and after treatment with beclomethasone/formoterol FDC (visit 2) (19.7 (12.8-34.7) ppb) 
was very close to statistical significance (P = 0.0584, Wilcoxon matched-pairs signed rank test). 
Taken together, this evidence might suggest a selective effect of inhaled beclomethasone on 
FENO in those patients with COPD who have higher FENO concentrations at baseline. As 
patients with COPD at visit 1 were on a constant full dose of inhaled fluticasone, delivered 
through DPI, for at least 2 months, further reduction in FENO concentrations after 4-week 
treatment with inhaled beclomethasone (visit 2), might reflect a greater anti-inflammatory 
effect of the microparticle formulation. 
 
Measurement of PGE2 in sputum supernatants  
PGE2 concentrations were detected in 49 out of a total of 56 sputum samples. In 7 samples, 
sputum PGE2 concentrations were undetectable. One patient with COPD had undetectable 
sputum PGE2 concentrations at all visits (4 samples) and was excluded from statistical analysis. 
At the other 3 undetectable samples, an arbitrary concentration value of 1 pg/mL, 
corresponding to 50% of the analytical technique detection limit (2 pg/mL), was assigned. 
Median sputum PGE2 concentrations in patients with COPD at visit 1 to visit 4 are shown in s-
Table 6. 
Compared with visit 3, lower sputum PGE2 concentrations were observed at visit 4 (P = 0.008) 
and at visit 3 (P = 0.021) (s-Table 6). 
Median sputum PGE2 concentrations at visit 2 (post-treatment with inhaled 
beclomethasone/formoterol) were lower (3.75 (1.98-54.9) pg/mL) than those observed at 
visit 3 (post-treatment with inhaled formoterol alone) (40.1 (8.3-47.0) pg/mL), although this 
difference was not statistically significant (P = 0.21), likely due to the high inter-individual 
variability. 
These data suggest that treatment with ICS combinations, containing both fluticasone 
propionate and beclomethasone, reduces sputum concentrations of PGE2, an eicosanoid which 
has pro-inflammatory effects in the airways. 
 
Measurement of 15-F2t-isoprostane in sputum supernatants  
15-F2t-isoprostane concentrations were detected in 30 out of a total of 56 sputum samples. In 
26 samples, sputum 8-isoprostane concentrations were undetectable. Five patients with COPD 
had undetectable sputum 15-F2t-isoprostane concentrations at all visits (20 samples) and were 
excluded from statistical analysis. At the other 6 undetectable samples, an arbitrary 
concentration value of 1 pg/mL, corresponding to 50% of the analytical technique detection 
limit (2 pg/mL), was assigned. 
Median sputum 15-F2t-isoprostane concentrations in patients with COPD at visit 1 to visit 4 are 
shown in s-Table 6. 
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There was no within-group difference in sputum 15-F2t-isoprostane concentrations (P = 0.84) 
(s-Table 6) suggesting that this biomarker of oxidative stress is resistant to ICS treatment in 
line with previous studies [24]. 
 
Measurement of PGE2 in EBC 
PGE2 concentrations were detected in 43 out of a total of 56 EBC samples. In 13 samples, EBC 
PGE2 concentrations were undetectable. Two patients with COPD had undetectable EBC 
concentrations at all visits (8 samples) and were excluded from statistical analysis. At the other 
5 undetectable samples, an arbitrary concentration value of 1 pg/mL, corresponding to 50% 
of the analytical technique detection limit (2 pg/mL), was assigned. 
Median EBC PGE2 concentrations in patients with COPD at visit 1 to visit 4 are shown in Table 
4. There was no within-group difference in EBC PGE2 concentrations (P = 0.19) (s-Table 6).  
 
Measurement of 15-F2t-isoprostane in EBC 
15-F2t-isoprostane concentrations were detected in 46 out of a total 56 EBC samples. In 10 
samples, EBC 15-F2t-isoprostane concentrations were undetectable. At these samples, an 
arbitrary concentration value of 1 pg/mL, corresponding to 50% of the analytical technique 
detection limit (2 pg/mL), was assigned. 
Median EBC 15-F2t-isoprostane concentrations in patients with COPD at visit 1 to visit 4 are 
shown in s-Table 6. 
There was no within-group difference in EBC 15-F2t-isoprostane concentrations (P = 0.60) (s-
Table 6) suggesting that this biomarker of oxidative stress is resistant to ICS treatment in line 
with previous studies [25]. 
 
Sputum cell analysis 
Sputum was successfully induced and collected in all patients at all visits. Fifty-six sputum 
samples were collected. Corresponding cytospins were prepared and slides were stained with 
May-Grunwald-Giemsa as described Methods. Sputum slides were read as described in 
Methods. Thirteen sputum slides were discarded because of high salivary squamous cells (> 
30% of total sputum cells). No patient with COPD had sputum eosinophilia, as defined by 
sputum cell counts > 3%, at visit 1 (screening visit).  
Medians and interquartile range of sputum cell types are shown in s-Table 7. Neutrophils were 
the predominant cell types in sputum obtained from patients with COPD.  
Within-group comparison was performed with Friedman test in the eight patients who had a 
complete set of sputum slides (visit 1 to visit 4). 
There was no within-group difference in neutrophil, macrophage, eosinophil, basophil, 
bronchial epithelial cell counts (s-Table 8). Basophil and bronchial epithelial cell counts are not 
shown in Table 5 as counts were mostly 0. 
 
Correlations  
Correlations between multidimensional variables in 14 patients with COPD at visit 1 to visit 4 
(n = 56) are shown as a heatmap (Figure 4). 
There was a negative correlation between quartz crystal sensor 4 (r = -0.35, P = 0.023) and 7 
(r = -0.31, P = 0.041) and sputum neutrophil cell counts (Figure 4). Negative correlations 
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between quartz crystal sensor 3 (r = -0.26, P = 0.88), 5 (r = -0.29, P = 0.056) and 6 (r = -0.27, P 
= 0.075) and sputum neutrophils were close to statistical significance.  
Apart from carbon polymer sensor 2 (r = 0.31, P = 0.021), 3 (r = 0.30, P = 0.026), 4 (r = 0.35, P 
= 0.007), 5 (r = 0.51, P = 6.58-5), 6 (r = 0.27, P = 0.048), 9 (r = 0.31, P = 0.019), 12 (r = 0.28, P = 
0.037), 15 (r = 0.31, P = 0.022), 18 (r = 0.27, P = 0.042), 19 (r = 0.29, P = 0.031), 23 (r = 0.45, P 
= 0.001), 25 (r = 0.31, P = 0.022), 26 (r = 0.35, P = 0.007), 28 (r = 0.29, P = 0.028), 29 (r = 0.32, 
P = 0.016), 30 (r = 0.32, P = 0.015), 31 (r = 0.51, P = 6.89-5), which were correlated with EBC 
phenol concentrations, there was no correlation between carbon polymer sensors and other 
outcome measures, including pulmonary function tests, sputum neutrophil and macrophages 
cell counts, PGE2 concentrations in sputum supernatants and EBC, and 15-F2t-isoprostane 
concentrations in sputum supernatants and EBC (Figure 4).  
FEV1/FVC values were negatively correlated with sputum neutrophil cell counts (r = -0.34; P = 
0.028) (Figure 4). Negative correlations between sputum neutrophils and FEV1 percentage of 
predicted values (r = -0.30, P = 0.053) and FEF25%-75% percentage of predicted values (r = -027, 
P = 0.075) were close to statistical significance (Figure 4).  
There was a correlation between EBC PGE2 and formate (r = 0.78, P = 5.06-11), acetone (r = 0.63, 
P = 1.64-6), lactate (r = 0.64, P = 6.03-7), n-butyrate (r = 0.82, P = 5.89-13), propionate (r = 0.59, 
P = 8.26-6), and acetate (r = 0.71, P = 1.23-8) concentrations in EBC, suggesting that these EBC 
metabolites might be suitable as inflammatory outcome measures.  
 
Multidimensional integrated model for assessment of pharmacological treatment 
In the 14 COPD study subjects, multidimensional pairwise discrimination models were built 
(Table 4). The multidimensional models discriminated between visit 1 versus visit 3 (accuracy 
= 71.5%, P < 0.01), mainly based on sputum supernatant PGE2 and FEV1/FVC ratio; between 
visit 1 versus visit 4 (accuracy = 82.5%, P < 0.01), mainly based on EBC formate, e-noses, and 
EBC PGE2; between visit 3 versus visit 4 (accuracy = 74.6%, P < 0.01), mainly based on sputum 
PGE2 and EBC acetate concentrations.  
The multidimensional models showed higher accuracy than the models based on spirometry 
alone (s-Table 9). The sensitivity and specificity reported in s-Table 9 follow the standard 
definitions of proportion of true positives and proportion of true negatives, respectively. It is 
worth noting that they appear equal for all the comparisons. Furthermore, scores plot from 
PLS analysis are centrosymmetric. This seeming uncommon behaviour is fully understandable 
given the pairwise nature of the analyses performed. In a multilevel PLS, between subject 
variation is separated from within subject variation by subtracting the individual specific 
average. In the two class cases, this construction leads to a matrix with a two-block structure 
with opposite signs, thus producing symmetric PLS scores. During cross-validation, when a 
multilevel PLS model is built from the training set, the entire variation splitting procedure is 
performed [26,27]. The procedure should, therefore, be adapted to keep the paired data 
structure both in the training and in the test set. As a result, complete individuals are left out 
of the training set (per individual validation, not per sample). At each step, if a sample of one 
individual is mistaken, inevitably the other is mistaken in the opposite way, leading to a fully 
symmetric confusion matrix. Of course, this symmetry is broken when considering more than 
just two time points. 
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DISCUSSION 
Correlations  
In the EBC, the strong correlations between PGE2 and small molecular weight metabolites 
detected by NRM spectroscopy are unlikely to be explained by individual variability in aerosol 
particle formation [28] as there was no correlation EBC 15-F2t-isoprostane and EBC 
metabolites nor between EBC PGE2 and EBC 15-F2t-isoprostane.  
Persistent neutrophilic airway inflammation is a typical characteristic of COPD, which persists 
even after smoking cessation and sputum neutrophil cell counts are a direct measure of airway 
inflammation which can be used for assessing the anti-inflammatory effects of drugs [29]. We 
report a negative correlation between the response of some quartz crystal sensors, in terms of 
relative changes in sensor frequency [(ƒmax-ƒ0)/ƒ0] (Hz), and sputum neutrophil cell counts. 
These data suggest that the quartz crystal sensor e-nose is potentially useful for assessing 
neutrophilic airway inflammation and that the higher neutrophilic airway inflammation the 
lower e-nose response. 
The response of 15 out of 32 carbon polymer sensors was correlated with EBC phenol 
concentrations. However, the biological meaning of these data has to be defined. There was no 
correlation between any carbon polymer sensor and the inflammatory outcomes measured in 
this study, including sputum neutrophil and macrophages cell counts, PGE2 concentrations in 
sputum supernatants and EBC, 15-F2t-isoprostane concentrations in sputum supernatants and 
EBC. However, these findings do not exclude the potential utility of carbon polymer sensor e-
nose for assessing airway inflammation as 1) inflammation that characterizes COPD is a 
complex, heterogeneous, pathophysiological process involving many mediators, whereas only 
a limited number of inflammatory outcomes was measured in the present study; 2) 
correlations were studied in 14 patients with COPD considering all 4 visits (n = 56) in a time 
frame of 10 weeks during which pharmacological treatment was changed three times: this 
might have caused different effects on e-nose sensors and inflammatory outcome measure, 
thus, resulting in non-significant correlations. 
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s-Figure 1. Nuclear Overhauser effect spectroscopy (NOESY) 1H-NMR spectra of exhaled breath 
condensate samples obtained from one randomly selected COPD study subject at visit 1 (red), 
visit 2 (green), visit 3 (light blue), and visit 4 (purple).  
 
 
 
s-Figure 2. Pairwise partial least square (PLS) analysis of exhaled breath condensate in 14 
subjects with COPD at visit 1 (red dots) and visit 4 (blue dots) (classification accuracy = 0.72, 
P = 0.01).  
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s-Figure 3. A) Formate peak in exhaled breath condensate (EBC) NMR spectra obtained from 
14 patients with COPD at visit 1 (red lines) and visit 4 (green lines). B) Box-and-Whiskers plot 
of formate levels in EBC obtained by analysing NMR spectra from 14 patients with COPD at 
visit 1 and visit 4. Median arbitrary units and median absolute deviation are shown. 
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s-Table 1. Lung function tests, pre-bronchodilator values* 
 V1  
Screening 
(n = 14) 
V2 
Baseline 
(n = 14) 
V3 
Post-
withdrawal 
(n = 14) 
V4 
Post-
treatment 
(n = 14) 
P value 
FEV1, L 1.66 ± 0.21 1.68 ± 0.22 1.65 ± 0.21 1.67 ± 0.21 0.907 
FEV1, % predicted 61.8 ± 6.9 62.7 ± 7.0 61.9 ± 6.7 
 
62.4 ± 6.5 
 
0.962 
FVC, L 2.80 ± 0.28 2.86 ± 0.28 2.92 ± 0.28 2.91 ± 0.28 0.440 
FVC, % predicted 79.9 ± 6.3 81.8 ± 5.9 
 
84.0 ± 6.0 
 
83.3 ± 5.5 0.534 
FEV1/FVC, % 58.1 ± 3.21 57.2 ± 3.1 55.3 ± 3.21 56.3 ± 3.3 0.008 
PEF, L/sec 4.81 ± 0.652 5.24 ± 0.722 4.89 ± 0.70 4.93 ± 0.62 0.044 
PEF, % predicted 65.5 ± 8.12 71.3 ± 8.92 66.8 ± 8.8 67.2 ± 7.4 0.033 
FEF25%-75%, 
L/sec 
0.92 ± 0.14 0.94 ± 0.153 0.86 ± 0.133 0.92 ± 0.14 0.029 
FEF25%-75%, % 
predicted 
32.4 ± 4.6 32.9 ± 4.93 30.2 ± 4.23 32.6 ± 5.4 0.026 
*Data are expressed as numbers or mean ± SEM. Within-group comparisons were performed with ANOVA for 
repeated measures and paired t test. P < 0.05 was considered significant.  
1: V1 vs V3; 2: V1 vs V2; 3: V2 vs V3. 
Abbreviations: FEF25%-75%, forced expiratory flow at 25%-75% of the forced vital capacity; FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity; PEF, peak expiratory flow; V, visit. 
 
 
s-Table 2. Lung function tests, post-bronchodilator values* 
 V1 (n = 14) V2 (n = 14) V3 (n = 14) V4 (n = 14) P Value 
FEV1, L 1.77 ± 0.22 1.80 ± 0.22 1.79 ± 0.22 1.79 ± 0.22 0.902 
FEV1, % predicted 66.2 ± 7.0 67.6 ± 7.2 67.0 ± 7.0 
 
66.4 ± 7.0 
 
0.854 
FVC, L 2.98 ± 0.28 3.01 ± 0.28 3.07 ± 0.26 3.06 ± 0.28 0.547 
FVC, % predicted 85.3 ± 6.2 86.4 ± 6.0 
 
88.7 ± 5.9 
 
87.5 ± 5.6 
 
0.587 
FEV1/FVC, % 58.3 ± 3.3 58.5 ± 3.3 56.5 ± 3.1 56.7 ± 3.3 0.110 
PEF, L/sec 5.38 ± 0.72 5.29 ± 0.64 5.19 ± 0.70 5.12 ± 0.71 0.427 
PEF, % predicted 73.1 ± 8.9 72.4 ± 7.9 70.9 ± 8.70 69.4 ± 8.50 0.437 
FEF25%-75%, 
L/sec 
0.99 ± 0.15 1.03 ± 0.16 0.96 ± 0.15 0.96 ± 0.16 0.447 
FEF25%-75%, % 
predicted 
34.7 ± 4.8 36.3 ± 5.2 33.7± 4.9 34.0 ± 5.5 0.493 
*Data are expressed as numbers or mean ± SEM. Within-group comparisons were performed with ANOVA for 
repeated measures and paired t test. P < 0.05 was considered significant. 
Abbreviations: FEF25%-75%, forced expiratory flow at 25%-75% of the forced vital capacity; FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity; PEF, peak expiratory flow; V, visit. 
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s-Table 3. Paired comparison of exhaled breath condensate (EBC) metabolite concentrations at 
each visit using Wilcoxon signed-rank test. Metabolite concentrations are reported as median 
arbitrary units ± median absolute deviation (MAD). 
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s-Table 4. Classification accuracies and P values among different pharmacological treatments 
from visit 1 to visit 4 based on a monodimensional PLS model built on EBC NMR spectroscopy 
data in 14 patients with COPD. The significant variables in the univariate analysis are also 
reported (Wilcoxon signed-rank test P values). 
Abbreviations: EBC, exhaled breath condensate; NMR, nuclear magnetic resonance; PLS, partial least squares. 
 
 
s-Table 5. FENO values in 14 patients with COPD at visit 1 to visit 4.* 
 V1 
(n = 14) 
V2 
(n = 14) 
V3 
(n = 14) 
V4 
(n = 14) 
Overall P 
value 
FENO 
(ppb) 
21.9 
(12.7-28) 
17.6 
(12.3-20.3) 
18.5 
(11.8-29) 
13.2 
(11.8-21.7) 
0.35 
*Data are expressed as medians and interquartile ranges. Within-group comparisons were performed with 
Friedman test and Wilcoxon matched-pairs signed rank test. Abbreviations: FENO, fraction of exhaled nitric oxide; 
V, visit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison Overall accuracy Variable (P value) 
Visit 1 vs. Visit 2 42.0% (P > 0.05) - 
Visit 1 vs. Visit 3 55.3% (P > 0.05) - 
Visit 1 vs. Visit 4 72.0% (0.01) Formate (0.029) 
Visit 2 vs. Visit 3 53.3% (P > 0.05) - 
Visit 2 vs. Visit 4 63.3% (P > 0.05) - 
Visit 3 vs. Visit 4 57.3% (P > 0.05) Acetate (0.009) 
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s-Table 6. PGE2 and 15-F2t-isoprostane concentrations in sputum and EBC*. 
 V1 V2 V3 V4 Overall  
P value 
n 13 13 13 13  
Sputum PGE2 
(pg/mL) 
18.6  
(2-24.6)1 
3.8  
(2-54.9) 
40.1  
(8.3-47)1,2 
10.4  
(3.5-20.8)2 
0.04 
 V1 V2 V3 V4 Overall  
P value 
n 9 9 9 9  
Sputum  
15-F2t-isoprostane 
(pg/mL) 
25  
(9.9-45.5) 
25.5  
(13.2-45.4) 
33.2  
(7.7-41.5) 
13.5  
(7.8-26.2) 
0.84 
 V1 V2 V3 V4 Overall  
P value 
n 12 12 12 12  
EBC PGE2 
(pg/mL) 
18.7  
(10.6-
30.4) 
19.1  
(11.9-55.1) 
14.7  
(7-26.1) 
11.3 
(4-18.7) 
0.19 
 V1 V2 V3 V4 Overall  
P value 
n 14 14 14 14  
EBC  
15-F2t-isoprostane 
(pg/mL) 
18.3  
(1.4-37) 
24  
(9.7-35.7) 
20.8  
(15.1-
32.8) 
21.3  
(8.1-32.7) 
0.60 
*Data are expressed as median and interquartile range. Within-group, between-visit comparisons were performed 
with Friedman’s test. If overall P was lower than 0.05, considered significant, Wilcoxon matched-pairs signed rank 
test was performed. 1: P = 0.021; 2: P = 0.008.  
One patient with COPD had undetectable sputum PGE2 concentrations at all visits (4 samples). Five patients with 
COPD had undetectable sputum 15-F2t-isoprostane concentrations at all visits (20 samples). Two patients with 
COPD had undetectable EBC PGE2 concentrations at all visits (8 samples). At undetectable samples, an arbitrary 
concentration value of 1 pg/mL, corresponding to 50% of the analytical technique detection limit (2 pg/mL), was 
assigned. Abbreviations: EBC, exhaled breath condensate; PGE2, prostaglandin E2; V, visit. 
 
 
s-Table 7. Within-group comparison of percentage sputum cell counts in the 8 patients with 
COPD who had a complete set of sputum slides (visit 1 to visit 4)*. 
 V1 V2 V3 V4 P value 
n 8 8 8 8  
Neutrophils, % 82.5  
(57.3-91.6) 
85.5  
(77.6-95.5) 
86.5 
 (72.3-93.9) 
83.3  
(68.4-89.6) 
0.55 
Macrophages, % 10.5  
(4.1-39.8) 
11.3  
(2.8-17.4) 
10  
(1.7-15) 
7.8  
(4.4-18) 
0.91 
Eosinophils, % 0 (0-0.5) 0 (0-0.8) 0.5 (0-2.9) 0.5 (0-3.3) 0.20 
Lymphocytes, % 0 (0-0.4) 0 (0-0.5) 0 (0-0.4) 0 (0-0.4) 0.87 
*Data are expressed as medians and interquartile range. Percentage of basophil and bronchial epithelial cell counts 
was 0 and is not shown. Within-group comparisons were performed with Friedman test. Abbreviation: V, visit. 
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s-Table 8. Percentage sputum cell counts in all valid sputum slides (n = 43)*. 
 V1 V2 V3 V4 P value 
n 10 12 11 10  
Neutrophils, % 85.8  
(67.8-93.4) 
87.5  
(78-96) 
87  
(73-89) 
83.5  
(72.1-90.8) 
n.s. 
Macrophages, % 10.5  
(2.9-25.3) 
7.8  
(1.8-17.4) 
11  
(3-13.5) 
7.8  
(4-18) 
n.s. 
Eosinophils, % 0.3 (0-0.6) 0 (0-1) 0 (0-1) 0.5 (0-2.8) n.s. 
Lymphocytes, % 0 (0-0.1) 0 (0-0.4) 0 (0-0) 0 (0-1) n.s. 
*Data are expressed as medians and interquartile range. Thirteen sputum slides were excluded due to squamous 
cell counts > 30%. Sputum cell counts are expressed as a percentage of total non-squamous cells. Percentage of 
basophils and bronchial epithelial cells was 0. Comparisons were performed with Mann-Withney test. 
Abbreviations: n.s., not significant for all comparisons within the group; V, visit. 
 
 
s-Table 9. Comparison between a multidimensional integrated model including breathomics 
and a model based on spirometry alone used for assessing the effects of pharmacological 
treatment in 14 patients with COPD. 
 
Abbreviations: AUC, area under the curve; OR, odds ratio. 
*P-values have been obtained through 100 fold permutation tests and are referred to the AUC values. 
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Mammographic density and breast cancer prevention: a metabolomic epigenetic 
and inflammatory markers integrated approach 
 
 
 
Introduction 
High mammographic breast density (MBD) is an established risk factor for breast 
cancer (BC); beside genetic and hormonal causes, high fat diet seems to correlate with 
high MBD. Furthermore, healthy diet and regular physical activity (PA) resulted to be 
positively associated with MBD and reduced BC risk. 
This study, called DAMA (Diet, physical Activity and MAmmography), is a factorial 
randomized trial involving healthy nonsmoking postmenopausal women not using 
hormone replacement therapy and having MBD >50%, is aimed at evaluating the 
ability of a 24-month intervention based on moderate-intensity PA and/or dietary 
modification focused on plant foods with a low glycemic load, low in saturated fats and 
alcohol, and rich in olive oil, antioxidants and fiber, to reduce the percent MBD. 
Metabolomics, epigenetics and inflammatory markers are the techniques chosen to 
characterize the effects of these life style interventions in these women. 
 
 
Patients and Methods 
Study population 
For the metabolomic part of the DAMA study 321 women were enrolled, and subjected 
to four different arms of treatment: no treatment (controls), diet, physical activity, and 
diet coupled with physical activity. At the baseline and after the treatment (follow up) 
plasma EDTA samples were collected (Figure 1). 
 
 
Figure 1. The experimental design 
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Unfortunately, 9 samples did not meet the quality requisites requested for a high 
quality metabolomic analysis (i.e. samples were hemolyzed), therefore they were 
excluded and the NMR analyses were performed on the remaining 453 samples. 
 
NMR analyses 
All plasma samples were analyzed following the standard operating procedures (1): 
frozen plasma samples were thawed at room temperature and shaken before use, a 
total of 350 µL of a sodium phosphate buffer (10.05 g Na2HPO4·7H2O; 0. 2g NaN3; 0.4 g 
sodium trimethylsilyl [2,2,3,3-2H4]propionate (TMSP) in 500 mL of H2O with 20% 
(v/v) 2H2O;  pH 7.4) was added to 350 µL of each sample, and the mixture was 
homogenized by vortexing for 30 s. A total of 600 µL of this mixture was transferred 
into a 5 mm NMR tube for the NMR analysis, and for each plasma sample three different 
monodimensional 1H NMR spectra were acquired: 
1) a standard nuclear Overhauser effect spectroscopy pulse sequence NOESY 
1Dpresat (32 scans, 98304 data points, spectral width of 18028 Hz, acquisition 
time of 2.7 s, relaxation delay of 4 s and mixing time of 0.01 s) was applied to obtain 
spectra in which signals of both low and high molecular weight metabolites are 
visible. 
2) a standard spin echo Carr-Purcell-Meiboom-Gill (2) (CPMG) pulse sequence (32 
scans, 73728 data points, spectral width of 12019 Hz, total spin echo (2nτ) of 80 
ms, acquisition time of 3.1 s, and relaxation delay of 4 s) was used for the selective 
observation of low molecular weight metabolites.  
3) a standard diffusion-edited pulse sequence (3) (32 scans, 98304 data points, 
spectral width of 18028 Hz, acquisition time of 2.7 s, and relaxation delay of 4 s) 
was applied to detect selectively high molecular weight metabolites. 
Free induction decays were multiplied by an exponential function equivalent to a 0.3 
Hz line-broadening factor before applying Fourier transform. Transformed spectra 
were automatically corrected for phase and baseline distortions and calibrated 
(anomeric glucose signal 5.24 ppm) using TopSpin 3.2.  
Each 1D spectrum in the range 0.2-10.00 ppm was segmented into 0.02 ppm chemical 
shift bins and the corresponding spectral areas were integrated using AMIX software 
(version 3.8.4, Bruker BioSpin). Binning is a mean to reduce the number of total 
variables, to compensate for subtle signal shifts, and filter noise in the spectra, making 
the analysis more robust and reproducible (4,5). The region between 4.19 and 5.11 
ppm containing the residual water signal and the regions containing EDTA signals 
(3.59-3.65 ppm, 3.09-3.25 ppm, 2.69-2.73 ppm, and 2.57-2.59 ppm) were removed and 
the dimension of the system was reduced to 432 bins. 
 
Statistical analysis 
Data analyses were performed using the open source software R (6). Multivariate 
analysis was conducted on processed data. Data reduction was carried out by means of 
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projection into a principal component analysis (PCA) subspace, only the minimum 
number of components that maximized the accuracy were retained in the model and 
the canonical analysis (CA) was applied to obtain the supervised separation of the 
groups of interest. For the purpose of classification, K-nearest neighbors (k-NN) 
method (k=5) applied on the PCA-CA scores was used. Accuracy, sensitivity and 
specificity for the different classifications were assessed by means of 100 cycles of a 
Monte Carlo cross-validation scheme (MCCV, R script in-house developed). Briefly, 
90% of the data were randomly chosen at each iteration as a training set to build the 
model, the remaining 10% was tested and sensitivity, specificity and accuracy for the 
classification were assessed.  
Multilevel partial least square analysis (mPLS)(7) was used to analyze the spectra from 
the same subject obtained at paired visits, using the algorithm implemented in the R-
library “plsgenomics” and the standard R function “cancor”. Accuracy, sensitivity and 
specificity were assessed by means of a Monte Carlo cross-validation scheme. 
Metabolites were assigned in the CPMG NMR spectra by using matching routines of 
AMIX 3.8.4 (Bruker BioSpin) in combination with the BBIOREFCODE (Bruker BioSpin), 
and freely available dataset i.e. Human Metabolome DataBase (HMDB)(8). Metabolites 
quantification was determined on the whole spectra by an in-house developed 
software in MATLAB programming suite (Takis et al., in preparation).  This algorithm 
is based upon the unconstrained non-linear minimization (fitting) of the metabolite 
NMR signals, employing a combination of Lorentzian-Gaussian functions.  By this 
approach, each NMR region of interest is decomposed and deconvoluted into its 
component parts, and then integrated to obtain the metabolite concentrations in 
arbitrary units. Kruskal-Wallis (9) or Wilcoxon signed-rank test (10) were chosen to 
infer differences between the metabolites concentrations of groups on the biological  
assumption that metabolite concentrations are not normally distributed, and false 
discovery rate correction was applied using the Benjamini-Hochberg method (11). An 
adjusted P-value < 0.05 was deemed significant. 
 
 
Results 
Multivariate statistical analyses 
Differences among patients who underwent treatments and the other ones have been 
investigated: no statistically significant accuracies for both no physical activity vs 
physical activity (Figure 2) and diet vs no diet (Figure 3) comparisons were found using 
all the three typologies of NMR spectra acquired. 
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Figure 2. PCA-CA score plots of the first two principal components for the comparison 
between subjects that did not perform physical activity (No PA, red dots) and subjects 
that practiced physical activity (PA, green dots) are reported for each kind of NMR 
spectra: NOESY, CPMG, and Diffusion. 
 
 
Figure 3. PCA-CA score plots of the first two principal components for the comparison 
between subjects that did not follow a specific diet (No D, cyan dots) and subjects that 
adopted the DAMA diet (D, purple dots) are reported for each kind of NMR spectra: 
NOESY, CPMG, and Diffusion. 
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Intervention arms were also compared pairwise obtaining weak discrimination 
accuracies, the comparison diet vs physical activity using diffusion spectra with 59.4% 
discrimination accuracy showed the best results. Each intervention arm was compared 
at baseline and follow up using two approaches: PCA-CA models to discover 
interindividual variations and mPLS to unravel intraindividual variability at the two-
time points. Results are reported in Table 1. 
 
Table 1. Comparisons of each intervention arm at baseline and follow up. 
Baseline vs Follow up PCA-CA model 
multilevel PLS 
model 
Control 
NOESY 70.7% 82.5% 
CPMG 75.8% 89.2% 
Diffusion 56.7% 63.8% 
Diet 
NOESY 72.9% 87.1% 
CPMG 80.0% 84.7% 
Diffusion 68.8% 83.9% 
Physical activity 
NOESY 69.4% 80.0% 
CPMG 72.8% 88.9% 
Diffusion 67.4% 79.5% 
Physical activity + Diet 
NOESY 69.2% 88.0% 
CPMG 83.3% 87.4% 
Diffusion 63.1% 74.0% 
 
Univariate statistical analyses 
In each CPMG spectrum 24 metabolites (leucine, isoleucine, valine, isobutyrate, 3-
hydroxybutyrate, alanine, acetate, acetone, acetoacetate, pyruvate, glutamine, citrate, 
glycine, glycerol, creatine, creatinine, lactate, proline, threonine, glucose, tyrosine, 
histidine, phenylalanine, formate) were unambiguously assigned and quantified. Only 
acetone levels showed to be statistically higher in the comparison between no physical 
activity vs physical activity at follow up (P-value 0.02), no statistical significance was 
found comparing diet vs no diet at follow up. No statistically significant metabolites 
were found for the same comparisons considering the differences between follow up 
and baseline. No statistically significant metabolite was found comparing metabolite 
concentrations among intervention arms; the same analysis was performed 
considering the differences of follow up and baseline for each metabolite concentration 
but no statistical significance was found. Conversely, statistically significant 
metabolites were found comparing each subject of each intervention arm at baseline 
and follow up: controls (Table2), diet (Table 3), physical activity (Table 4), and physical 
activity+diet (Table 5). 
 
RESULTS | 241 
Table 2. Pairwise comparison of metabolites at baseline and follow up for the controls. 
Controls baseline vs follow up 
 P-value 
P-value 
adjusted Effect size log2(FC) 
Leucine 6.37E-01 9.12E-01 0.0078 0.0137 
Isoleucine 2.03E-01 4.44E-01 -0.0893 -0.0067 
Valine 6.59E-01 9.12E-01 0.0658 -0.0245 
isobutyrate 1.98E-01 4.44E-01 0.1273 -0.0217 
3-hydroxybutyrate 2.35E-01 4.69E-01 -0.0618 -0.1671 
Alanine 2.07E-02 1.46E-01 0.2192 -0.1599 
Acetate 6.00E-01 9.12E-01 0.0365 0.0158 
Acetone 3.75E-01 6.93E-01 -0.1049 0.0233 
acetoacetate 7.42E-02 2.97E-01 -0.1899 0.4053 
Glutamine 1.59E-01 4.25E-01 -0.0991 0.0199 
Citrate 8.59E-01 9.31E-01 0.0078 -0.0329 
Glycine 7.54E-01 9.12E-01 0.0215 0.0077 
Glycerol 9.31E-01 9.31E-01 -0.0356 0.0336 
Creatine 1.53E-01 4.25E-01 -0.0801 0.153 
Creatinine 5.29E-01 9.06E-01 -0.0124 -0.0359 
Lactate 7.20E-01 9.12E-01 0.0422 -0.0018 
Threonine 6.07E-02 2.91E-01 -0.1979 0.0946 
Glucose 9.02E-02 3.09E-01 0.0957 -0.0184 
Tyrosine 2.43E-02 1.46E-01 0.1758 -0.1713 
Histidine 9.13E-01 9.31E-01 -0.0238 -0.0104 
phenylalanine 7.60E-01 9.12E-01 0.0348 -0.0457 
Formate 1.52E-07 3.66E-06 0.6783 -0.5065 
Pyruvate 1.95E-02 1.46E-01 -0.256 0.2318 
Proline 8.47E-01 9.31E-01 0.0055 -0.0942 
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Table 3. Pairwise comparison of metabolites at baseline and follow up for the diet 
group. 
Diet baseline vs follow up 
 P-value 
P-value 
adjusted Effect size log2(FC) 
Leucine 6.37E-01 9.12E-01 0.0078 0.0137 
Isoleucine 2.03E-01 4.44E-01 -0.0893 -0.0067 
Valine 6.59E-01 9.12E-01 0.0658 -0.0245 
Isobutyrate 1.98E-01 4.44E-01 0.1273 -0.0217 
3-hydroxybutyrate 2.35E-01 4.69E-01 -0.0618 -0.1671 
Alanine 2.07E-02 1.46E-01 0.2192 -0.1599 
Acetate 6.00E-01 9.12E-01 0.0365 0.0158 
Acetone 3.75E-01 6.93E-01 -0.1049 0.0233 
Acetoacetate 7.42E-02 2.97E-01 -0.1899 0.4053 
Glutamine 1.59E-01 4.25E-01 -0.0991 0.0199 
Citrate 8.59E-01 9.31E-01 0.0078 -0.0329 
Glycine 7.54E-01 9.12E-01 0.0215 0.0077 
Glycerol 9.31E-01 9.31E-01 -0.0356 0.0336 
Creatine 1.53E-01 4.25E-01 -0.0801 0.153 
Creatinine 5.29E-01 9.06E-01 -0.0124 -0.0359 
Lactate 7.20E-01 9.12E-01 0.0422 -0.0018 
Threonine 6.07E-02 2.91E-01 -0.1979 0.0946 
Glucose 9.02E-02 3.09E-01 0.0957 -0.0184 
Tyrosine 2.43E-02 1.46E-01 0.1758 -0.1713 
Histidine 9.13E-01 9.31E-01 -0.0238 -0.0104 
Phenylalanine 7.60E-01 9.12E-01 0.0348 -0.0457 
Formate 1.52E-07 3.66E-06 0.6783 -0.5065 
Pyruvate 1.95E-02 1.46E-01 -0.256 0.2318 
Proline 8.47E-01 9.31E-01 0.0055 -0.0942 
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Table 4. Pairwise comparison of metabolites at baseline and follow up for the physical 
activity group. 
Physical activity baseline vs follow up 
 P-value 
P-value 
adjusted Effect size log2(FC) 
Leucine 9.97E-01 9.97E-01 -0.0389 5.00E-04 
Isoleucine 7.78E-01 9.39E-01 -0.0389 0.0055 
Valine 8.10E-01 9.39E-01 -0.0019 -0.0343 
isobutyrate 7.23E-01 9.39E-01 -0.0571 0.0622 
3-hydroxybutyrate 6.92E-01 9.39E-01 -0.0134 0.1699 
Alanine 8.61E-01 9.39E-01 0.0121 0.0227 
Acetate 4.12E-01 8.78E-01 0.111 -0.2056 
Acetone 5.60E-01 8.96E-01 0.0057 0.0088 
acetoacetate 6.85E-03 5.48E-02 -0.2736 0.3146 
Glutamine 1.52E-01 7.31E-01 -0.081 0.0253 
Citrate 4.03E-01 8.78E-01 0.1008 -0.0483 
Glycine 3.14E-01 8.78E-01 -0.0179 -0.022 
Glycerol 4.75E-01 8.78E-01 -0.0574 -0.0102 
Creatine 2.48E-01 8.78E-01 0.0472 -0.0567 
Creatinine 3.85E-01 8.78E-01 0.0338 -0.0241 
Lactate 4.60E-01 8.78E-01 -0.0835 0.1652 
Threonine 9.84E-01 9.97E-01 -0.023 -0.0254 
Glucose 4.51E-01 8.78E-01 0.0644 -0.0101 
Tyrosine 5.99E-01 8.98E-01 -0.058 0.0316 
Histidine 8.61E-01 9.39E-01 0.0099 0.0282 
phenylalanine 5.33E-01 8.96E-01 -0.0201 -0.0055 
Formate 2.95E-09 7.08E-08 0.7315 -0.5673 
Pyruvate 6.68E-03 5.48E-02 -0.3045 0.2525 
Proline 6.95E-02 4.17E-01 -0.132 0.1731 
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Table 5. Pairwise comparison of metabolites at baseline and follow up for the physical 
activity+diet group. 
Physical activity + diet baseline vs follow up 
 P-value 
P-value 
adjusted Effect size log2(FC) 
Leucine 7.79E-01 8.99E-01 0.0565 -5.09E-02 
Isoleucine 4.79E-01 6.76E-01 0.082 -0.0168 
Valine 8.24E-01 8.99E-01 -0.0043 0.0176 
Isobutyrate 5.66E-02 2.27E-01 -0.199 0.263 
3-hydroxybutyrate 3.05E-01 6.09E-01 0.0255 0.0551 
Alanine 3.63E-01 6.30E-01 0.0764 -0.0206 
Acetate 8.70E-01 9.08E-01 -0.0136 0.0816 
Acetone 8.06E-02 2.77E-01 -0.042 -0.0768 
Acetoacetate 5.56E-02 2.27E-01 -0.1379 0.167 
Glutamine 4.39E-02 2.27E-01 -0.1471 0.0279 
Citrate 2.29E-02 1.83E-01 -0.1617 0.0139 
Glycine 9.70E-01 9.70E-01 0.0221 -0.0542 
Glycerol 1.48E-01 3.96E-01 -0.1729 0.2525 
Creatine 7.92E-01 8.99E-01 -0.036 0.1458 
Creatinine 6.06E-01 7.66E-01 -0.0221 0.0302 
Lactate 1.95E-01 4.69E-01 0.1154 -0.1489 
Threonine 1.48E-01 3.96E-01 -0.1008 0.187 
Glucose 3.68E-01 6.30E-01 0.0532 -0.0418 
Tyrosine 1.79E-02 1.83E-01 0.2046 -0.2563 
Histidine 4.48E-01 6.72E-01 -0.0638 0.0295 
Phenylalanine 6.01E-01 7.66E-01 -0.0129 0.0094 
Formate 8.81E-08 2.11E-06 0.6423 -0.4761 
Pyruvate 2.49E-01 5.44E-01 -0.1431 0.127 
Proline 4.19E-01 6.70E-01 -0.0522 -0.0194 
 
Baseline clinical data vs metabolomics data 
Any possible clusterization of NMR spectra at baseline due to different breast density 
percentage according to the Volpara method (VBD) (Figure 4), body mass index (BMI) 
(Figure 5), and age (Figure 6) was assessed. 
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Figure 4. PCA-CA score plots of the first two principal components for the comparison 
between VBD groups: A) all tertiles; B) 1° vs 3° tertiles. 
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Figure 5. PCA-CA score plots of the first two principal components for the comparison 
between BMI groups: A) all tertiles; B) 1° vs 3° tertiles. 
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Figure 6. PCA-CA score plots of the first two principal components for the comparison 
between age groups: 50-59 vs 60-69 groups. 
 
Considering baseline metabolite concentrations, for the VBD leucine, isoleucine, valine, 
and glucose showed statistically significant P-values and statistically significant 
correlations (Figure 7). 
 
 
Figure 7. A) Metabolite univariate analysis among three VBD tertiles (Kruskal test has 
been used); B) Pearson correlation between metabolite concentrations and VBD. 
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Only citrate is significant in the BMI comparison, and no significance was found in the 
age analysis. 
Correlations among metabolites and lipid blood fractions (total cholesterol, HDL 
cholesterol, and triglycerides) were investigated (Figure 8). Interestingly, many 
metabolites showed statistically significant correlations; in particular, branched amino 
acids and glucose (significant in the VBD analysis) correlated with triglycerides 
concentrations and anticorrelated with HDL cholesterol concentrations. Acetone, the 
unique metabolite significant in the comparison between physical activity vs no 
physical activity, also showed the same trend. 
 
 
Figure 8. Correlations among metabolite concentrations and lipid blood fractions 
 
 
Conclusions 
 No statistically significant differences can be found comparing the interventions 
arms at follow up. Conversely, each interventions arm compared at baseline and 
follow up with the mPLS algorithm showed high discrimination accuracies. 
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 Lowering of formate levels has been observed at follow up in each group. Formate 
production is strictly connected to folate metabolism, as formate is the only non-
folate-linked intermediate of folate cycle, and homocysteine production. 
Furthermore, folic acid is often administered to post-menopausal women to 
contrast hot flashes, probably indicating a metabolic deficiency. Therefore, further 
investigation on this metabolite need to be performed. 
 Using baseline mammographic density already available, we demonstrated for the 
first time that this information in present in the plasma metabolic fingerprint. 
Indeed, we discriminated high and low breast density with 70% accuracy.  
 Four metabolites (leucine, isoleucine, valine and glucose) showed statistically 
significant correlation with breast density, indicating that this characteristic could 
be correlated with metabolic alterations and moreover, that metabolomic could 
represent a promising tool to monitor the efficacy of possible treatments. 
 The metabolomic data coupled with epigenetic and inflammatory markers, that 
will be soon available, could contribute to provide further insight into the 
pathogenesis of BC and may allow the development of novel strategies for primary 
prevention of breast cancer in high-MBD women. 
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4.4 Veterinary metabolomics 
Although so far human medicine has mainly led metabolomic research, also several 
potential applications for metabolomics in veterinary are possible for what concerns 
investigation of disease mechanisms and pathogeneses, disease diagnosis, 
optimization of health, nutrition and production, monitoring of pharmaceutical 
treatments, and drug discovery. In this work of thesis two metabolomic veterinary 
studies are presented demonstrating the usefulness of this approach in this field. 
In the first study proposed, NMR-based metabolomics has been used to reveal new 
potential biomarkers for acute calf bronchopneumonia (see paragraph 4.4.1), one of 
the main health issues in dairy calves for which no gold standard method of diagnosis 
is available. Blood plasma water and lipid extracts of 50 diseased and 10 healthy dairy 
calves were analyzed; our results showed that the groups of interest have two 
distinguishable metabolic fingerprints using both water soluble (95.2% accuracy) and 
lipid extracts (97.7% accuracy). Furthermore, alterations in several metabolites (2-
methylglutarate, phenylalanine, phosphatidylcholine, ethanol, dimethylsulfone, 
propionate, acetate, allantoin, free cholesterol, cholesterol-C18, fatty acids) resulted to 
be associated with processes involved in the pathogenesis of acute bronchopneumonia 
(oxidant stress, energy deficit, and surfactant insufficiency), contributing to the 
understanding of the pathophysiological mechanisms of that disease in calves. 
In the second study, parameters of production, biochemical profile, plasma NMR-based 
metabolomics, abundance of mRNA of gluconeogenic enzymes and lipid oxidation 
genes were used to investigate the effects of dietary boron supplementation on 
peripartum dairy cows’ health to prevent negative energy balance related diseases at 
the onset of lactation in the transition period, roughly defined as three weeks prior to 
calving until three weeks after calving, (see paragraph 4.4.2). This cow pathological 
condition, which comprises glucose deficit, excessive lipolysis and ketogenesis, can 
lead to serious metabolic disorders impairing health and productivity of transition 
dairy cows. 
For our aim, four different groups of dairy cows, control group (21 cows), experimental 
group 1 fed with diet containing 60 ppm boron (24 cows), experimental group 2 fed 
with diet containing 120 ppm boron (18 cows), experimental group 3 fed with diet 
containing 180 ppm boron (21 cows), at three specific time points (pre-partum, 
partum, post-partum) were studied. Relevant differences have been observed among 
the control group and the three experimental groups at post-partum, but also 
statistically significant results were found comparing each group at the three time 
points. Our data support the evidence that dietary boron appears to be effective in 
minimizing negative energy balance, preventing metabolic disorders and improving 
animal health; in particular, the lipid soluble metabolome seems to be the most affected 
by the boron administration, confirming its lipotropic effect. 
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4.4.1 Plasma metabolomics in calves with acute bronchopneumonia 
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Supplementary materials: 
Supplemental Table 1. Concentrations in arbitrary units (mean ± SD) of the metabolites 
assigned in the water soluble extracts. P-values form the comparison healthy-diseased are also 
reported: the metabolites in bold are significantly different (p-value<0.05) in the comparison 
(the lipid assignments have been done according to available literature Basoglu et al 2014). 
 
 
  
Number Water soluble metabolite MSI level of identification 
Database Compound ID 
1 Isoleucine 1 HMDB HMDB00172 
2 Valine 1 HMDB HMDB00883 
3 Propionate 1 HMDB HMDB00237 
4 2-methylglutarate 1 HMDB HMDB00422 
5 Ethanol 1 HMDB HMDB00108 
6 3-hydroxybutyrate 1 HMDB HMDB00357 
7 Fucose 1 HMDB HMDB00174 
8 Lactate 1 HMDB HMDB00190 
9 Alanine 1 HMDB HMDB00161 
10 Acetate 1 HMDB HMDB00042 
11 N-acetyl signals of glycoproteins / / / 
12 Methionine 1 HMDB HMDB00696 
13 Pyruvate 1 HMDB HMDB00243 
14 Dimethyl-sulfone 1 HMDB HMDB04983 
15 Choline 1 HMDB HMDB00097 
16 Methanol 1 HMDB HMDB01875 
17 Creatine 1 HMDB HMDB00064 
18 Creatinine 1 HMDB HMDB00562 
19 Glucose 1 HMDB HMDB00122 
20 Allantoin 1 HMDB HMDB00462 
21 3-methyl-histidine 1 HMDB HMDB00479 
22 Tyrosine 1 HMDB HMDB00158 
23 Phenylalanine 1 HMDB HMDB00159 
24 Formate 1 HMDB HMDB00142 
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Supplemental Fig 1. PCA-CA-kNN score plot, discrimination between diseased calves (red dots, 
n = 50) and healthy calves (blue dots, n = 10), using a matrix were the lipophilic and hydrophilic 
data-sets are merged. Sensitivity, specificity and accuracy are also reported. 
 
 
 
 
Supplemental Fig 2. PCA-CA-kNN score plot, discrimination between diseased calves (red dots, 
n = 50) and healthy calves (blue dots, n = 10), using the spectra of the water soluble extracts 
with the 0.002 binning size. Sensitivity, specificity and accuracy are also reported.  
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Supplemental Fig 3. PCA-CA-kNN score plot, discrimination between diseased calves (red dots, 
n = 50) and healthy calves (blue dots, n = 10), using the spectra of the lipid extracts with the 
0.002 binning size. Sensitivity, specificity and accuracy are also reported. 
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4.4.2 Effects of boron supplementation on peripartum dairy cow’s health 
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Supplementary materials: 
Supplemental Table 1 Biochemical parameters.  
 
P-values for “capital letters” comparisons, i.e. for the comparison of the metabolites levels in the four treatment 
groups at the same sampling point. P-values for “minuscules” comparisons, i.e. for the comparison of the metabolites 
levels in the three sampling points for the same treatment group. 
 Period Control Exp 1 Exp 2 Exp 3 
AST, UI/L 
Prepartum 74.571±3.308b 84.125±3.388 82.166±3.477 88.714±10.432 
Partum 94.714±5.797a 98.25±5.9 93.333±3.148 87±8.159 
Postpartum 94.857±5.629a 81.75±4.647 95.5±5.038 96.142±5.654 
ALT, UI/L 
Prepartum 34.571±2.998AB 27.5±3.105B 38.666±1.054Aa 32.1428±2.676AB 
Partum 30.714±3.563 26.125±2.279 28±1.914b 27±2.609 
Postpartum 26±3.429 26.875±2.868 33.5±2.348ab 33.285±1.96 
LDH, UI/L 
Prepartum 2229.428±69.392AB 2066.125±75.345B 2293.333±26.889ABa 2454±55.345Aa 
Partum 2498.285±98.392A 2162.875±69.412B 2101.166±56.336Bb 2194.857±54.686Bb 
Postpartum 2457±158.931A 2009.625±81.156B 2157.666±44.66ABab 2278.714±70.661ABab 
GGT, UI/L 
Prepartum 23.285±1.972 21.25±1.013 23.666±2.485 24.857±1.932 
Partum 29.714±4.848 22.875±3.073 17.666±1.837 25.857±1.92 
Postpartum 32.142±4.245 22.75±1.46 23.5±1.024 24.571±1.888 
CPK, UI/L 
Prepartum 353.142±193.28 171.125±22.195 455±199.149 164.285±34.46 
Partum 207.428±22.238 232±22.477 248.666±44.364 159.285±20.549 
Postpartum 203.571±18.289AB 173.25±16.409B 281.166±36.016A 240.285±22.059AB 
Ca, mg/dL 
Prepartum 8.971±0.124A 7.175±0.199B 8.616±0.164Aa 8.757±0.084Aa 
Partum 8.614±0.196A 7.45±0.233B 7.7±0.204Bb 7.728±0.217Bb 
Postpartum 9.042±0.275A 7.8±0.244B 8.933±0.201Aa 9.014±0.112Aa 
Mg, mg/dL 
Prepartum 2.171±0.108 2.2±0.136 2.433±0.066 2.385±0.124 
Partum 2.428±0.168 2.45±0.11 2.65±0.071 2.528±0.161 
Postpartum 2.242±0.137 2.237±0.08 2.733±0.145 2.771±0.18 
P, mg/dL 
Prepartum 7.142±0.537 6.05±0.267 7.1±0.146a 7.014±0.209 
Partum 6.114±0.427 6.05±0.268 5.633±0.412b 5.957±0.347 
Postpartum 7.314±0.501 5.975±0.165 7.266±0.324a 6.214±0.418 
Glucose, 
g/dL 
Prepartum 56.571±3.077Ab 64.125±3.291Ab 62.833±2.613Ab 41.428±1.586Bb 
Partum 78.571±0.841Aa 75.25±2.373Aa 76.5±2.86Aa 59.142±1.818Ba 
Postpartum 77±3.007Aa 68.125±1.994Aab 70.666±2.389Aab 55.571±2.398Ba 
Protein, 
g/dL 
Prepartum 8.214±0.204Aab 6.937±0.387B 8.166±0.172Aa 8.528±0.194Aa 
Partum 7.842±0.084Ab 6.837±0.246B 7±0.238ABb 7.4±0.286ABb 
Postpartum 8.642±0.224Aa 7.625±0.188B 8.316±0.164ABa 8.428±0.149Aa 
Albumin, 
g/dL 
Prepartum 3.7±0.053A 3.125±0.116Bb 3.866±0.055A 3.714±0.059A 
Partum 3.685±0.079 3.537±0.067a 3.733±0.12 3.685±0.085 
Postpartum 3.385±0.214AB 3.1±0.103Bb 3.766±0.108A 3.685±0.11A 
Cholesterol, 
mg/dL 
Prepartum 143.428±8.055b 183±27.969 154.333±21.004ab 182.285±17.965ab 
Partum 178.285±24.187Aab 105.25±11.262B 89.333±8.11Bb 112.142±11.11Bb 
Postpartum 222.857±26.607a 190.125±28.277 232.333±37.505a 223.142±33.455a 
TG, mg/dL 
Prepartum 5.965±2.145C 14.167±1.353ABa 8.613±0.47BC 17.105±1.835A 
Partum 10.517±2.902 15.011±0.529a 10.456±2.203 17.959±1.494 
Postpartum 3.296±0.651B 4.910±0.832Bb 5.528±0.818B 14.450±1.33A 
BUN, mg/dL 
Prepartum 8.714±0.521b 9.125±0.953 8.5±0.223b 7.285±0.285b 
Partum 9.857±0.704ab 11.75±0.901 10.5±0.806ab 9.7143±0.644a 
Postpartum 11.4286±0.528a 11.375±0.679 11.8333±0.654a 9.7143±0.473a 
AOP, 
mmol//L 
Prepartum 0.386±0.015A 0.369±0.014Aab 0.344±0.015AB 0.295±0.013Bab 
Partum 0.368±0.017 0.404±0.013a 0.408±0.022 0.373±0.021a 
Postpartum 0.328±0.024 0.329±0.0101b 0.337±0.033 0.292±0.028b 
LPO, µM/L Prepartum 0.214±0.055 0.287±0.074 0.344±0.109 0.347±0.069 
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Supplemental Table 2 Gene primers. 
F: forward 
R: reverse 
*Castañeda-Gutiérrez E., Pelton S.H., Gilbert R.O., Butler W.R. (2009). “Effect of peripartum dietary energy 
supplementation of dairy cows on metabolites, liver function and reproductive variables”, Anim Reprod Sci 112(3-
4):301-315. 
**without references, designed according to genebank mRNA access number. 
 
 
Supplemental Table 3 Concentrations in arbitrary units (median ± mad) of the metabolites 
assigned in the water soluble extracts. 
  Control Exp 1 Exp 2 Exp 3 
P-
value* 
Valine 
Prepartum 
0.001545 ± 
0.000389 
0.00166 ± 
0.000238 
0.002064 ± 
0.000171 
0.001332 ± 
0.000076 
> 0.05 
Partum 
0.001345 ± 
0.000325 
0.001549 
± 
0.000291 
0.001594 ± 
0.000227 
0.001492 ± 
0.000101 
> 0.05 
Postpartum 
0.001387 ± 
0.000141 
0.001313 
± 
0.000288 
0.001162 ± 
0.000194 
0.000972 ± 
0.000169 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 0.0150  
Isobutyrate 
Prepartum 
0.00101 ± 
0.00011 
0.000926 
± 
0.000043 
0.000966 ± 
0.00003 
0.000828 ± 
0.000048 
> 0.05 
Partum 
0.001077 ± 
0.000061 
0.000969 
± 
0.000154 
0.001131 ± 
0.000096 
0.001095 ± 
0.000083 
> 0.05 
Postpartum 
0.00094 ± 
0.000076 
0.001216 
± 
0.000038 
0.001156 ± 
0.000094 
0.001194 ± 
0.000049 
> 0.05 
P-value** > 0.05 0.0295 > 0.05 0.0082  
3-methyl-2-
oxovalerate 
Prepartum 
0.001424 ± 
0.000057 
0.001267 
± 
0.000118 
0.001482 ± 
0.000113 
0.00114 ± 
0.000054 
> 0.05 
Partum 
0.001408 ± 
0.000088 
0.001302 
± 
0.000166 
0.001364 ± 
0.000172 
0.00115 ± 
0.000208 
> 0.05 
Oligonucleotid ID Nucleotid Sequence 
PCR product 
(bp)  
References 
YWHAZ-F 5’- TGTAGGAGCCCGTAGGTCATCT -3’ 102 NM_174814.2** 
 YWHAZ-R 5’- TTCTCTCTGTATTCTCGAGCCATCT-3’ 
PEPCK-F 5’- AGGACAAATCCCAACGCCAT -3’ 103 Castañeda-Gutiérrez et al. 
2008* PEPCK-R 5’- GCTGATCAATGCCTTCCCAGT -3’ 
CPT1-F 5’- GCAGCGTTCTTCGTGACGTTA -3’ 115 Castañeda-Gutiérrez et al. 
2008* CPT1-R 5’- ACCTGTCGAAACACCTGCCAT -3’ 
PPARα-F 5’- GAAGGCTACTCCACGTTTCTT -3’ 124 NM_001034036.1** 
PPARα-R 5’- AGACCGCTGAACACCATTAC -3’ 
PC-F 5’- CGGGAAGGTGATAGACATCAAG -3’ 102 NM_177946.4** 
PC-R 5’- GAGGTCACTACAGTCTCCATCT -3’ 
GAPDH 
GCTGAACGGGAAACTCACT 
CCTGCTTCACCACCTTCTT 
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Postpartum 
0.001458 ± 
0.000195 
0.001528 
± 0.00017 
0.001458 ± 
0.000195 
0.001358 ± 
0.000072 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
1,2-propanediol 
Prepartum 
0.002951 ± 
0.000203 
0.002436 
± 0.00022 
0.003113 ± 
0.000332 
0.003199 ± 
0.000407 
> 0.05 
Partum 
0.002598 ± 
0.000113 
0.002971 
± 0.00048 
0.003277 ± 
0.000556 
0.002674 ± 
0.000183 
> 0.05 
Postpartum 
0.003154 ± 
0.000188 
0.003778 
± 
0.000696 
0.004125 ± 
0.000686 
0.003053 ± 
0.000237 
> 0.05 
P-value** > 0.05 0.0295 > 0.05 > 0.05  
Ethanol 
Prepartum 
0.002375 ± 
0.000175 
0.002347 
± 
0.000131 
0.002666 ± 
0.000246 
0.002521 ± 
0.000276 
> 0.05 
Partum 
0.002565 ± 
0.000167 
0.002661 
± 
0.000211 
0.003069 ± 
0.000281 
0.002509 ± 
0.000264 
> 0.05 
Postpartum 
0.002498 ± 
0.000026 
0.002497 
± 
0.000184 
0.002523 ± 
0.000115 
0.002186 ± 
0.000127 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
β-hydroxybutyrate 
Prepartum 
0.007957 ± 
0.000667 
0.008044 
± 
0.001819 
0.006963 ± 
0.000427 
0.007185 ± 
0.000576 
> 0.05 
Partum 
0.013711 ± 
0.001751 
0.009615 
± 
0.002023 
0.011431 ± 
0.001749 
0.012456 ± 
0.001708 
> 0.05 
Postpartum 
0.008206 ± 
0.000754 
0.011056 
± 
0.001742 
0.009405 ± 
0.001929 
0.010376 ± 
0.000967 
> 0.05 
P-value** 0.0207 > 0.05 > 0.05 0.0082  
Lactate 
Prepartum 
0.013407 ± 
0.001244 
0.013832 
± 
0.003519 
0.01391 ± 
0.00345 
0.018604 ± 
0.001213 
> 0.05 
Partum 
0.015958 ± 
0.001047 
0.011206 
± 
0.003186 
0.011375 ± 
0.00304 
0.012167 ± 
0.000424 
> 0.05 
Postpartum 
0.009858 ± 
0.000173 
0.015158 
± 0.00385 
0.016261 ± 
0.001923 
0.019241 ± 
0.005225 
0.0467 
P-value** 0.0094 > 0.05 > 0.05 0.0293  
Arginine+lysine 
Prepartum 
0.005815 ± 
0.000255 
0.005535 
± 
0.000592 
0.006306 ± 
0.000297 
0.005613 ± 
0.000203 
> 0.05 
Partum 
0.005827 ± 
0.000389 
0.005598 
± 
0.000305 
0.005157 ± 
0.000911 
0.005534 ± 
0.000182 
> 0.05 
Postpartum 
0.005801 ± 
0.000306 
0.005548 
± 
0.000732 
0.005993 ± 
0.000507 
0.005884 ± 
0.000323 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
Acetate Prepartum 
0.026579 ± 
0.003512 
0.025619 
± 
0.007022 
0.023037 ± 
0.00326 
0.029494 ± 
0.006499 
> 0.05 
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Partum 
0.027055 ± 
0.004448 
0.027905 
± 
0.004776 
0.031321 ± 
0.003363 
0.033624 ± 
0.002216 
> 0.05 
Postpartum 
0.025257 ± 
0.002301 
0.02744 ± 
0.005711 
0.026013 ± 
0.005507 
0.028738 ± 
0.00273 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
Propionate 
Prepartum 
0.000765 ± 
0.000072 
0.000675 
± 
0.000086 
0.00065 ± 
0.000055 
0.00067 ± 
0.000052 
> 0.05 
Partum 
0.000784 ± 
0.000018 
0.000823 
± 
0.000088 
0.000892 ± 
0.000064 
0.00089 ± 
0.000084 
> 0.05 
Postpartum 
0.000776 ± 
0.000061 
0.000884 
± 
0.000118 
0.000835 ± 
0.000031 
0.000786 ± 
0.000062 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 0.0293  
Citrate 
Prepartum 
0.002904 ± 
0.000298 
0.003264 
± 
0.000364 
0.002936 ± 
0.000252 
0.00276 ± 
0.000262 
> 0.05 
Partum 
0.003101 ± 
0.000375 
0.003024 
± 
0.000439 
0.003093 ± 
0.000235 
0.003238 ± 
0.000198 
> 0.05 
Postpartum 
0.002744 ± 
0.000399 
0.001822 
± 
0.000247 
0.002818 ± 
0.000246 
0.001632 ± 
0.000447 
> 0.05 
P-value** > 0.05 0.0295 > 0.05 0.0239  
Dimethylsulfone 
Prepartum 
0.001318 ± 
0.000169 
0.000967 
± 
0.000277 
0.000573 ± 
0.0001 
0.001142 ± 
0.000291 
> 0.05 
Partum 
0.001351 ± 
0.00032 
0.001446 
± 
0.000332 
0.001375 ± 
0.000356 
0.001702 ± 
0.000291 
> 0.05 
Postpartum 
0.001617 ± 
0.000216 
0.000676 
± 
0.000177 
0.000813 ± 
0.000201 
0.001138 ± 
0.000176 
0.0497 
P-value** > 0.05 > 0.05 > 0.05 0.0239  
Betaine 
Prepartum 
0.011642 ± 
0.002282 
0.012563 
± 
0.001815 
0.013733 ± 
0.001551 
0.013899 ± 
0.001714 
> 0.05 
Partum 
0.004601 ± 
0.001345 
0.003735 
± 
0.000753 
0.003339 ± 
0.00042 
0.004245 ± 
0.000532 
> 0.05 
Postpartum 
0.004515 ± 
0.000211 
0.007997 
± 
0.002121 
0.008013 ± 
0.001236 
0.008271 ± 
0.001732 
> 0.05 
P-value** 0.0094 0.0085 > 0.05 0.0082  
Methanol 
Prepartum 
0.00364 ± 
0.000194 
0.00409 ± 
0.00111 
0.003855 ± 
0.000576 
0.003889 ± 
0.000895 
> 0.05 
Partum 
0.004056 ± 
0.000585 
0.003755 
± 
0.000874 
0.002918 ± 
0.000061 
0.003666 ± 
0.000356 
> 0.05 
Postpartum 
0.003159 ± 
0.000178 
0.002813 
± 
0.000379 
0.002989 ± 
0.00049 
0.003701 ± 
0.000412 
> 0.05 
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P-value** > 0.05 > 0.05 > 0.05 > 0.05  
Creatine 
Prepartum 
0.005219 ± 
0.000196 
0.004956 
± 0.00054 
0.005527 ± 
0.000404 
0.005036 ± 
0.000052 
> 0.05 
Partum 
0.004786 ± 
0.000381 
0.004673 
± 
0.000303 
0.004309 ± 
0.000676 
0.004431 ± 
0.000142 
> 0.05 
Postpartum 
0.004545 ± 
0.000461 
0.005671 
± 0.0005 
0.005912 ± 
0.000444 
0.005268 ± 
0.000344 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 0.0181  
Creatinine 
Prepartum 
0.003151 ± 
0.000057 
0.002854 
± 
0.000442 
0.00266 ± 
0.000095 
0.002679 ± 
0.000259 
> 0.05 
Partum 
0.002345 ± 
0.000036 
0.002376 
± 
0.000108 
0.002349 ± 
0.000176 
0.002218 ± 
0.000102 
> 0.05 
Postpartum 
0.002303 ± 
0.000093 
0.002554 
± 0.00012 
0.002706 ± 
0.000075 
0.002629 ± 
0.00013 
> 0.05 
P-value** 0.0094 > 0.05 > 0.05 > 0.05  
Glucose 
Prepartum 
0.002939 ± 
0.000668 
0.004677 
± 
0.001304 
0.004528 ± 
0.000545 
0.00361 ± 
0.00036 
> 0.05 
Partum 
0.004657 ± 
0.000728 
0.004308 
± 
0.000846 
0.003425 ± 
0.000648 
0.004126 ± 
0.000846 
> 0.05 
Postpartum 
0.003987 ± 
0.000323 
0.005548 
± 0.00039 
0.004483 ± 
0.000506 
0.005754 ± 
0.000468 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 0.0390  
Allantoin 
Prepartum 
0.000833 ± 
0.000075 
0.000832 
± 
0.000062 
0.000817 ± 
0.000059 
0.000702 ± 
0.000164 
> 0.05 
Partum 
0.000922 ± 
0.000105 
0.001033 
± 
0.000091 
0.000945 ± 
0.000079 
0.000932 ± 
0.000034 
> 0.05 
Postpartum 
0.000961 ± 
0.000043 
0.000787 
± 
0.000068 
0.000993 ± 
0.000232 
0.000931 ± 
0.000143 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
Tyrosine 
Prepartum 
0.00133 ± 
0.000084 
0.001445 
± 
0.000225 
0.001481 ± 
0.000196 
0.001196 ± 
0.000163 
> 0.05 
Partum 
0.001355 ± 
0.000204 
0.001209 
± 
0.000143 
0.001452 ± 
0.000074 
0.001193 ± 
0.000114 
> 0.05 
Postpartum 
0.001129 ± 
0.000123 
0.001019 
± 0.00018 
0.00114 ± 
0.000121 
0.001261 ± 
0.000163 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
Hippurate 
Prepartum 
0.002712 ± 
0.000371 
0.002549 
± 
0.000246 
0.002499 ± 
0.000229 
0.002349 ± 
0.000201 
> 0.05 
Partum 
0.002502 ± 
0.000113 
0.002397 
± 
0.000228 
0.002674 ± 
0.000052 
0.002237 ± 
0.000132 
> 0.05 
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Postpartum 
0.001961 ± 
0.00029 
0.002184 
± 
0.000227 
0.002654 ± 
0.000098 
0.002519 ± 
0.000192 
> 0.05 
P-value** 0.0442 > 0.05 > 0.05 > 0.05  
Formate 
Prepartum 
0.000313 ± 
0.000025 
0.000321 
± 
0.000087 
0.00024 ± 
0.000022 
0.000274 ± 
0.000019 
> 0.05 
Partum 
0.000292 ± 
0.000011 
0.000313 
± 
0.000032 
0.000287 ± 
0.00004 
0.000288 ± 
0.00005 
> 0.05 
Postpartum 
0.000329 ± 
0.000044 
0.000338 
± 
0.000032 
0.000344 ± 
0.000027 
0.00037 ± 
0.00002 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
The p-values of Kruskal test for every comparison are also reported: a p-value < 0.05 is deemed statistically relevant 
and reported in bold. *P-values for “horizontal” comparisons, i.e. for the comparison of the metabolites levels in the 
four treatment groups at the same sampling point. ** P-values for “vertical” comparisons, i.e. for the comparison of 
the metabolites levels in the three sampling points for the same treatment group. 
 
 
Supplemental Table 4 Concentrations in arbitrary units (median ± mad) of the metabolites 
assigned in the lipid soluble extracts. 
  Control Exp 1 Exp 2 Exp 3 P-value* 
Cholesterol-C18 
Prepartum 
0.018879 ± 
0.000551 
0.013072 ±  
0.001 
0.012813 ± 
0.00085 
0.01321 ± 
0.001138 
0.0028 
Partum 
0.02084 ± 
0.00025 
0.014482 ± 
0.001821 
0.016506 ± 
0.000768 
0.016969 ± 
0.001165 
0.0036 
Postpartum 
0.021398 ± 
0.001095 
0.013847 ± 
0.001393 
0.009115 ± 
0.001063 
0.013077 ± 
0.001705 
0.0032 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
Unknown lipid 
fraction 
Prepartum 
0.006395 ± 
0.000294 
0.080324 ± 
0.004757 
0.080689 ± 
0.006389 
0.072675 ± 
0.006113 
0.0022 
Partum 
0.005415 ± 
0.000339 
0.0765 ± 
0.003924 
0.058733 ± 
0.003619 
0.058164 ± 
0.00824 
0.0026 
Postpartum 
0.00586 ± 
0.000154 
0.104578 ± 
0.00663 
0.099285 ± 
0.009836 
0.092195 ± 
0.002339 
0.0032 
P-value** > 0.05 0.0117 > 0.05 0.0313  
-CH3 signals of 
fatty acids and 
cholesterol 
Prepartum 
0.140281 ± 
0.00308 
0.14921 ± 
0.001499 
0.14518 ± 
0.001821 
0.144731 ± 
0.002957 
0.0311 
Partum 
0.149857 ± 
0.001365 
0.154581 ± 
0.006414 
0.151488 ± 
0.003607 
0.158237 ± 
0.003001 
> 0.05 
Postpartum 
0.152827 ± 
0.004265 
0.159909 ± 
0.00432 
0.140916 ± 
0.008381 
0.152726 ± 
0.004179 
> 0.05 
P-value** > 0.05 > 0.05 > 0.05 > 0.05  
(-CH2)n signals 
of fatty acids 
Prepartum 
0.167777 ± 
0.004883 
0.18462 ± 
0.000672 
0.188863 ± 
0.003086 
0.187693 ± 
0.004885 
0.0060 
Partum 
0.16086 ± 
0.001865 
0.173023 ± 
0.00859 
0.175282 ± 
0.003704 
0.164126 ± 
0.002662 
0.0127 
Postpartum 
0.163449 ± 
0.002581 
0.173378 ± 
0.007461 
0.177668 ± 
0.011752 
0.174012 ± 
0.013136 
0.0431 
P-value** > 0.05 > 0.05 > 0.05 0.0404  
-CH2-CH2-CO of 
fatty acids and 
Prepartum 
0.079475 ± 
0.000838 
0.088859 ± 
0.000436 
0.08785 ± 
0.001689 
0.087398 ± 
0.000845 
0.0022 
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total 
cholesterol 
Partum 
0.081965 ± 
0.001132 
0.090698 ± 
0.001798 
0.087328 ± 
0.001955 
0.091023 ± 
0.00236 
0.0026 
Postpartum 
0.082647 ± 
0.001722 
0.095239 ± 
0.002559 
0.092957 ± 
0.005108 
0.093799 ± 
0.003683 
0.0041 
P-value** > 0.05 0.0379 > 0.05 > 0.05  
-CH2-CO signals 
of fatty acids 
Prepartum 
0.008488 ± 
0.000446 
0.005856 ± 
0.000283 
0.00571 ± 
0.00019 
0.006221 ± 
0.000619 
0.0022 
Partum 
0.009471 ± 
0.000336 
0.006768 ± 
0.000943 
0.007731 ± 
0.000274 
0.008029 ± 
0.000248 
0.0117 
Postpartum 
0.00978 ± 
0.000572 
0.006139 ± 
0.000766 
0.004794 ± 
0.00034 
0.006626 ± 
0.001256 
0.0032 
P-value** 0.0186 > 0.05 > 0.05 0.0404  
Polyunsaturate
d fatty acid 
Prepartum 
0.018882 ± 
0.000141 
0.016748 ± 
0.000475 
0.016292 ± 
0.000154 
0.015743 ± 
0.000572 
0.0047 
Partum 
0.019163 ± 
0.00042 
0.01657 ± 
0.000758 
0.01773 ± 
0.000509 
0.017661 ± 
0.000452 
0.0117 
Postpartum 
0.0181 ± 
0.000606 
0.01343 ± 
0.000256 
0.013405 ± 
0.00076 
0.013949 ± 
0.000511 
0.0032 
P-value** > 0.05 0.0117 > 0.05 0.0313  
-N(CH3)3 signals 
of 
Phosphatidylch
oline and 
sphingomyelin 
Prepartum 
0.037791 ± 
0.000988 
0.042644 ± 
0.000845 
0.042847 ± 
0.001453 
0.043019 ± 
0.000846 
0.0063 
Partum 
0.039928 ± 
0.001313 
0.041994 ± 
0.002578 
0.04421 ± 
0.001326 
0.039473 ± 
0.001364 
> 0.05 
Postpartum 
0.038806 ± 
0.000527 
0.034165 ± 
0.001511 
0.034377 ± 
0.00458 
0.034962 ± 
0.005533 
> 0.05 
P-value** > 0.05 0.0117 > 0.05 0.0404  
Backbone 
signals of total 
plasma 
triglycerides 
Prepartum 
0.001118 ± 
0.000163 
0.000874 ± 
0.000108 
0.001023 ± 
0.000111 
0.000925 ± 
0.000054 
0.0478 
Partum 
0.000636 ± 
0.000155 
0.000605 ± 
0.000082 
0.000525 ± 
0.000021 
0.000725 ± 
0.00009 
> 0.05 
Postpartum 
0.000825 ± 
0.000211 
0.000964 ± 
0.000066 
0.001053 ± 
0.000101 
0.001008 ± 
0.000135 
> 0.05 
P-value** 0.0186 0.0251 > 0.05 0.0313  
Esterified 
cholesterol 
Prepartum 
0.000149 ± 
0.000011 
0.000937 ± 
0.000063 
0.000925 ± 
0.000081 
0.000833 ± 
0.000079 
0.0022 
Partum 
0.000123 ± 
0.000008 
0.00083 ± 
0.000045 
0.000668 ± 
0.000076 
0.000685 ± 
0.00009 
0.0026 
Postpartum 
0.000153 ± 
0.000019 
0.001255 ± 
0.000084 
0.001302 ± 
0.000063 
0.001112 ± 
0.00007 
0.0032 
P-value** > 0.05 0.0117 > 0.05 0.0313  
Phosphoglyceri
des 
Prepartum 
0.003507 ± 
0.00006 
0.003859 ± 
0.000101 
0.003914 ± 
0.000095 
0.003909 ± 
0.000054 
0.0077 
Partum 
0.003658 ± 
0.000048 
0.003899 ± 
0.000203 
0.003972 ± 
0.000159 
0.003533 ± 
0.000094 
> 0.05 
Postpartum 
0.003516 ± 
0.00016 
0.003113 ± 
0.000049 
0.003242 ± 
0.000391 
0.003298 ± 
0.000307 
> 0.05 
P-value** > 0.05 0.0163 > 0.05 > 0.05  
-CH=CH- signals 
of fatty acids 
Prepartum 
0.03941 ± 
0.001208 
0.033743 ± 
0.00058 
0.032929 ± 
0.001094 
0.032801 ± 
0.002418 
0.0028 
Partum 
0.04171 ± 
0.000703 
0.034755 ± 
0.000996 
0.038011 ± 
0.000785 
0.037826 ± 
0.001124 
0.0069 
Postpartum 
0.040628 ± 
0.001306 
0.028953 ± 
0.000853 
0.028882 ± 
0.001304 
0.030534 ± 
0.002516 
0.0032 
P-value** > 0.05 0.0117 > 0.05 0.0313  
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Sphingomyelin 
Prepartum 
0.00097 ± 
0.000026 
0.001047 ± 
0.000063 
0.00103 ± 
0.000037 
0.001052 ± 
0.000076 
> 0.05 
Partum 
0.000923 ± 
0.00005 
0.000889 ± 
0.000061 
0.000888 ± 
0.000009 
0.000804 ± 
0.00001 
> 0.05 
Postpartum 
0.000981 ± 
0.000104 
0.001098 ± 
0.000077 
0.00112 ± 
0.000048 
0.001091 ± 
0.000154 
> 0.05 
P-value** > 0.05 0.0200 > 0.05 0.0404  
The p-values of Kruskal test for every comparison are also reported: a p-value < 0.05 is deemed statistically relevant 
and reported in bold. *P-values for “horizontal” comparisons, i.e. for the comparison of the metabolites levels in the 
four treatment groups at the same sampling point. ** P-values for “vertical” comparisons, i.e. for the comparison of 
the metabolites levels in the three sampling points for the same treatment group. 
 
 
Supplemental Fig. 1 PCA-CA score plots of water-soluble extracts, discrimination among control 
group (C) (red dots), experimental group 1 (Exp 1) fed with diet containing 60 ppm boron (blue 
dots), experimental group 2 (Exp 2) fed with diet containing 120 ppm boron (green dots) and 
experimental group 3 (Exp 3) fed with diet containing 180 ppm boron (purple dots) at three 
different times: prepartum, partum and postpartum. The confusion matrix and the accuracy of 
each comparison are also reported. 
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Supplemental Fig. 2 PCA-CA score plots of water-soluble extracts, discrimination among 
prepartum (pink dots), partum (orange dots) and postpartum (cyan dots) times considering 
the same group: control, Exp 1, Exp 2 and Exp 3 groups. The confusion matrix and the accuracy 
of each comparison are also reported. 
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Chapter 5 
5. Conclusions 
 
 
The results achieved during these three years of research activity and reported in this 
thesis have allowed me to further illustrate the potential of NMR-based metabolomics 
in biomedicine. Metabolomics showed to be definitely a promising and powerful tool 
for better understanding biological systems, for deep comprehension of the effects of 
environment, lifestyle, and diet on the physiological status, for stratifying patients 
according to their own personal risk, and for monitoring efficacy or toxicity of drug 
treatments or life style interventions. The results obtained in each study here 
presented, by characterizing the molecular fingerprint of diseases or phenotypes 
through an untargeted approach, opened new significant perspectives. Therefore, it 
can be concluded that fingerprinting analysis by NMR has the potential not only to 
increase our knowledge on specific diseases, but also to be translated in clinical 
practice for diagnostic or prognostic purposes. 
Despite this huge potential, metabolomics is still a relatively young discipline and many 
efforts need to be made to standardize procedures and to better characterize the 
metabolome. Metabolomics data could be greatly affected by various simple 
parameters, such as diet, microbiome, age, sex, and ethnicity; therefore, these aspects 
have to be further investigated to avoid misinterpretations of results. This thesis 
partially contributes to this aspect by characterizing the effects of sex and age on 
plasma metabolome of healthy volunteers.  
Our results show how metabolomics can lead to design new non-invasive, rapid, 
economic, and sensitive diagnostic and prognostic tests. We have shown that serum 
NMR-metabolomics can be used for patient risk stratification both in early breast 
cancer patients with the aim at predicting the risk of recurrence, and in acute coronary 
syndrome patients, to evaluate the risk of death within two years after the 
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cardiovascular event. However, especially in the first case, a very large multicentre 
study (11 hospitals involved in South East of Asia and Africa, to the best of our 
knowledge, the broadest metabolomic breast cancer study), the major challenge was 
to overcome the problems related to the adoption of different protocols during sample 
collections and storage: since standardization of sample collection, handling and 
storage constitutes an essential condition to preserve sample stability and obtain 
reproducible results, the adoption of standard operating procedures for the 
preanalytical phase represents one of the turning points for the successful translation 
of metabolomics in very large multicenter studies and then into clinical practice. 
The results obtained by our research activities demonstrate that alterations in 
metabolomic fingerprint can be associated to a pathophysiological state of an organism 
(e.g. Alzheimer’s disease, chronic inflammatory rheumatic diseases, primary biliary 
cirrhosis). Moreover, the characterization of the metabolic fingerprint can be used to 
monitor patients during pharmacological treatments or life style interventions (e.g. the 
study on COPD treatment with ICS/LABA and the DAMA study). However, despite the 
importance of the collected data, the majority of these studies, as most metabolomic 
researches in the literature, are small scale studies, in which the number of samples 
ranges from tens to hundreds.  Overcoming this limitation by much larger 
epidemiological studies, covering the analysis of tens of thousands of specimens, 
represents the next challenge for metabolomics and is expected to provide solid bases 
for the use of metabolomics for large population screening. 
Another challenge of metabolomic research is its integration with classical clinical 
tools and other omics technologies (proteomics, transcriptomics, and genomics) 
providing a holistic perspective on complex interactions occurring in biological 
systems. Perfectly in line with this idea, we are working to improve our approach: 1) 
we are trying to integrate the metabolomic score able to predict the breast cancer risk 
of recurrence with the Oncotype DX score. This score is based on a genomic test that 
analyzes the activity of a group of genes that can affect how a cancer is likely to behave 
and respond to treatment. By combing these two different features we hope to improve 
our prediction accuracy and so to provide a tool that could be really implemented in 
the clinical practice, helping the clinicians to make a more informed decision about 
whether or not to recommend chemotherapy to treat early-stage, hormone-receptor-
positive breast cancer. 2) Since our group has already defined the metabolic fingerprint 
of CD with good results (even in comparison with CBP), we are planning to integrate 
our knowledge with a comprehensive systems medicine approach involving both 
metabolomics of serum and urine and metagenomic analyses of the faecal gut 
microbiota, providing new insights into the complex mechanisms underpinning this 
disease and into how dysbiosis contributes to the pathogenesis. 3) we plan to integrate 
the data on NMR plasma metabolomic fingerprint with epigenetic and inflammatory 
markers to disentangle the mechanism of high breast density and cancer, and to deeply 
investigate the effects of life style treatments in these high-risk women. 
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In conclusion, these three years of research activity have contributed to the 
demonstration of the usefulness of metabolomics in biomedicine by a combination of 
biochemistry, analytical chemistry, bioinformatics and clinical data, and, moreover, it 
has shown that NMR-metabolomics can be really a valuable contributor to the 
development and implementation of precision medicine. 
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